Pyridazinone heterocyclic compound Myosin II inhibitors and their uses

Abstract

The present invention discloses a pyridazinone cyclic compound represented by formula (I), its stereoisomer, deuterated product, solvate, pharmaceutically acceptable salt or cocrystal, and pharmaceutical compositions containing them, as well as their use in the manufacture of drugs for treating / preventing myosin II-mediated diseases, wherein each group in formula (I) is as defined in the specification. [C1] TIFF2026501712000288.tif36156

Description

[Technical Field]

[0001] The present invention relates to Myosin II inhibitors, their stereoisomers, pharmaceutically acceptable salts, solvates, co-crystals or deuterated forms, and their use in the manufacture of medicaments for treating Myosin II-mediated related diseases. [Background technology]

[0002] Skeletal muscle has two major functions of great importance to the human body: first, muscle contraction, which forms the state of movement and maintains posture; and second, skeletal muscle is the site of glucose, fatty acids, and amino acids metabolism. During normal daily activities, skeletal muscle contraction is closely related to muscle stress, breakdown, and remodeling, which are crucial for muscle adaptation. However, in patients with progressive muscular dystrophies, such as Duchenne muscular dystrophy (DMD), muscle contraction causes extensive muscle breakdown several times in succession, which is difficult to repair. As patients age, these changes eventually accumulate and develop into a pathological process, resulting in excessive inflammation, fibrosis, and the accumulation of fat deposits in muscles, leading to a rapid decline in physical function and ultimately death.

[0003] DMD is a genetic disease that affects skeletal muscles. Becker muscular dystrophy (BMD) is a variant of DMD and was first described by the German physician Elbecker in the 1950s. It is characterized by progressive muscle degeneration and weakness. Currently, there is still a need for drugs that can treat patients with DMD or BMD. Summary of the Invention [Means for solving the problem]

[0004] The present invention provides compounds of formula (I), formula (Ia), formula (Ib), formula (II), formula (III), formula (IV), formula (V), formula (VA), formula (VI), formula (VII), formula (VIII), formula (IX), stereoisomers, deuterated products, solvates, or pharmaceutically acceptable salts or cocrystals thereof, which have excellent effects such as good activity, excellent physicochemical properties, ease of formulation, excellent pharmacokinetic properties, high bioavailability, and low toxicity and side effects.

[0005] The compound of formula (I), formula (Ia), formula (Ib), formula (II), formula (II-a), formula (III), formula (III-a), formula (IV), formula (V), formula (VA), formula (VI), formula (VII), formula (VIII), formula (IX), a stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or co-crystal thereof, [ka] [ka] During the ceremony, R 1 , R 2 , R 3 are each independently H, deuterium, or R A1 , -O-HaloC 1-4 Alkyl group, -NH-haloC 1-4 Alkyl group, -OC 1-4 Alkyl group, C 1-4 Alkoxy group, halogen, cyano group, nitro group, OH, C 1-4 Alkyl group, C 2-6 Alkenyl group, -NH-C 1-4 Alkyl group, -N(C 1-4 alkyl)2, -NH-C 3-10 Cycloalkyl groups, -NHC(O)C 1-4 alkyl groups, or 4-10 membered heterocycloalkyl groups containing 1-3 heteroatoms selected from N, O, and S, or C 5-6 alkoxy groups, wherein the alkyl, alkoxy, cycloalkyl, and heterocycloalkyl groups are optionally selected from halogen, D, CN, OH, C1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 Alkoxy group, C 3-10 It is further substituted with 1 to 3 groups selected from a cycloalkyl group, a 4 to 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, a phenyl group, and NH, with the proviso that R 1 , R 2 and R 3 are not simultaneously selected from H, In some embodiments, R 1 , R 2 , R 3 are each independently H, deuterium, or R A1 , -O-HaloC 1-4 Alkyl group, -NH-haloC 1-4 Alkyl group, -OC 1-4 Alkyl group, C 1-4 Alkoxy group, halogen, cyano group, nitro group, C 1-4 Alkyl group, C 2-6 Alkenyl group, -NH-C 1-4 Alkyl group, -N(C 1-4 alkyl)2, -NH-C 3-10 Cycloalkyl groups, -NHC(O)C 1-4 alkyl groups, or 4-10 membered heterocycloalkyl groups containing 1-3 heteroatoms selected from N, O, and S, or C 5-6 alkoxy groups, wherein the alkyl, alkoxy, cycloalkyl, and heterocycloalkyl groups are optionally selected from halogen, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 Alkoxy group, C 3-10It is further substituted with 1 to 3 groups selected from a cycloalkyl group, a 4 to 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, a phenyl group, and NH, with the proviso that R 1 , R 2 and R 3 are not simultaneously selected from H, In some embodiments, R 1 , R 2 , R 3 are each independently H, deuterium, or R A1 , -O-HaloC 1-2 Alkyl group, -NH-haloC 1-2 Alkyl group, -OC 1-2 Alkyl group, C 1-2 Alkoxy group, halogen, cyano group, nitro group, OH, C 1-2 Alkyl group, C 2-4 Alkenyl group, -NH-C 1-2 Alkyl group, -N(C 1-2 alkyl)2, -NH-C 3-6 Monocyclic cycloalkyl groups, -NH-C 7-10 Bicyclic cycloalkyl groups, -NHC(O)C 1-2 alkyl group, a 4- to 6-membered monocyclic heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, or a 7- to 10-membered bicyclic heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, or C 5-6 alkoxy groups, wherein the alkyl, alkoxy, cycloalkyl, and heterocycloalkyl groups are optionally selected from halogen, D, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 Alkoxy group, C 3-5 Monocyclic cycloalkyl groups, C 7-10further substituted with 1, 2 or 3 groups selected from a bicyclic cycloalkyl group, a 4-, 5- or 6-membered heterocycloalkyl group containing 1, 2 or 3 heteroatoms selected from N, O, S, a phenyl group and NH; In some embodiments, R 1 is R A1 , -O-HaloC 1-4 alkyl groups, and R 2 , R 3 are independently H, deuterium, and C 2-4 Alkenyl group, C 2-4 Alkynyl group, halogen, cyano group, nitro group, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 alkyl groups, In some embodiments, R 1 is R A1 , -O-HaloC 1-4 alkyl groups, and R 2 , R 3 are independently H, deuterium, and C 2-4 Alkenyl group, C 2-4 Alkynyl group, halogen, cyano group, nitro group, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 alkyl groups, In some embodiments, R 1 -O-HaloC 1-4 alkyl groups, and R 2 , R 3 are independently H, deuterium, and C 2-4 Alkenyl group, C 2-4 Alkynyl group, halogen, cyano group, nitro group, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 alkyl groups, In some embodiments, R 1 -O-HaloC 1-4 alkyl groups, and R 2 , R 3are each independently selected from H; In some embodiments, R 1 -O-HaloC 1-3 alkyl groups, and R 2 , R 3 are each independently selected from H; In some embodiments, R 3 is selected from H, In some embodiments, R 1 is R A1 Selected from R 2 , R 3 are independently H, deuterium, and C 2-4 Alkenyl group, C 2-4 Alkynyl group, halogen, cyano group, nitro group, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 alkyl groups, In some embodiments, R 1 is R A1 Selected from R 2 , R 3 are each independently selected from H, deuterium, a vinyl group, and an ethynyl group; In some embodiments, R 1 teeth, [ka] -CH2CH3, -CH2CH2CH3, [ka] R A1 is selected from R A1 is Haro C 2-6 Alkenyl group, C 2-6 Alkynyl group, -O-(CH2) r -R a , C 3-10 a cycloalkyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C 1-4 Alkyl-R a , -C1-4 Alkyl-OR a , -C 1-4 Alkyl-NR b R a , -NR b -S(O)2-R a , -NR b -S(O)2-NR b R a , -O-NR b R a , -NH-OR b , -Se-(CH2) r -R a The alkynyl, heteroaryl, alkyl, and cycloalkyl groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; In some embodiments, R A1 is Haro C 2-6 Alkenyl group, C 2-6 Alkynyl group, -O-(CH2) r -R a , C 3-10 a cycloalkyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C 1-4 Alkyl-R a , -C 1-4 Alkyl-OR a , -C 1-4 Alkyl-NR b R a , -NR b -S(O)2-R a , -NR b -S(O)2-NR b R a , -O-NR b R a , -NH-OR b , -Se-(CH2) r-Ra, wherein the alkynyl, heteroaryl, alkyl, and cycloalkyl groups are optionally selected from halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; In some embodiments, R A1 is Haro C 2-6 Alkenyl group, C 2-6 Alkynyl group, -O-(CH2) r -R a , C 3-10 a cycloalkyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C 1-4 Alkyl-R a , -C 1-4 Alkyl-OR a , -C 1-4 Alkyl-NR b R a , -NR b -S(O)2-R a , -NR b -S(O)2-NR b R a , -O-NR b R a , -NH-OR b The alkynyl, heteroaryl, alkyl, and cycloalkyl groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; In some embodiments, R A1 is Haro C 2-6 Alkenyl group, C 2-6an alkynyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C 1-4 Alkyl-R a , -C 1-4 Alkyl-OR a , -C 1-4 Alkyl-NR b R a , -NR b -S(O)2-R a , -NR b -S(O)2-NR b R a The alkynyl, heteroaryl, and alkyl groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; In some embodiments, R A1 is Haro C 2-4 Alkenyl group, C 2-4 Alkynyl group, -O-(CH2) r -R a , C 3-6 a monocyclic cycloalkyl group, a 5- to 6-membered monocyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; an 8- to 10-membered bicyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C 1-2 Alkyl-R a , -C 1-2 Alkyl-OR a , -C 1-2 Alkyl-NR b R a , -NR b -S(O)2-R a , -NR b -S(O)2-NR b R a , -O-NR b R a , -NH-OR bThe alkynyl, heteroaryl, and alkyl groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 is further substituted with 1 to 3 groups selected from an alkoxy group and NH2, and r is selected from 0 or 1; In some embodiments, R A1 is Haro C 2-4 Alkenyl group, C 2-4 an alkynyl group, a 5- to 6-membered monocyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; an 8- to 10-membered bicyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C 1-2 Alkyl-R a , -C 1-2 Alkyl-OR a , -C 1-2 Alkyl-NR b R a , -NR b -S(O)2-R a , -NR b -S(O)2-NR b R a , -O-NR b R a , -NH-OR b The alkynyl, heteroaryl, and alkyl groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1, 2, or 3 groups selected from alkoxy groups and NH; In some embodiments, R A1 is Haro C 2-4 Alkenyl group, C 2-4an alkynyl group, a 5- to 6-membered monocyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; an 8- to 10-membered bicyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C 1-2 Alkyl-R a , -C 1-2 Alkyl-OR a , -C 1-2 Alkyl-NR b R a , -NR b -S(O)2-R a , -NR b -S(O)2-NR b R a The alkynyl, heteroaryl, and alkyl groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1, 2, or 3 groups selected from alkoxy groups and NH; In some embodiments, R A1 is Haro C 2-4 Alkenyl group, C 2-4 an alkynyl group, a 5- to 6-membered monocyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C 1-2 Alkyl-R a , -C 1-2 Alkyl-OR a , -C 1-2 Alkyl-NR b R a , -NR b -S(O)2-R a , -NR b -S(O)2-NR b R a The alkynyl, heteroaryl, and alkyl groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1, 2, or 3 groups selected from alkoxy groups and NH; In some embodiments, R A1 is Haro C 2-4 Alkenyl group, C 2-4 Alkynyl group, 5- or 6-membered monocyclic heteroaryl group containing 1, 2, or 3 heteroatoms selected from N, O, and S, -CH2-R a , -CH2-OR a , -CH2-NR b R a , -NR b -S(O)2-R a , -NR b -S(O)2-NR b R a wherein the alkynyl group, heteroaryl group, and CH2 are optionally selected from halogen, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1, 2, or 3 groups selected from alkoxy groups and NH; In some embodiments, R A1 is C 3-6 monocyclic cycloalkyl groups, 4- to 6-membered monocyclic heteroaryl groups containing 1 to 3 heteroatoms selected from N, O, and S, 8- to 10-membered benzo(a) groups containing 1 to 3 heteroatoms selected from N, O, and S, 3-6 Cycloalkyl groups, -OR a , -O-CH2-R a wherein the cycloalkyl group, heteroaryl group, benzo C 3-6 The cycloalkyl group may optionally be substituted with halogen, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C1-2 further substituted with 1, 2, or 3 groups selected from alkoxy groups and NH; In some embodiments, R A1 is a halovinyl group, a halopropenyl group, an ethynyl group, a propynyl group, a pyrrolyl group, a furyl group, a thienyl group, an imidazolyl group, an oxazolyl group, a thiazolyl group, a pyrazolyl group, an isoxazolyl group, a pyridyl group, a pyridazinyl group, a pyrimidinyl group, a pyrazinyl group, -CH2-R a , -CH2-OR a , -CH2-NR b R a , -NR b -S(O)2-R a , -NR b -S(O)2-NR b R a wherein said ethynyl group, propynyl group, pyrrolyl group, furyl group, thienyl group, imidazolyl group, oxazolyl group, thiazolyl group, pyrazolyl group, isoxazolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, CH2 is optionally selected from F, Cl, deuterium, CN, OH, methyl group, ethyl group, —CH2F, —CHF2, —CF3, —CH2CH2F, —CH2CHF2, —CH2CF3, —CHFCH2F, —CHFCHF2, —CHFCF3, —CF2CH2F, —CF2CHF2, —CF2CF3, —CH2D, —CHD2, —CD3, —CH2CH2D, —CH2CHD2, —CH2CD3, —CHDCH2D, —C further substituted by 1, 2 or 3 groups selected from HDCHD2, -CHDCD3, -CD2CH2D, -CD2CHD2, -CD2CD3, a methoxy group, an ethoxy group, -OCHF2, -OCH2F, -OCF3, -OCH2CH2F, -OCH2CHF2, -OCH2CF3, -OCHFCH2F, -OCHFCHF2, -OCHFCF3, -OCF2CH2F, -OCF2CHF2, -OCF2CF3, -OCHD2, -OCH2D, -OCD3, -OCH2CH2D, -OCH2CHD2, -OCH2CD3, -OCHDCH2D, -OCHDCHD2, -OCHDCD3, -OCD2CH2D, -OCD2CHD2, -OCD2CD3 and NH2; In some embodiments, R A1teeth, [ka] is selected from In some embodiments, R A1 teeth, [ka] is selected from In some embodiments, R A1 teeth, [ka] or [ka] is selected from In some embodiments, R A1 teeth, [ka] is selected from In some embodiments, R A1 teeth, [ka] is selected from Each R a CN, Halo C 1-6 Alkyl group, C 3-10 a cycloalkyl group, a 4- to 10-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 6- to 10-membered aryl group; a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C(O)-R a1 wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally selected from halogen, ═O, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; In some embodiments, each R a CN, Halo C 1-4 Alkyl group, C 3-6 Monocyclic cycloalkyl groups, C 7-10 Spirocyclic cycloalkyl groups, C 4-8 Bridged Cycloalkyl Groups, C 4-9 Fused-ring cycloalkyl groups, 4- to 6-membered monocyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, 7- to 10-membered spirocyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, 4- to 8-membered bridged cyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, 4- to 6-membered fused-ring heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, phenyl groups, 8- to 10-membered aryl groups, 5- to 6-membered monocyclic heteroaryl groups containing 1 to 3 heteroatoms selected from N, O, and S, 8- to 10-membered bicyclic heteroaryl groups containing 1 to 3 heteroatoms selected from N, O, and S, -C(O)-R a1 wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally selected from halogen, ═O, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1 to 3 groups selected from an alkoxy group and NH; In some embodiments, each R a CN, Halo C 1-4 Alkyl group, C 3-6monocyclic cycloalkyl groups, 4- to 6-membered monocyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, 7- to 10-membered spirocyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, 4- to 8-membered bridged cyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, 4- to 6-membered fused cyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, phenyl groups, 8- to 10-membered aryl groups, 5- to 6-membered monocyclic heteroaryl groups containing 1 to 3 heteroatoms selected from N, O, and S, 8- to 10-membered bicyclic heteroaryl groups containing 1 to 3 heteroatoms selected from N, O, and S, -C(O)-R a1 wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally selected from halogen, ═O, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1 to 3 groups selected from an alkoxy group and NH; In some embodiments, each R a is CN, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CHFCH2F, -CHFCHF2, -CHFCF3, -CF2CH2F, -CF2CHF2, -CF2CF3, cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, azetidinyl group, azacyclopentyl group, oxetanyl group, oxacycloalkyl group, piperazinyl group, piperidinyl group, tetrahydropyranyl group, morpholinyl group, pyranyl group, phenyl group, pyrrolyl group, furyl group, thienyl group, imidazolyl group, oxazolyl group, thiazolyl group, pyrazolyl group, isoxazolyl group, pyridyl group, pyridazinyl group, pyrimidinyl group, pyrazinyl group, [ka] -C(O)-R a1wherein said groups are optionally selected from F, Cl, ═O, deuterium, CN, OH, a methyl group, an ethyl group, —CH2F, —CHF2, —CF3, —CH2CH2F, —CH2CHF2, —CH2CF3, —CHFCH2F, —CHFCHF2, —CHFCF3, —CF2CH2F, —CF2CHF2, —CF2CF3, —CH2D, —CHD2, —CD3, —CH2CH2D, —CH2CHD2, —CH2CD3, —CHDCH2D, —CHDCHD2, —CHDCD3, —CD2CH2D, —CD2CHD2, —CD2CD3, a methoxy group, an ethyl group, further substituted with 1, 2, 3 groups selected from methoxy groups, -OCHF2, -OCH2F, -OCF3, -OCH2CH2F, -OCH2CHF2, -OCH2CF3, -OCHFCH2F, -OCHFCHF2, -OCHFCF3, -OCF2CH2F, -OCF2CHF2, -OCF2CF3, -OCHD2, -OCH2D, -OCD3, -OCH2CH2D, -OCH2CHD2, -OCH2CD3, -OCHDCH2D, -OCHDCHD2, -OCHDCD3, -OCD2CH2D, -OCD2CHD2, -OCD2CD3 and NH2; Each R b are H, deuterium, and C 1-4 Alkyl group, C 3-6 Cycloalkyl groups, haloC 1-4 Alkyl groups, deuterated C 1-4 alkyl group, and in some embodiments, each R b are H, deuterium, and C 1-4 Alkyl group, C 3-6 In some embodiments, each R b are H, deuterium, and C 1-2 Alkyl group, C 3-4 In some embodiments, each R b is selected from H, deuterium, and a methyl group; R a1 are OH, NH2, -NHC 1-4 Alkyl group, -N(C 1-4 alkyl)2, -NHC 3-10 Cycloalkyl groups, C 1-4 Alkoxy group, C 1-6 Alkyl group, C3-10 In some embodiments, R is selected from a cycloalkyl group, a 6- to 10-membered aryl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S. a1 are OH, NH2, -NHC 1-2 Alkyl group, -N(C 1-2 alkyl)2, -NHC 3-7 Cycloalkyl groups, C 1-2 Alkoxy group, C 1-2 Alkyl group, C 3-7 a cycloalkyl group, a phenyl group, an 8- to 10-membered bicyclic aryl group, a 5- to 6-membered heteroaryl group containing 1-3 heteroatoms selected from N, O, and S, or an 8- to 10-membered bicyclic heteroaryl group containing 1-3 heteroatoms selected from N, O, and S; and in some embodiments, R a1 are OH, NH2, -NHC 1-2 Alkyl group, -N(C 1-2 alkyl)2, -NHC 3-4 Cycloalkyl groups, C 1-2 Alkoxy group, C 1-2 Alkyl group, C 3-4 In some embodiments, R is selected from the group consisting of cycloalkyl, phenyl, piperazinyl, piperidinyl, tetrahydropyranyl, morpholinyl, pyranyl, phenyl, pyrrolyl, furyl, thienyl, imidazolyl, oxazolyl, thiazolyl, pyrazolyl, isoxazolyl, pyridyl, pyridazinyl, pyrimidinyl, and pyrazinyl groups. a1 is C 1-2 Alkyl group, C 3-7 selected from a cycloalkyl group, a phenyl group, a piperazinyl group, a piperidinyl group, a tetrahydropyranyl group, a morpholinyl group, a pyranyl group, a phenyl group, a pyrrolyl group, a furyl group, a thienyl group, an imidazolyl group, an oxazolyl group, a thiazolyl group, a pyrazolyl group, an isoxazolyl group, a pyridyl group, a pyridazinyl group, a pyrimidinyl group, and a pyrazinyl group; X is CR 10or N; in some embodiments, X is selected from CH or N; in some embodiments, X is selected from CH; in some embodiments, X is selected from N; X1 is selected from O, S, and in some embodiments, X1 is selected from O, and in some embodiments, X1 is selected from S; R 4 , R 5 are independently H, deuterium, and C 3-10 Cycloalkyl groups, C 2-6 Alkenyl group, C 2-6 Alkynyl group, halogen, amino group, -NH-C 1-4 Alkyl group, -N(C 1-4 Alkyl)2, C 1-4 Alkyl group, halo C 1-4 alkyl groups, 4- to 10-membered heterocycloalkyl groups containing 1-3 heteroatoms selected from N, O, and S, 5- to 10-membered heteroaryl groups containing 1-3 heteroatoms selected from N, O, and S, and 6- to 10-membered aryl groups. In some embodiments, R 4 , R 5 are independently H, deuterium, and C 3-4 Monocyclic cycloalkyl groups, C 7-8 Bicyclic cycloalkyl groups, C 2-4 Alkenyl group, C 2-4 Alkynyl group, F, Cl, amino group, -NH-C 1-2 Alkyl group, -N(C 1-2 Alkyl)2, C 1-2 Alkyl group, halo C 1-2 alkyl group, a 4- to 6-membered monocyclic heterocycloalkyl group containing 1, 2, or 3 heteroatoms selected from N, O, or S, a 7- to 10-membered bicyclic heterocycloalkyl group containing 1, 2, or 3 heteroatoms selected from N, O, or S, a 5- to 6-membered monocyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, or S, an 8- to 10-membered bicyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, or S, a phenyl group, or an 8- to 10-membered bicyclic aryl group; 4 , R 5are independently H, deuterium, and C 3-4 Monocyclic cycloalkyl groups, C 7-8 Bicyclic cycloalkyl groups, C 2-4 Alkenyl group, C 2-4 Alkynyl group, F, Cl, amino group, -NH-C 1-2 Alkyl group, -N(C 1-2 Alkyl)2, C 1-2 Alkyl group, halo C 1-2 alkyl groups, and 4-6 membered monocyclic heterocycloalkyl groups containing 1, 2, or 3 heteroatoms selected from N, O, and S; and in some embodiments, R 4 , R 5 are independently H, deuterium, and C 3-4 Monocyclic cycloalkyl groups, C 7-8 Bicyclic cycloalkyl groups, C 2-4 Alkenyl group, C 2-4 alkynyl groups, 4-5 membered monocyclic heterocycloalkyl groups containing 1, 2, or 3 heteroatoms selected from N, O, and S; and in some embodiments, R 4 , R 5 are independently H, deuterium, and C 3-4 Monocyclic cycloalkyl groups, C 2-4 Alkenyl group, C 2-4 alkynyl groups, and in some embodiments, R 4 , R 5 are each independently selected from H, deuterium, cyclopropyl, cyclobutyl, vinyl, and propenyl; and in some embodiments, R 4 , R 5 are each independently selected from H, and in some embodiments, R 5 is selected from H, R 6 , R 7 , R 8 , R 9 , R 10 are each independently H, deuterium, or R A2 , halogen, OH, CN, amino group, C 1-4 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C1-4 Alkoxy group, haloC 1-4 Alkyl group, -NH-C 1-4 Alkyl group, -N(C 1-4 alkyl)2, -S(O)R c , -S(O) 2 R c , -C(O)R c , -C(O)OR c , -C(O)N(R c )2, -OC(O)R c The alkyl, alkenyl, alkynyl, and alkoxy groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; In some embodiments, R 6 , R 7 , R 8 , R 9 , R 10 are each independently H, deuterium, or R A2 , F, Cl, OH, CN, amino group, C 1-2 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-2 Alkoxy group, haloC 1-2 Alkyl group, -NH-C 1-2 Alkyl group, -N(C 1-2 alkyl)2, -S(O)R c , -S(O) 2 R c , -C(O)R c , -C(O)OR c , -C(O)N(R c )2, -OC(O)R c The alkyl, alkenyl, alkynyl, and alkoxy groups are optionally selected from F, Cl, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1, 2, or 3 groups selected from alkoxy groups and NH; In some embodiments, R 7 , R 8 are each independently H, deuterium, or R A2 , F, Cl, OH, CN, amino group, C 1-2 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-2 Alkoxy group, haloC 1-2 Alkyl group, -NH-C 1-2 Alkyl group, -N(C 1-2 alkyl), wherein the alkyl, alkenyl, alkynyl, and alkoxy groups are optionally selected from F, Cl, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 is further substituted with 1, 2, or 3 groups selected from an alkoxy group and NH; R 6 , R 9 , R 10 are each independently H, deuterium, F, Cl, OH, CN, amino group, C 1-2 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-2 Alkoxy group, haloC 1-2 Alkyl group, -NH-C 1-2 Alkyl group, -N(C 1-2 alkyl), wherein the alkyl, alkenyl, alkynyl, and alkoxy groups are optionally selected from F, Cl, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C1-2 further substituted with 1, 2, or 3 groups selected from alkoxy groups and NH; In some embodiments, R 7 , R 8 are each independently H, deuterium, or R A2 , F, Cl, OH, CN, amino group, C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkyl group, -NH-C 1-2 Alkyl group, -N(C 1-2 alkyl), wherein the alkyl, alkenyl, alkynyl, and alkoxy groups are optionally further substituted with 1, 2, or 3 groups selected from F, Cl, deuterium, CN, OH, and NH; R 6 , R 9 , R 10 are each independently H, deuterium, F, Cl, OH, CN, amino group, C 1-2 alkyl groups, said alkyl groups being optionally further substituted with 1, 2, 3 groups selected from F, Cl, deuterium, OH; In some embodiments, R 7 are each independently R A2 Selected from R 6 , R 8 , R 9 , R 10 are each independently H, deuterium, F, Cl, OH, CN, amino group, C 1-2 alkyl groups, said alkyl groups being optionally further substituted with 1, 2, 3 groups selected from F, Cl, deuterium, OH; In some embodiments, R 8 are each independently R A2 Selected from R 6 , R 7 , R 9 , R 10 are each independently H, deuterium, F, Cl, OH, CN, amino group, C 1-2 alkyl groups, said alkyl groups being optionally further substituted with 1, 2, 3 groups selected from F, Cl, deuterium, OH; In some embodiments, R 7 are each independently R A2 Selected from R 6 , R 8 , R 9 , R 10 are each independently H, deuterium, F, Cl, OH, CN, amino group, C 1-2 alkyl groups, In some embodiments, R 8 are each independently R A2 Selected from R 6 , R 7 , R 9 , R 10 are each independently H, deuterium, F, Cl, OH, CN, amino group, C 1-2 alkyl groups, In some embodiments, R 7 , R 8 are each independently H, deuterium, F, Cl, OH, CN, a methyl group, or R A2 Selected from R 6 , R 9 , R 10 are each independently selected from H, deuterium, F, Cl, OH, CN, and a methyl group; In some embodiments, R 6 , R 9 , R 10 are independently H, deuterium, halogen, C 1-6 Alkyl group, halo C 1-6 alkyl groups, and in some embodiments, R 6 , R 9 , R 10 are independently H, deuterium, halogen, C 1-3 Alkyl group, halo C 1-3 alkyl groups, and in some embodiments, R 6 , R 9 , R 10 are each independently selected from H, deuterium, F, Cl, a methyl group, a trifluoromethyl group, and a difluoromethyl group; R A2 is -(CH2) r -(C3-10 cycloalkyl), -(CH2) r -(4- to 10-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from N, O, S, and Si), or -(CH) r -(5-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -P(O)(R c )2, -Si(R c )3, -SF5, N3, B(OH)2, or -S(O)(=NH)R c wherein the cycloalkyl, heterocycloalkyl, and heteroaryl groups are optionally selected from halogen, ═O, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, C 3-6 Cycloalkyl groups, 4- to 7-membered heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; In some embodiments, R A2 is -(CH2) r -(4- to 10-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from N, O, S, and Si), or -(CH) r -(5-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -P(O)(R c )2, -Si(R c )3, -SF5, N3, B(OH)2, or -S(O)(=NH)R c The heterocycloalkyl and heteroaryl groups are optionally selected from halogen, ═O, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, C 3-6Cycloalkyl groups, 4- to 7-membered heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; In some embodiments, R A2 is -(CH2) r -(4-10 membered heterocycloalkyl containing 1-3 heteroatoms selected from N, O, and S), or -(CH) r -(5-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -P(O)(R c )2, -Si(R c )3, -SF5, -S(O)(=NH)R c The heterocycloalkyl group and the heterocyclic aryl group are optionally selected from halogen, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 and in some embodiments, R A2 is -(CH2) r -(4-6 membered monocyclic heterocycloalkyl containing 1-3 heteroatoms selected from N, O, and S), -(CH2) r -(7-10 membered spirocyclic heterocycloalkyl containing 1-3 heteroatoms selected from N, O, and S), -(CH2) r -(5-6 membered monocyclic heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -(CH2) r -(8-10 membered bicyclic heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -P(O)(R c )2, -Si(R c )3, -SF5, -S(O)(=NH)R c The heterocycloalkyl group and the heterocyclic aryl group are optionally selected from halogen, D, CN, OH, C 1-2Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1 to 3 groups selected from an alkoxy group and NH; In some embodiments, R A2 is -(CH2) r -(4-6 membered monocyclic heterocycloalkyl containing 1-3 heteroatoms selected from N, O, and S), -(CH2) r -(5-6 membered monocyclic heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -P(O)(R c )2, -Si(R c )3, -SF5, -S(O)(=NH)R c The heterocycloalkyl group and the heterocyclic aryl group are optionally selected from halogen, D, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 and in some embodiments, R A2 is -(CH2) r -(4-6 membered monocyclic heterocycloalkyl containing 1-3 heteroatoms selected from N, O, and S), -(CH2) r -(5-6 membered monocyclic heteroaryl containing 1-3 heteroatoms selected from N, O, S), wherein the heterocycloalkyl group, heteroaryl group is optionally selected from halogen, D, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1 to 3 groups selected from an alkoxy group and NH; In some embodiments, R A2 teeth, [ka] is selected from In some embodiments, R A2 teeth, [ka] is selected from In some embodiments, R A2 teeth, [ka] is selected from Each R c are independently H, OH, C 1-4 Alkyl group, C 3-7 Cycloalkyl groups, haloC 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 an alkoxy group, or NH; and in some embodiments, each R c are each independently C 1-2 Alkyl group, C 3-4 Cycloalkyl groups, haloC 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 and in some embodiments, each R c are each independently C 1-2 Alkyl group, C 3-4 In some embodiments, each R c are each independently C 1-2 alkyl groups, Each r is independently selected from 0, 1, 2, or 3; in some embodiments, each r is independently selected from 0 and 1; L1 is a bond, O, NH, S, -CD2-, -CHD-, -CR L1 R L2 -, C 1-4 alkyl group, —C(O)—, S(O), S(O)2, said alkyl group optionally being selected from R L1 In some embodiments, L is selected from a bond, O, and in some embodiments, L is selected from a bond; L2 is O, NH, S, -CH2-, -CD2-, -CHD-, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, C 2-4 alkyl group, -C(O)-, S(O), S(O)2, said alkyl group optionally having 1 to 3 R L1 In some embodiments, L2 is further substituted with -CH2-, -CD2-, -CHD-, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, C 2-4 alkyl group, -C(O)-, S(O), S(O)2, said alkyl group optionally having 1 to 3 R L1 In some embodiments, L2 is further substituted with -CH2-, -CR L1 R L2 -, -CHR L2 -,-CDR L2 In some embodiments, L2 is selected from -, -C(O)-, and in some embodiments, L2 is selected from -CH2-, and in some embodiments, L2 is -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, -C(O)-, R A4 is -CH2-C 1-4 Alkyl-C 3-6 Cycloalkyl groups, -CH2-CR A4c =CR A4a R A4b , -CH2-CH=CH-CH=CR A4a RA4b , -CH(C 1-2 Alkyl)-CR A4c =CR A4a R A4b , -C(C 1-2 Alkyl)2-CR A4c =CR A4a R A4b , L3-R A4’ In some embodiments, R A4 is -CH2-C 1-4 Alkyl-C 3-6 Cycloalkyl groups, -CH2-CH=CR A4a R A4b , -CH2-CF=CR A4a R A4b , -CH2-C(CN)=CR A4a R A4b , -CH2-C(CH3)=CR A4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , -CHCH3-CR A4c =CR A4a R A4b , -CH(CH2CH3)-CR A4c =CR A4a R A4b , -C(CH3)2-CR A4c =CR A4a R A4b , -C(CH2CH3)2-CR A4c =CR A4a R A4b , L3-R A4’ In some embodiments, R A4 is -CH2-C 1-4 Alkyl-C 3-6 Cycloalkyl groups, -CH2-CR A4c =CR A4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , L3-R A4’ or -CHCH3-CR A4c =CR A4a R A4b In some embodiments, R A4 is -CH2-C1-4 Alkyl-C 3-6 Cycloalkyl groups, -CH2-CH=CR A4a R A4b , -CH2-CF=CR A4a R A4b , -CH2-C(CH3)=CR A4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , L3-R A4’ or -CHCH3-CH=CR A4a R A4b In some embodiments, R A4 is -CH2-C 1-4 Alkyl-C 3-6 Cycloalkyl groups, -CH2-CF=CR A4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , L3-R A4’ or -CHCH3-CH=CR A4a R A4b In some embodiments, R A4 is -CH2-C 1-4 Alkyl-C 3-6 Cycloalkyl groups, -CH2-C(CH3)=CR A4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , L3-R A4’ or -CHCH3-CH=CR A4a R A4b In some embodiments, R A4 is -CH2-C 1-4 Alkyl-C 3-6 Cycloalkyl groups, -CH2-CH=CR A4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , L3-R A4’ or -CHCH3-CH=CR A4a R A4b is selected from In some embodiments, R A4 is -CH2-C 1-4 Alkyl-C 3-6 Cycloalkyl groups, -CH2-CF=CR A4a R A4b , L3-R A4’ or -CHCH3-CH=CR A4a R A4b In some embodiments, R A4 is -CH2-C 1-4 Alkyl-C 3-6 Cycloalkyl groups, -CH2-C(CH3)=CR A4a R A4b , L3-R A4’ or -CHCH3-CH=CR A4a R A4b In some embodiments, R A4 is -CH2-C 1-4 Alkyl-C 3-6 Cycloalkyl groups, -CH2-CH=CR A4a R A4b , L3-R A4’ or -CHCH3-CH=CR A4a R A4b In some embodiments, R A4 is -CH2-C 1-4 Alkyl-C 3-6 cycloalkyl group or -CHCH3-CH=CR A4a R A4b In some embodiments, R A4 teeth, [ka] In some embodiments, R A4 is -CH2-CH=CR A4a R A4b , L3-R A4’ or -CHCH3-CH=CR A4a R A4b In some embodiments, R A4 teeth, [ka] or [ka] In some embodiments, R A4 teeth, [ka] or [ka] is selected from In some embodiments, R A4 teeth, [ka] or [ka] is selected from R A4c H, halogens, deuterium, CN, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 In some embodiments, R A4c H, halogens, deuterium, C 1-4 Alkyl group, halo C 1-4 Alkyl group, C 1-4 In some embodiments, R A4c H, halogen, C 1-4 alkyl groups, and in some embodiments, R A4c is selected from H, R A4a , R A4b is a 3- to 6-membered monocyclic carbocyclic ring together with the carbon atom to which it is attached, C 7-10 Spirocyclic carbocycle, C7-10 Bridged carbocyclic ring or C 7-10 Form a fused carbocycle, or a 4- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, or a 6-membered fused carbocycle, wherein the carbocycle or heterocycle optionally contains halogen, ═O, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, -COC 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 substituted with 1 to 3 groups selected from an alkoxy group and NH, wherein the carbocycle comprises a cycloalkyl group and an aryl group, and the heterocycle comprises a heterocycloalkyl group and a heteroaryl group; In some embodiments, R A4a , R A4b forms a 3- to 6-membered carbocyclic ring together with the carbon atom to which it is attached, and in some embodiments, R A4a , R A4b forms a 3-, 4-, 5-, or 6-membered carbocyclic ring together with the carbon atom to which it is attached, and in some embodiments, R A4a , R A4b together with the carbon atom to which it is attached form a 3-, 4-, 5-, or 6-membered cycloalkyl group, and in some embodiments, R A4a , R A4b together with the carbon atom to which it is attached form a 4-, 5-, or 6-membered cycloalkyl group, and in some embodiments, R A4a , R A4b represents a 4-, 5-, or 6-membered monocyclic cycloalkyl group together with the carbon atom to which it is attached, C 7-10 Spirocyclic carbocycle, C 7-10 Fused ring carbocycles, 6-membered fused ring carbocycles, 5- and 6-membered heterocyclic cycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, the cycloalkyl groups and heterocycloalkyl groups optionally containing halogen, ═O, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, -COC 1-2 Alkyl group, C1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 substituted with 1 to 3 groups selected from an alkoxy group and NH; In some embodiments, R A4a , R A4b represents a 4-, 5-, or 6-membered monocyclic cycloalkyl group together with the carbon atom to which it is attached, C 7-10 Spirocyclic carbocycle, C 7-10 Form a fused ring carbocycle, a 5- or 6-membered heterocyclic cycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, and the cycloalkyl group, heterocycloalkyl group optionally contains halogen, ═O, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, -COC 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 substituted with 1 to 3 groups selected from an alkoxy group and NH; L3 is C 3-6 Cycloalkyl group, or -CH(C 1-2 Alkyl)-C 1-4 alkyl group, wherein the cycloalkyl group is optionally selected from 1 to 3 R L3 is replaced by In some embodiments, L3 is C 3-6 Cycloalkyl groups, -CH(C 1-2 Alkyl)-C 1-4 In some embodiments, L is selected from C 3-6 Cycloalkyl groups, -CH(C 1-2 Alkyl)-C 1-2 In some embodiments, L is selected from a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, -CH(CH)-CH-*, where * is selected from R 4A’ represents the linking site with Each R L3 are independently halogen, =O, deuterium, CN, OH, C 1-4Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, -COC 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 selected from an alkoxy group and NH; Optionally, two R on adjacent ring atoms L3 together with the atoms connected thereto form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1-3 heteroatoms selected from N, O, and S, and in some embodiments, form a C4 cycloalkyl group or a C5 cycloalkyl group, and in some embodiments, form a heteroaryl group such as a pyrazolyl group, an imidazolyl group, a thiazolyl group, a thienyl group, an oxazolyl group, a furyl group, or a 5-membered heterocycloalkyl group containing 1-2 N, O, or S heteroatoms, and in some embodiments, the carbocyclic ring or heterocyclic ring is optionally substituted; R A4’ is H, C 3-6 a cycloalkyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S, or a 4- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, and the cycloalkyl group, heteroaryl group, and heterocycloalkyl group may optionally be selected from halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 and in some embodiments, R A4’ is C 3-6 A cycloalkyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S, and the cycloalkyl group, the heteroaryl group, optionally contains halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 and in some embodiments, R A4’ is C 4、5、6 A cycloalkyl group, a 5- to 6-membered monocyclic heteroaryl group containing 1, 2, or 3 heteroatoms selected from N, O, and S, and an 8- to 10-membered bicyclic heteroaryl group containing 1, 2, or 3 heteroatoms selected from N, O, and S, wherein the cycloalkyl group and the heteroaryl group are optionally selected from F, Cl, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 and in some embodiments, R A4’ is C 4、5 cycloalkyl groups, 5-6 membered monocyclic heteroaryl groups containing 1, 2, or 3 heteroatoms selected from N, O, and S, and the heteroaryl groups are optionally selected from F, Cl, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 further substituted with 1, 2, 3 groups selected from alkyl groups and NH2; R L1 , R L2 are each independently a halogen, OH, CN, an amino group, or C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 cycloalkyl groups, 4-6 membered heterocycloalkyl groups containing 1-3 heteroatoms selected from N, O, and S; and in some embodiments, R L1 , R L2 are independently F, Cl, OH, CN, amino group, C 1-2 Alkyl group, C 1-2Alkoxy group, C 3-4 In some embodiments, R is selected from the group consisting of a cycloalkyl group, a 4- or 5-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S. L1 , R L2 are independently F, Cl, OH, CN, amino group, C 1-2 Alkyl group, C 1-2 In some embodiments, R L1 , R L2 are independently F, Cl, OH, CN, and C 1-2 Alkyl group, C 1-2 In some embodiments, R L1 , R L2 are independently F, C 1-2 alkyl groups, One option is R 2 , R 4 L1, together with the atom to which it is linked, forms a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be selected from R A3 and in some embodiments, R 2 , R 4 L1, together with the atom to which it is attached, is selected from a 6- to 7-membered cycloalkyl group, a phenyl group, and the cycloalkyl group is optionally selected from R A3 and in some embodiments, R 2 , R 4 , L1 together with the atom to which it is connected forms a cyclohexyl group, a phenyl group, and the cyclohexyl group is optionally A3 and in some embodiments, R 2 , R 4 , L1 together with the atom to which it is connected forms a cyclohexyl group, a phenyl group, and in some embodiments, R 2 , R 4 together with the atoms to which it is connected, C 5-7Forms a cycloalkyl group, and in some embodiments, R 2 , R 4 together with the atom to which it is linked, form a cyclopentyl group, a cyclohexyl group, or a cycloheptyl group, One option is R 4 , R 5 together with the atom to which it is linked, form a 5- to 7-membered monocyclic carbocycle or a 5- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be A3 and in some embodiments, R 4 , R 5 together with the atom to which it is linked, form a phenyl group, a 5- to 6-membered cycloalkyl group, or a 5- to 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S, and the cycloalkyl group may optionally be R A3 and in some embodiments, R 4 , R 5 forms, together with the atom to which it is linked, a phenyl group, a cyclopentyl group, a cyclohexyl group, a pyrrolyl group, a furyl group, a thienyl group, an imidazolyl group, an oxazolyl group, a thiazolyl group, a pyrazolyl group, an isoxazolyl group, a pyridyl group, a pyridazinyl group, a pyrimidinyl group, or a pyrazinyl group; One option is R L1 and R 9 together with the atom to which it is linked, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be A3 and in some embodiments, R L1 and R 9 together with the atoms to which it is attached form a 5- to 6-membered cycloalkyl group, said cycloalkyl group optionally being selected from R A3 and in some embodiments, R L1 and R 9 forms a cyclopentyl group or a cyclohexyl group together with the atom to which it is linked, One option is R L2 and R 9 together with the atom to which it is linked, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be A3 and in some embodiments, R L2 and R 9 together with the atoms to which it is attached form a 5- to 6-membered cycloalkyl group, said cycloalkyl group optionally being selected from R A3 and in some embodiments, R L2 and R 9 forms a cyclopentyl group or a cyclohexyl group together with the atom to which it is linked, Each R A3 are each independently =O, halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 In some embodiments, each R A3 are independently =O, F, Cl, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 In some embodiments, each R A3are each independently =O, F, Cl, deuterium, CN, OH, a methyl group, an ethyl group, -CH2F, -CHF2, -CF3, -CH2CH2F, -CH2CHF2, -CH2CF3, -CHFCH2F, -CHFCHF2, -CHFCF3, -CF2CH2F, -CF2CHF2, -CF2CF3, -CH2D, -CHD2, -CD3, -CH2CH2D, -CH2CHD2, -CH2CD3, -CHDCH2D, -CHDCHD2, -CHDCD3, -CD2CH2D, -CD2CHD2, -CD2CD3, a methoxy group, the group substitutions are selected from ethoxy groups, -OCHF, -OCHFF, -OCF, -OCHCHF, -OCHCHF, -OCHCF, -OCHFCHF, -OCHFCHF, -OCHFCF, -OCFCHF, -OCFCHF, -OCFCF, -OCHD, -OCHD, -OCD, -OCHCHD, -OCHCHD, -OCHCD, -OCHDCHD, -OCHDCHD, -OCHDCD, -OCDCHD, -OCDCHD, -OCDCD, and NH; R 11a , R 11b , R 12a , R 12b are independently H, deuterium, OH, and C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 Alkoxy group, C 3-6 cycloalkyl groups, or R 11a , R 11b , R 12a , R 12b Any two of these, together with the atoms connecting them, are C 3-6 Forming a cycloalkyl group, optionally ═O, [ka] Halogens, deuterium, CN, OH, C 1-3 Alkyl group, halo C 1-3 Alkyl groups, deuterated C 1-3 Alkyl group, C1-3 Alkoxy group, haloC 1-3 Alkoxy group, deuterated C 1-3 is further substituted with 1 to 3 groups selected from an alkoxy group; In some embodiments, R 11a , R 11b , R 12a , R 12b are independently H, deuterium, OH, and C 1-3 Alkyl group, halo C 1-3 alkyl group, or R 11a and R 11b , or R 12a and R 12b are C together with the atoms connected to them. 3-6 forming a cycloalkyl group, In some embodiments, R 11a , R 11b , R 12a , R 12b are independently H, deuterium, OH, and C 1-3 Alkyl group, halo C 1-3 alkyl group, or R 11a and R 11b , or R 12a and R 12b together with the atoms to which they are attached form a cyclopropyl group, As a condition, R 6 and R 10 , R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these together with the atom connecting them forms a 4- to 8-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and the carbocyclic ring, the heterocycloalkyl group may optionally be ═O, [ka] Halogens, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted by 1 to 3 groups selected from an alkoxy group, a 5 to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, a 5 to 7-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and NH; In some embodiments, the compounds described herein satisfy at least one of the following conditions: The compounds described herein satisfy one, two, three, or four of the following conditions: (1). R 1 , R 2 and R 3 At least one group of R A1 is selected from (2). R 4 and R 5 At least one group of 3-10 Cycloalkyl groups, C 2-6 Alkenyl group, C 2-6 alkynyl groups, (3). R 4 , R 5 together with the atom to which it is linked, form a 5- to 7-membered monocyclic carbocycle or a 5- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be A3 and R 1 is R A1 or -O-HaloC 1-4 alkyl groups, (4). R 6 , R 7 , R 8 , R 9 , R 10 At least one group of R A2 or R 6 and R 10 , R 10 and R 7 , R 7 and R 8 , R 8 and R 9A pair of these, together with the atoms connected thereto, forms a 4- to 7-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, or an 8-membered carbocyclic ring, or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the carbocyclic ring, the heterocycloalkyl group, optionally contains ═O, a halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; (5). R 2 , R 4 L1, together with the atom to which it is linked, forms a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be selected from R A3 and R 1 is not a heterocycloalkyl group, (6). L1 is O, NH, S, -CD2-, -CHD-, -CR L1 R L2 -, C 1-4 alkyl group, —C(O)—, S(O), S(O)2, said alkyl group optionally being selected from R L1 is further substituted with (7). L2 is O, NH, S, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, -C(O)-, S(O), S(O)2; (8). R A4 is -CH2-CR A4c =CR A4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , L3-R A4’ or —CH(C 1-2 Alkyl)-CR A4c =CRA4a R A4b , -C(C 1-2 Alkyl)2-CR A4c =CR A4a R A4b is selected from (9). X1 is selected from S; (10). R L2 and R 9 together with the atom to which it is linked, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be A3 is further substituted with 1 to 3 groups selected from In some embodiments, the compounds described herein satisfy at least one of the following conditions: In some embodiments, the compounds described herein satisfy one, two, three, or four of the following conditions: (1). R 1 , R 2 and R 3 At least one group of R A1 is selected from (2). R 4 and R 5 At least one group of 3-10 Cycloalkyl groups, C 2-6 Alkenyl group, C 2-6 alkynyl groups, (3). R 4 , R 5 together with the atom to which it is linked, form a 5- to 7-membered monocyclic carbocycle or a 5- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be A3 and R 1 is R A1 or -O-HaloC 1-4 alkyl groups, (4). R 6 , R 7 , R 8 , R 9 , R 10 At least one group of R A2 is selected from (5). R 2 , R 4 L1, together with the atom to which it is linked, forms a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be selected from R A3 and R 1 is not a heterocycloalkyl group, (6). L1 is O, NH, S, -CD2-, -CHD-, -CR L1 R L2 -, C 1-4 alkyl group, —C(O)—, S(O), S(O)2, said alkyl group optionally being selected from R L1 is further substituted with (7). L2 is O, NH, S, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, -C(O)-, C 2-4 alkyl group, S(O), S(O)2, and the alkyl group is selected from 1 to 3 R L1 is replaced by (8). R A4 is -CH2-CR A4c =CR A4a R A4b , L3-R A4’ or —CH(C 1-2 Alkyl)-CR A4c =CR A4a R A4b , -C(C 1-2 Alkyl)2-CR A4c =CR A4a R A4b is selected from (9). X1 is selected from S.

[0006] The compounds described herein satisfy at least one of the following conditions, and in some embodiments, the compounds described herein satisfy one, two, three, or four of the following conditions: (1). R 1 , R 2 and R3 At least one group of R A1 is selected from (2). R 4 and R 5 At least one group of 3-10 Cycloalkyl groups, C 2-6 Alkenyl group, C 2-6 alkynyl groups, (3). R 4 , R 5 together with the atom to which it is linked, form a 5- to 7-membered monocyclic carbocycle or a 5- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be A3 and R 1 is R A1 or -O-HaloC 1-4 alkyl groups, (4). R 6 , R 7 , R 8 , R 9 , R 10 At least one group of R A2 or R 6 and R 10 , R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these, together with the atoms connected thereto, forms a 4- to 7-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, or an 8-membered carbocyclic ring, or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the carbocyclic ring, the heterocycloalkyl group, optionally contains ═O, a halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; (5). R2 , R 4 L1, together with the atom to which it is linked, forms a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be selected from R A3 and R 1 is not a heterocycloalkyl group, (6). L1 is O, NH, S, -CD2-, -CHD-, -CR L1 R L2 -, C 1-4 alkyl group, —C(O)—, S(O), S(O)2, said alkyl group optionally being selected from R L1 is further substituted with (7). L2 is O, NH, S, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, -C(O)-, S(O), S(O)2; (8). R A4 is -CH2-CH=CR A4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , L3-R A4’ or —CH(C 1-2 Alkyl)-CR A4c =CR A4a R A4b , -C(C 1-2 Alkyl)2-CR A4c =CR A4a R A4b is selected from (9). X1 is selected from S; (10). R L2 and R 9 together with the atom to which it is linked, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be A3 is further substituted with 1 to 3 groups selected from In some embodiments, the compounds described herein satisfy at least one of the following conditions: In some embodiments, the compounds described herein satisfy one, two, three, or four of the following conditions: (1). R 1 , R 2 and R 3 At least one group of R A1 is selected from (2). R 4 and R 5 At least one group of 3-10 Cycloalkyl groups, C 2-6 Alkenyl group, C 2-6 alkynyl groups, (3). R 4 , R 5 together with the atom to which it is linked, form a 5- to 7-membered monocyclic carbocycle or a 5- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be A3 and R 1 is R A1 or -O-HaloC 1-4 alkyl groups, (4). R 6 , R 7 , R 8 , R 9 , R 10 At least one group of R A2 is selected from (5). R 2 , R 4 L1, together with the atom to which it is linked, forms a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be selected from R A3 and R 1 is not a heterocycloalkyl group, (6). L1 is O, NH, S, -CD2-, -CHD-, -CR L1 R L2 -, C 1-4alkyl group, —C(O)—, S(O), S(O)2, said alkyl group optionally being selected from R L1 is further substituted with (7). L2 is O, NH, S, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, -C(O)-, C 2-4 alkyl group, S(O), S(O)2, and the alkyl group is selected from 1 to 3 R L1 is replaced by (8). R A4 is -CH2-CH=CR A4a R A4b , L3-R A4’ or —CH(C 1-2 Alkyl)-CR A4c =CR A4a R A4b , -C(C 1-2 Alkyl)2-CR A4c =CR A4a R A4b is selected from (9). X1 is selected from S; In some embodiments, the compounds described herein satisfy at least one of the following conditions: In some embodiments, the compounds described herein satisfy one, two, three, or four of the following conditions: (1). R 1 , R 2 and R 3 At least one group of R A1 is selected from (2). R 4 and R 5 at least one group selected from the group consisting of C 3-7 Cycloalkyl groups, C 2-4 Alkenyl group, C 2-4 alkynyl groups, (3). R 7 , R 8 At least one group of R A2 is selected from (4). L2 is -CR L1 R L2-, -CHR L2 -,-CDR L2 -, -C(O)-, (5). R 7 and R 8 , R 8 and R 9 A pair of these together with the atoms connected thereto form a 4- to 7-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, or an 8-membered carbocyclic ring or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the carbocyclic ring or heterocycloalkyl group may optionally be ═O, a halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; In some embodiments, the compounds described herein satisfy at least one of the following conditions: In some embodiments, the compounds described herein satisfy one, two, three, or four of the following conditions: (1). R 1 , R 2 and R 3 At least one group of R A1 is selected from (2). R 7 , R 8 At least one group of R A2 is selected from (3). R 7 and R 8 , R 8 and R 9 A pair of these, together with the atoms connected thereto, forms a 4- to 7-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, or an 8-membered carbocyclic ring or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the carbocyclic ring or heterocycloalkyl group may optionally be ═O, a halogen, deuterium, CN, OH, C1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; In some embodiments, the compounds described herein satisfy at least one of the following conditions: In some embodiments, the compounds described herein satisfy one, two, three, or four of the following conditions: (1). R 7 , R 8 At least one group of R A2 is selected from (2). R 4 and R 5 At least one group of 3-10 Cycloalkyl groups, C 2-6 Alkenyl group, C 2-6 alkynyl groups, (3). R 4 , R 5 together with the atom to which it is linked, form a 5- to 7-membered monocyclic carbocycle or a 5- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be A3 is further substituted with 1 to 3 groups selected from (4). R 2 , R 4 together with the atom to which it is linked, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be A3 is further substituted with 1 to 3 groups selected from (5). L2 is -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, -C(O)-, C 2-4 alkyl groups, wherein the alkyl groups are selected from 1 to 3 R L1 is replaced by (6). R7 and R 8 , R 8 and R 9 A pair of these together with the atoms connected thereto form a 4- to 7-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, or an 8-membered carbocyclic ring or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the carbocyclic ring or heterocycloalkyl group may optionally be ═O, a halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; In some embodiments, the compounds described herein satisfy at least one of the following conditions: In some embodiments, the compounds described herein satisfy one, two, three, or four of the following conditions: (1). R 1 is R A1 is selected from (2). R 4 and R 5 wherein at least one group is selected from a cyclopropyl group, a vinyl group, and an ethynyl group; (3). R 4 , R 5 forms, together with the atom to which it is linked, a phenyl group, a cyclohexyl group, a cyclopentyl group, a thienyl group, a furyl group, a pyrrolyl group, a pyrazolyl group, or an isoxazolyl group; (4). R 7 , R 8 At least one group of R A2 is selected from (5). R 2 , R 4 L1 together with the atom to which it is linked forms a cyclohexyl group or a phenyl group; (6). L1 is selected from O; (7) L2 is selected from -C(O)-, -CHF-, -CF2-, and -C(CH3)2-; (8). R 7 and R 8 , R 8 and R 9 A pair of these together with the atoms connected thereto form a 4- to 7-membered carbocyclic ring or an 8-membered carbocyclic ring or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the carbocyclic ring, heterocycloalkyl group may optionally be substituted with ═O, F, Cl, deuterium, OH, C 1-2 Alkyl group, halo C 1-2 is further substituted with 1 to 3 groups selected from alkyl groups, In some embodiments, R 6 and R 10 , R 10 and R 7 , R 7 and R 8 , R 8 and R 9 One pair of C together with the atoms connected to them 4-8 A cycloalkyl group or a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si is formed, and the cycloalkyl group or heterocycloalkyl group optionally has ═O, [ka] Halogens, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted by 1 to 3 groups selected from an alkoxy group, a 5 to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, a 5 to 7-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and NH; In some embodiments, R 6 and R 10 , R 10 and R 7 , R7 and R 8 , R 8 and R 9 One pair of C together with the atoms connected to them 4-6 Monocyclic cycloalkyl groups, C 6-8 Bicyclic Bridged Cycloalkyl Groups, C 6-8 Bicyclic fused cycloalkyl groups, C 6-8 Bicyclic spirocycloalkyl groups, 5-7 membered heterocycloalkyl groups containing one Si heteroatom, said cycloalkyl group, heterocycloalkyl group optionally containing 1-3 =O, [ka] Halogens, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with a group selected from an alkoxy group and NH; In some embodiments, R 6 and R 10 , R 10 and R 7 , R 7 and R 8 , R 8 and R 9 One pair of C together with the atoms connected to them 4-6 forming a monocyclic cycloalkyl group, said cycloalkyl group optionally being selected from the group consisting of ═O, [ka] Halogens, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; In some embodiments, R7 and R 8 are C together with the atoms connected to them. 4-8 forming a cycloalkyl group, said cycloalkyl group optionally being selected from the group consisting of ═O, [ka] Halogens, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted by 1 to 3 groups selected from an alkoxy group, a 5 to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, a 5 to 7-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and NH; In some embodiments, R 7 and R 8 are C together with the atoms connected to them. 4-6 Monocyclic cycloalkyl groups, C 6-8 Bicyclic Bridged Cycloalkyl Groups, C 6-8 Bicyclic fused cycloalkyl groups, C 6-8 forming a bicyclic spirocycloalkyl group, said cycloalkyl group optionally being selected from the group consisting of: ═O, [ka] Halogens, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; In some embodiments, R 7 and R 8 are C together with the atoms connected to them. 4-6forming a monocyclic cycloalkyl group, said cycloalkyl group optionally being selected from the group consisting of ═O, [ka] Halogens, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; In some embodiments, R 6 and R 10 , R 10 and R 7 , R 7 and R 8 , R 8 and R 9

[0049] One set of the following, together with the atoms connected thereto, is a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cyclobutenyl group, a cyclopentenyl group, a cyclohexenyl group, [ka] and optionally halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; In some embodiments, R 7 and R 8 together with the atom connected thereto, represents a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cyclobutenyl group, a cyclopentenyl group, a cyclohexenyl group, [ka] and optionally halogen, deuterium, CN, OH, C 1-3Alkyl group, halo C 1-3 Alkyl groups, deuterated C 1-3 Alkyl group, C 1-3 Alkoxy group, haloC 1-3 Alkoxy group, deuterated C 1-3 It is further substituted with 1 to 3 groups selected from an alkoxy group and NH2.

[0007] Specifically, in the first technical solution, the present invention provides a compound represented by formula (I) or (Ia), a stereoisomer, a deuterated product, a solvate, or a pharmaceutically acceptable salt thereof: [ka] During the ceremony, R 1 , R 2 , R 3 are each independently H, deuterium, or R A1 , -O-HaloC 1-4 Alkyl group, -NH-haloC 1-4 Alkyl group, -OC 1-4 Alkyl group, C 1-4 Alkoxy group, C 5-6 Alkoxy group, halogen, cyano group, nitro group, C 1-4 Alkyl group, C 2-6 Alkenyl group, -NH-C 1-4 Alkyl group, -N(C 1-4 alkyl)2, -NH-C 3-10 Cycloalkyl groups, -NHC(O)C 1-4 The alkyl group, alkoxy group, cycloalkyl group, and heterocycloalkyl group are optionally selected from alkyl groups and 4 to 10-membered heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, and the ... halogen atoms, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl group, deuterium group C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterium group C 1-4 Alkoxy group, C 3-10It is further substituted with a group selected from a cycloalkyl group, a 4- to 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, a phenyl group, and NH, with the proviso that R 1 , R 2 and R 3 are not simultaneously selected from H, R A1 is Haro C 2-6 Alkenyl group, C 2-6 Alkynyl group, -O-(CH2) r -R a , C 3-10 a cycloalkyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C 1-4 Alkyl-R a , -C 1-4 Alkyl-OR a , -C 1-4 Alkyl-NR b R a , -NR b -S(O)2-R a , -NR b -S(O)2-NR b R a , -O-NR b R a , -NH-OR b or -Se-(CH2) r -R a wherein the alkynyl, heteroaryl, alkyl or cycloalkyl group is optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R a CN, Halo C 1-6 Alkyl group, C 3-10a cycloalkyl group, a 4- to 10-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 6- to 10-membered aryl group; a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C(O)-R a1 wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally selected from halogen, ═O, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R b are H, deuterium, and C 1-4 Alkyl group, C 3-6 Cycloalkyl groups, haloC 1-4 Alkyl groups, deuterated C 1-4 alkyl groups, R a1 are OH, NH2, -NHC 1-4 Alkyl group, -N(C 1-4 alkyl)2, -NHC 3-10 Cycloalkyl groups, C 1-4 Alkoxy group, C 1-6 Alkyl group, C 3-10 selected from a cycloalkyl group, a 6- to 10-membered aryl group, and a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; X is CR 10 or N, X1 is selected from O and S; R 4 , R 5 are independently H, deuterium, and C 3-10 Cycloalkyl groups, C 2-6 Alkenyl group, C 2-6 Alkynyl group, halogen, amino group, -NH-C 1-4 Alkyl group, -N(C 1-4 Alkyl)2, C 1-4 Alkyl group, halo C1-4 an alkyl group, a 4- to 10-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; and a 6- to 10-membered aryl group; R 6 , R 7 , R 8 , R 9 , R 10 are each independently H, deuterium, or R A2 , halogen, OH, CN, amino group, C 1-4 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 1-4 Alkoxy group, haloC 1-4 Alkyl group, -NH-C 1-4 Alkyl group, -N(C 1-4 alkyl)2, -S(O)R c , -S(O) 2 R c , -C(O)R c , -C(O)OR c , -C(O)N(R c )2, -OC(O)R c The alkyl, alkenyl, alkynyl, and alkoxy groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; R A2 is -(CH2) r -(4- to 10-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from N, O, S, and Si), or -(CH) r -(5-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -P(O)(R c )2, -Si(R c )3, -SF5, N3, B(OH)2, or -S(O)(=NH)Rc The heterocycloalkyl and heteroaryl groups are optionally selected from halogen, ═O, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, C 3-6 Cycloalkyl groups, 4- to 7-membered heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R c are independently H, OH, C 1-4 Alkyl group, C 3-7 Cycloalkyl groups, haloC 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 an alkoxy group, or NH2; each r is independently selected from 0, 1, 2, or 3; L1 is a bond, O, NH, S, -CD2-, -CHD-, -CR L1 R L2 -, C 1-4 alkyl group, —C(O)—, S(O), S(O)2, said alkyl group optionally being selected from R L1 is further substituted with L2 is O, NH, S, -CH2-, -CD2-, -CHD-, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, C 2-4 alkyl group, -C(O)-, S(O), S(O)2, said alkyl group optionally having 1 to 3 R L1 is further substituted with R A4 is -CH2-C 1-4 Alkyl-C 3-6 Cycloalkyl groups, -CH2-CR A4c =CRA4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , -CH(C 1-2 Alkyl)-CR A4c =CR A4a R A4b , -C(C 1-2 Alkyl)2-CR A4c =CR A4a R A4b , L3-R A4’ is selected from R A4c H, halogens, deuterium, CN, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 selected from an alkoxy group and NH; R A4a , R A4b is a 3- to 6-membered monocyclic carbocyclic ring together with the carbon atom to which it is attached, C 7-10 Spirocyclic carbocycle, C 7-10 Bridged cyclic carbocycle, C 7-10 Form a fused ring carbocycle, a 6-membered fused ring carbocycle, or a 4- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be halogen, ═O, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, -COC 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 substituted with 1 to 3 groups selected from an alkoxy group and NH2; and L3 is C 3-6 Cycloalkyl group, or -CH(C 1-2 Alkyl)-C 1-4 alkyl group, wherein the cycloalkyl group is optionally selected from 1 to 3 R L3 is replaced by Each R L3are independently halogen, =O, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, -COC 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 selected from an alkoxy group and NH; Optionally, two R on adjacent ring atoms L3 form, together with the atom(s) connecting thereto, a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O and S, R A4’ is H, C 3-6 a cycloalkyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S, or a 4- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, and the cycloalkyl group, heteroaryl group, and heterocycloalkyl group may optionally be selected from halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; R L1 , R L2 are each independently a halogen, OH, CN, an amino group, or C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 a cycloalkyl group, a 4- to 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; One option is R 2 , R 4 L1, together with the atom to which it is linked, forms a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be selected from R A3is further substituted with 1 to 3 groups selected from One option is R 4 , R 5 together with the atom to which it is linked, form a 5- to 7-membered monocyclic carbocycle or a 5- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be A3 and substituted with 1 to 3 groups selected from One option is R L2 and R 9 together with the atom to which it is linked, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be A3 further substituted with 1 to 3 groups selected from: One option is R 6 and R 10 , R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these together with the atoms connected thereto form a 4- to 7-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, or an 8-membered carbocyclic ring or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the carbocyclic ring or heterocycloalkyl group may optionally be ═O, a halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R A3 are each independently =O, halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C1-4 selected from alkoxy and NH group substitutions; As a condition, the compound satisfies at least one of the following conditions: (1). R 1 , R 2 and R 3 At least one group of R A1 is selected from (2). R 4 and R 5 At least one group of 3-10 Cycloalkyl groups, C 2-6 Alkenyl group, C 2-6 alkynyl groups, (3). R 4 , R 5 together with the atom to which it is linked, form a 5- to 7-membered monocyclic carbocycle or a 5- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be A3 and R 1 is R A1 or -O-HaloC 1-4 alkyl groups, (4). R 6 , R 7 , R 8 , R 9 , R 10 At least one group of R A2 or R 6 and R 10 , R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these together with the atoms connected thereto form a 4- to 7-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, or an 8-membered carbocyclic ring or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the carbocyclic ring or heterocycloalkyl group may optionally be ═O, a halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; (5). R 2 , R 4 L1, together with the atom to which it is linked, forms a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be selected from R A3 and R 1 is not a heterocycloalkyl group, (6). L1 is O, NH, S, -CD2-, -CHD-, -CR L1 R L2 -, C 1-4 alkyl group, —C(O)—, S(O), S(O)2, said alkyl group optionally being selected from R L1 is further substituted with (7). L2 is O, NH, S, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, -C(O)-, S(O), S(O)2; (8). R A4 is -CH2-CR A4c =CR A4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , L3-R A4’ , -CH(C 1-2 Alkyl)-CR A4c =CR A4a R A4b , -C(C 1-2 Alkyl)2-CR A4c =CR A4a R A4b is selected from (9). X1 is selected from S; (10). R L2 and R 9together with the atom to which it is linked, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be A3 It is further substituted with 1 to 3 groups selected from:

[0008] As an alternative to the first technical solution of the present invention, there is provided a compound represented by formula (I) or (Ia), a stereoisomer, a deuterated product, a solvate, or a pharmaceutically acceptable salt thereof, [ka] In the formula, R 1 , R 2 , R 3 are each independently H, deuterium, or R A1 , -O-HaloC 1-4 Alkyl group, -NH-haloC 1-4 Alkyl group, -OC 1-4 Alkyl group, C 1-4 Alkoxy group, halogen, cyano group, nitro group, C 1-4 Alkyl group, C 2-6 Alkenyl group, -NH-C 1-4 Alkyl group, -N(C 1-4 alkyl)2, -NH-C 3-10 Cycloalkyl groups, -NHC(O)C 1-4 alkyl groups, or 4-10 membered heterocycloalkyl groups containing 1-3 heteroatoms selected from N, O, and S, or C 5-6 alkoxy groups, wherein the alkyl, alkoxy, cycloalkyl, and heterocycloalkyl groups are optionally selected from halogen, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 Alkoxy group, C 3-10It is further substituted with 1 to 3 groups selected from a cycloalkyl group, a 4 to 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, a phenyl group, and NH, with the proviso that R 1 , R 2 and R 3 are not simultaneously selected from H, R A1 is Haro C 2-6 Alkenyl group, C 2-6 an alkynyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C 1-4 Alkyl-R a , -C 1-4 Alkyl-OR a , -C 1-4 Alkyl-NR b R a , -NR b -S(O)2-R a , -NR b -S(O)2-NR b R a or R A1 is -O-NR b R a , -NH-OR b The alkynyl, heteroaryl, and alkyl groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R a CN, Halo C 1-6 Alkyl group, C 3-10 a cycloalkyl group, a 4- to 10-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 6- to 10-membered aryl group; a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C(O)-R a1wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally selected from halogen, ═O, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R b are H, deuterium, and C 1-4 Alkyl group, C 3-6 Cycloalkyl groups, haloC 1-4 Alkyl groups, deuterated C 1-4 alkyl groups, R a1 are OH, NH2, -NHC 1-4 Alkyl group, -N(C 1-4 alkyl)2, -NHC 3-10 Cycloalkyl groups, C 1-4 Alkoxy group, C 1-6 Alkyl group, C 3-10 selected from a cycloalkyl group, a 6- to 10-membered aryl group, and a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; X is CR 10 or N, X1 is selected from O and S; R 4 , R 5 are independently H, deuterium, and C 3-10 Cycloalkyl groups, C 2-6 Alkenyl group, C 2-6 Alkynyl group, halogen, amino group, -NH-C 1-4 Alkyl group, -N(C 1-4 Alkyl)2, C 1-4 Alkyl group, halo C 1-4 an alkyl group, a 4- to 10-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; and a 6- to 10-membered aryl group; R 6 , R 7 , R 8 , R 9 , R 10 are each independently H, deuterium, or R A2 , halogen, OH, CN, amino group, C 1-4 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 1-4 Alkoxy group, haloC 1-4 Alkyl group, -NH-C 1-4 Alkyl group, -N(C 1-4 alkyl)2, -S(O)R c , -S(O) 2 R c , -C(O)R c , -C(O)OR c , -C(O)N(R c )2, -OC(O)R c The alkyl, alkenyl, alkynyl, and alkoxy groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; R A2 is -(CH2) r -(4- to 10-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from N, O, S, and Si), or -(CH) r -(5-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -P(O)(R c )2, -Si(R c )3, -SF5, N3, B(OH)2, or -S(O)(=NH)R c The heterocycloalkyl and heteroaryl groups are optionally selected from halogen, ═O, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, C 3-6 Cycloalkyl groups, 4- to 7-membered heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R c are independently H, OH, C 1-4 Alkyl group, C 3-7 Cycloalkyl groups, haloC 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 an alkoxy group, or NH2; each r is independently selected from 0, 1, 2, or 3; L1 is a bond, O, NH, S, -CD2-, -CHD-, -CR L1 R L2 -, C 1-4 alkyl group, —C(O)—, S(O), S(O)2, said alkyl group optionally being selected from R L1 is further substituted with L2 is O, NH, S, -CH2-, -CD2-, -CHD-, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, C 2-4 alkyl group, -C(O)-, S(O), S(O)2, said alkyl group optionally having 1 to 3 R L1 is further substituted with R A4 is -CH2-C 1-4 Alkyl-C 3-6 Cycloalkyl groups, -CH2-CR A4c =CR A4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , L3-R A4’ or —CH(C 1-2Alkyl)-CR A4c =CR A4a R A4b , -C(C 1-2 Alkyl)2-CR A4c =CR A4a R A4b or R A4 is -CH2-C 1-4 Alkyl-C 3-6 Cycloalkyl groups, -CH2-CF=CR A4a R A4b , -CH2-C(CH3)=CR A4a R A4b , -CH2-CH=CR A4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , L3-R A4’ or -CHCH3-CH=CR A4a R A4b , -C(C 1-2 alkyl)2-CH=CR A4a R A4b , -CH2-C(CN)=CR A4a R A4b or R A4 is -CH2-C 1-4 Alkyl-C 3-6 Cycloalkyl groups, -CH2-CH=CR A4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , L3-R A4’ or -CHCH3-CH=CR A4a R A4b is selected from R A4c H, halogens, deuterium, CN, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 selected from an alkoxy group and NH; R A4a , R A4bis a 3- to 6-membered monocyclic carbocyclic ring together with the carbon atom to which it is attached, C 7-10 Spirocyclic carbocycle, C 7-10 Bridged cyclic carbocycle, C 7-10 Form a fused carbocycle, or a 4- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, or a 6-membered fused carbocycle, wherein the carbocycle or heterocycle optionally contains halogen, ═O, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, -COC 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 substituted with 1 to 3 groups selected from an alkoxy group and NH; L3 is C 3-6 Cycloalkyl group, or -CH(C 1-2 Alkyl)-C 1-4 alkyl group, wherein the cycloalkyl group is optionally selected from 1 to 3 R L3 is replaced by Each R L3 are independently halogen, =O, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, -COC 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 selected from an alkoxy group and NH; Optionally, two R on adjacent ring atoms L3 form, together with the atom(s) connecting thereto, a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O and S, R A4’ is H, C 3-6a cycloalkyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S, or a 4- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, and the cycloalkyl group, heteroaryl group, and heterocycloalkyl group may optionally be selected from halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; R L1 , R L2 are each independently a halogen, OH, CN, an amino group, or C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 a cycloalkyl group, a 4- to 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; One option is R 2 , R 4 L1, together with the atom to which it is linked, forms a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be selected from R A3 is further substituted with 1 to 3 groups selected from One option is R 4 , R 5 together with the atom to which it is linked, form a 5- to 7-membered monocyclic carbocycle or a 5- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be A3 and substituted with 1 to 3 groups selected from One option is R L2 and R 9 together with the atom to which it is linked, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be A3further substituted with 1 to 3 groups selected from: One option is R 6 and R 10 , R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these together with the atoms connected thereto form a 4- to 7-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, or an 8-membered carbocyclic ring, and the carbocyclic ring or heterocycloalkyl group may optionally be ═O, a halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R A3 are each independently =O, halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 selected from alkoxy and NH group substitutions; As a condition, the compound satisfies at least one of the following conditions: (1). R 1 , R 2 and R 3 At least one group of R A1 is selected from (2). R 4 and R 5 At least one group of 3-10 Cycloalkyl groups, C 2-6 Alkenyl group, C 2-6 alkynyl groups, (3). R 4 , R 5together with the atom to which it is linked, form a 5- to 7-membered monocyclic carbocycle or a 5- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be A3 and R 1 is R A1 or -O-HaloC 1-4 alkyl groups, (4). R 6 , R 7 , R 8 , R 9 , R 10 At least one group of R A2 or R 6 and R 10 , R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these, together with the atoms connected thereto, forms a 4- to 7-membered carbocyclic ring or a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, and the carbocyclic ring or heterocycloalkyl group may optionally be ═O, halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; (5). R 2 , R 4 L1, together with the atom to which it is linked, forms a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be selected from R A3 and R 1 is not a heterocycloalkyl group, (6). L1 is O, NH, S, -CD2-, -CHD-, -CR L1 R L2 -, C 1-4alkyl group, —C(O)—, S(O), S(O)2, said alkyl group optionally being selected from R L1 is further substituted with (7). L2 is O, NH, S, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, -C(O)-, S(O), S(O)2; (8). R A4 is -CH2-CF=CR A4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , L3-R A4’ or -CHCH3-CH=CR A4a R A4b , -CH2-C(CN)=CR A4a R A4b , -CH(CH2CH3)-CH=CR A4a R A4b , -C(CH3)2-CH=CR A4a R A4b , -C(CH2CH3)2-CH=CR A4a R A4b or R A4 is -CH2-C(CH3)=CR A4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , L3-R A4’ or -CHCH3-CH=CR A4a R A4b or R A4 is -CH2-CH=CR A4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , L3-R A4’ or -CHCH3-CH=CR A4a R A4b is selected from (9). X1 is selected from S; (10). R L2 and R 9together with the atom to which it is linked, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be A3 It is further substituted with 1 to 3 groups selected from:

[0009] As an alternative to the first technical solution of the present invention, there is provided a compound represented by formula (I) or (Ia), a stereoisomer, a deuterated product, a solvate, or a pharmaceutically acceptable salt thereof, [ka] During the ceremony, R 1 , R 2 , R 3 are each independently H, deuterium, or R A1 , -O-HaloC 1-4 Alkyl group, -NH-haloC 1-4 Alkyl group, -OC 1-4 Alkyl group, C 1-4 Alkoxy group, halogen, cyano group, nitro group, OH, C 1-4 Alkyl group, C 2-6 Alkenyl group, -NH-C 1-4 Alkyl group, -N(C 1-4 alkyl)2, -NH-C 3-10 Cycloalkyl groups, -NHC(O)C 1-4 alkyl groups, or 4-10 membered heterocycloalkyl groups containing 1-3 heteroatoms selected from N, O, and S, or C 5-6 alkoxy groups, wherein the alkyl, alkoxy, cycloalkyl, and heterocycloalkyl groups are optionally selected from halogen, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 Alkoxy group, C 3-10It is further substituted with 1 to 3 groups selected from a cycloalkyl group, a 4 to 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, a phenyl group, and NH, with the proviso that R 1 , R 2 and R 3 are not simultaneously selected from H, R A1 is Haro C 2-6 Alkenyl group, C 2-6 an alkynyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C 1-4 Alkyl-R a , -C 1-4 Alkyl-OR a , -C 1-4 Alkyl-NR b R a , -NR b -S(O)2-R a , -NR b -S(O)2-NR b R a or R A1 is -O-NR b R a , -NH-OR b The alkynyl, heteroaryl, and alkyl groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R a CN, Halo C 1-6 Alkyl group, C 3-10 a cycloalkyl group, a 4- to 10-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 6- to 10-membered aryl group; a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C(O)-R a1wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally selected from halogen, ═O, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R b are H, deuterium, and C 1-4 Alkyl group, C 3-6 Cycloalkyl groups, haloC 1-4 Alkyl groups, deuterated C 1-4 alkyl groups, R a1 are OH, NH2, -NHC 1-4 Alkyl group, -N(C 1-4 alkyl)2, -NHC 3-10 Cycloalkyl groups, C 1-4 Alkoxy group, C 1-6 Alkyl group, C 3-10 selected from a cycloalkyl group, a 6- to 10-membered aryl group, and a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; X is CR 10 or N, X1 is selected from O and S; R 4 , R 5 are independently H, deuterium, and C 3-10 Cycloalkyl groups, C 2-6 Alkenyl group, C 2-6 Alkynyl group, halogen, amino group, -NH-C 1-4 Alkyl group, -N(C 1-4 Alkyl)2, C 1-4 Alkyl group, halo C 1-4 an alkyl group, a 4- to 10-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; and a 6- to 10-membered aryl group; R 6 , R 7 , R 8 , R 9 , R 10 are each independently H, deuterium, or R A2 , halogen, OH, CN, amino group, C 1-4 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 1-4 Alkoxy group, haloC 1-4 Alkyl group, -NH-C 1-4 Alkyl group, -N(C 1-4 alkyl)2, -S(O)R c , -S(O) 2 R c , -C(O)R c , -C(O)OR c , -C(O)N(R c )2, -OC(O)R c The alkyl, alkenyl, alkynyl, and alkoxy groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Or, as an option, R 7 and R 8 together with the atoms to which they are linked, form a 4- to 7-membered carbocyclic ring or a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, and the carbocyclic ring, heterocycloalkyl group may optionally be ═O, halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; RA2 is -(CH2) r -(4-10 membered heterocycloalkyl containing 1-3 heteroatoms selected from N, O, and S), or -(CH) r -(5-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -P(O)(R c )2, -Si(R c )3, -SF5, -S(O)(=NH)R c The heterocycloalkyl group and the heterocyclic aryl group are optionally selected from halogen, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R c are independently H, OH, C 1-4 Alkyl group, C 3-7 Cycloalkyl groups, haloC 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 an alkoxy group, or NH2; each r is independently selected from 0, 1, 2, or 3; L1 is a bond, O, NH, S, -CD2-, -CHD-, -CR L1 R L2 -, C 1-4 alkyl group, —C(O)—, S(O), S(O)2, said alkyl group optionally being selected from R L1 is further substituted with L2 is O, NH, S, -CH2-, -CD2-, -CHD-, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, C 2-4alkyl group, -C(O)-, S(O), S(O)2, said alkyl group optionally having 1 to 3 R L1 is further substituted with R A4 is -CH2-C 1-4 Alkyl-C 3-6 Cycloalkyl, -CH2-CH=CR A4a R A4b , L3-R A4’ or —CH(C 1-2 Alkyl)-CR A4c =CR A4a R A4b , -C(C 1-2 Alkyl)2-CR A4c =CR A4a R A4b is selected from R A4a , R A4b forms a 3- to 6-membered carbocyclic ring together with the carbon atom to which it is attached, L3 is C 3-6 Cycloalkyl groups, -CH(C 1-2 Alkyl)-C 1-4 alkyl groups, R A4’ is C 3-6 A cycloalkyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S, and the cycloalkyl group, the heteroaryl group, optionally contains halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; R L1 , R L2 are each independently a halogen, OH, CN, an amino group, or C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6a cycloalkyl group, a 4- to 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; One option is R 2 , R 4 L1, together with the atom to which it is linked, forms a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be selected from R A3 is further substituted with 1 to 3 groups selected from One option is R 4 , R 5 together with the atom to which it is linked, form a 5- to 7-membered monocyclic carbocycle or a 5- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be A3 and substituted with 1 to 3 groups selected from One option is R L1 and R 9 together with the atom to which it is linked, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be A3 is further substituted with 1 to 3 groups selected from Each R A3 are each independently =O, halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 selected from alkoxy and NH group substitutions; As a condition, the compound satisfies at least one of the following conditions: (1). R 1 , R 2 and R 3 At least one group of R A1 is selected from (2). R 4 and R 5 At least one group of 3-10Cycloalkyl groups, C 2-6 Alkenyl group, C 2-6 alkynyl groups, (3). R 4 , R 5 together with the atom to which it is linked, form a 5- to 7-membered monocyclic carbocycle or a 5- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be A3 and R 1 is R A1 or -O-HaloC 1-4 alkyl groups, (4). R 6 , R 7 , R 8 , R 9 , R 10 At least one group of R A2 is selected from (5). R 2 , R 4 L1, together with the atom to which it is linked, forms a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be selected from R A3 and R 1 is not a heterocycloalkyl group, (6). L1 is O, NH, S, -CD2-, -CHD-, -CR L1 R L2 -, C 1-4 alkyl group, —C(O)—, S(O), S(O)2, said alkyl group optionally being selected from R L1 is further substituted with (7). L2 is O, NH, S, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, -C(O)-, C 2-4 alkyl group, S(O), S(O)2, and the alkyl group is selected from 1 to 3 R L1 is replaced by (8). R A4 is -CH2-CH=CR A4aR A4b , L3-R A4’ or —CH(C 1-2 Alkyl)-CR A4c =CR A4a R A4b , -C(C 1-2 Alkyl)2-CR A4c =CR A4a R A4b is selected from (9). X1 is selected from S.

[0010] In a second technical solution of the present invention, there is provided a compound represented by formula (Ib), its stereoisomer, deuterated product, solvate, deuterated product, or pharmaceutically acceptable salt, [ka] During the ceremony, R 1 , R 2 , R 3 are each independently H, deuterium, or R A1 , -O-HaloC 1-4 Alkyl group, -NH-haloC 1-4 Alkyl group, -OC 1-4 Alkyl group, C 1-4 Alkoxy group, halogen, cyano group, nitro group, OH, C 1-4 Alkyl group, C 2-6 Alkenyl group, -NH-C 1-4 Alkyl group, -N(C 1-4 alkyl)2, -NH-C 3-10 Cycloalkyl groups, -NHC(O)C 1-4 alkyl groups, or 4-10 membered heterocycloalkyl groups containing 1-3 heteroatoms selected from N, O, and S, or C 5-6 alkoxy groups, wherein the alkyl, alkoxy, cycloalkyl, and heterocycloalkyl groups are optionally selected from halogen, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C1-4 Alkoxy group, C 3-10 It is further substituted with 1 to 3 groups selected from a cycloalkyl group, a 4 to 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, a phenyl group, and NH, with the proviso that R 1 , R 2 and R 3 are not simultaneously selected from H, R A1 is Haro C 2-6 Alkenyl group, C 2-6 an alkynyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C 1-4 Alkyl-R a , -C 1-4 Alkyl-OR a , -C 1-4 Alkyl-NR b R a , -NR b -S(O)2-R a , -NR b -S(O)2-NR b R a The alkynyl, heteroaryl, and alkyl groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R a CN, Halo C 1-6 Alkyl group, C 3-10 a cycloalkyl group, a 4- to 10-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 6- to 10-membered aryl group; a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C(O)-R a1wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally selected from halogen, ═O, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R b are H, deuterium, and C 1-4 Alkyl group, C 3-6 Cycloalkyl groups, haloC 1-4 Alkyl groups, deuterated C 1-4 alkyl groups, R a1 are OH, NH2, -NHC 1-4 Alkyl group, -N(C 1-4 alkyl)2, -NHC 3-10 Cycloalkyl groups, C 1-4 Alkoxy group, C 1-6 Alkyl group, C 3-10 selected from a cycloalkyl group, a 6- to 10-membered aryl group, and a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; X is CR 10 or N, R 4 , R 5 are independently H, deuterium, and C 3-10 Cycloalkyl groups, C 2-6 Alkenyl group, C 2-6 Alkynyl group, halogen, amino group, -NH-C 1-4 Alkyl group, -N(C 1-4 Alkyl)2, C 1-4 Alkyl group, halo C 1-4 an alkyl group, a 4- to 10-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; and a 6- to 10-membered aryl group; R 6 , R7 , R 8 , R 9 , R 10 are each independently H, deuterium, or R A2 , halogen, OH, CN, amino group, C 1-4 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 1-4 Alkoxy group, haloC 1-4 Alkyl group, -NH-C 1-4 Alkyl group, -N(C 1-4 alkyl)2, -S(O)R c , -S(O) 2 R c , -C(O)R c , -C(O)OR c , -C(O)N(R c )2, -OC(O)R c The alkyl, alkenyl, alkynyl, and alkoxy groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Or, as an option, R 7 and R 8 together with the atoms connected thereto, form a 4- to 7-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, or an 8-membered carbocyclic ring, or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the carbocyclic ring, the heterocycloalkyl group may optionally be ═O, a halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; RA2 is -(CH2) r -(4-10 membered heterocycloalkyl containing 1-3 heteroatoms selected from N, O, and S), or -(CH) r -(5-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -P(O)(R c )2, -Si(R c )3, -SF5, -S(O)(=NH)R c The heterocycloalkyl group and the heterocyclic aryl group are optionally selected from halogen, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R c are independently H, OH, C 1-4 Alkyl group, C 3-7 Cycloalkyl groups, haloC 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 an alkoxy group, or NH2; each r is independently selected from 0, 1, 2, or 3; L1 is a bond, O, NH, S, -CD2-, -CHD-, -CR L1 R L2 -, C 1-4 alkyl group, —C(O)—, S(O), S(O)2, said alkyl group optionally being selected from R L1 is further substituted with L2 is O, NH, S, -CH2-, -CD2-, -CHD-, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, C 2-4alkyl group, -C(O)-, S(O), S(O)2, said alkyl group optionally having 1 to 3 R L1 is further substituted with R L1 , R L2 are each independently a halogen, OH, CN, an amino group, or C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 a cycloalkyl group, a 4- to 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; One option is R 2 , R 4 L1, together with the atom to which it is linked, forms a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be selected from R A3 is further substituted with 1 to 3 groups selected from One option is R 4 , R 5 together with the atom to which it is linked, form a 5- to 7-membered monocyclic carbocycle or a 5- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be A3 and substituted with 1 to 3 groups selected from One option is R L1 and R 9 together with the atom to which it is linked, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be A3 is further substituted with 1 to 3 groups selected from Each R A3 are each independently =O, halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 selected from alkoxy and NH group substitutions; As a condition, the compound satisfies at least one of the following conditions: (1). R 1 , R 2 and R 3 At least one group of R A1 is selected from (2). R 4 and R 5 At least one group of 3-10 Cycloalkyl groups, C 2-6 Alkenyl group, C 2-6 alkynyl groups, (3). R 4 , R 5 together with the atom to which it is linked, form a 5- to 7-membered monocyclic carbocycle or a 5- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be A3 and R 1 is R A1 or -O-HaloC 1-4 alkyl groups, (4). R 6 , R 7 , R 8 , R 9 , R 10 At least one group of R A2 is selected from (5). R 2 , R 4 L1, together with the atom to which it is linked, forms a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be selected from R A3 and R 1 is not a heterocycloalkyl group, (6). L1 is O, NH, S, -CD2-, -CHD-, -CR L1 R L2 -, C 1-4 alkyl group, —C(O)—, S(O), S(O)2, said alkyl group optionally being selected from R L1 is further substituted with (7). L2 is O, NH, S, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, -C(O)-, C 2-4 alkyl group, S(O), S(O)2, and the alkyl group is selected from 1 to 3 R L1 is replaced by The definitions of other groups are consistent with any of the above technical proposals.

[0011] In the third technical solution of the present invention, the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt has the structure of formula (II): [ka] L2 is -CH2-, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, -C(O)-, X is CR 10 or N, R 4 , R 5 are independently H, deuterium, and C 3-7 Cycloalkyl groups, C 2-4 Alkenyl group, C 2-4 Alkynyl group, F, Cl, amino group, -NH-C 1-2 Alkyl group, -N(C 1-2 Alkyl)2, C 1-2 alkyl group, and a 4- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; R 7 , R 8 are each independently H, deuterium, or R A2 , F, Cl, OH, CN, amino group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-4 Alkoxy group, haloC 1-4 Alkyl group, -NH-C 1-2 Alkyl group, -N(C 1-2alkyl)2, -S(O)R c , -S(O) 2 R c , -C(O)R c , -C(O)OR c , -C(O)N(R c )2, -OC(O)R c is selected from R 9 , R 10 are each independently H, deuterium, F, Cl, OH, CN, amino group, C 1-2 alkyl groups, R A2 is -(CH2) r -(4-6 membered monocyclic heterocycloalkyl containing 1-3 heteroatoms selected from N, O, and S), -(CH2) r -(7-10 membered spirocyclic heterocycloalkyl containing 1-3 heteroatoms selected from N, O, and S), -(CH2) r -(5-6 membered monocyclic heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -(CH2) r -(8-10 membered bicyclic heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -P(O)(R c )2, -Si(R c )3, -SF5, -S(O)(=NH)R c The heterocycloalkyl and heteroaryl groups are optionally selected from halogen, D, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1 to 3 groups selected from an alkoxy group and NH; One option is R 7 and R 8 , R 8 and R 9A pair of these together with the atoms connected thereto form a 4- to 7-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, or an 8-membered carbocyclic ring or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the carbocyclic ring or heterocycloalkyl group may optionally be ═O, a halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; As a condition, the compound satisfies at least one of the following conditions: (1). R 1 , R 2 and R 3 At least one group of R A1 is selected from (2). R 4 and R 5 at least one group selected from the group consisting of C 3-7 Cycloalkyl groups, C 2-4 Alkenyl group, C 2-4 alkynyl groups, (3). R 7 , R 8 At least one group of R A2 is selected from (4). L2 is -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, -C(O)-, (5). R 7 and R 8 , R 8 and R 9 A pair of these together with the atoms connected thereto form a 4- to 7-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, or an 8-membered carbocyclic ring, and the carbocyclic ring or heterocycloalkyl group may optionally be ═O, a halogen, deuterium, CN, OH, C1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; The definitions of other groups are consistent with any of the above technical proposals.

[0012] As an alternative to the third technical solution of the present invention, the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt has the structure of formula (II): [ka] L2 is -CH2-, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, -C(O)-, X is CR 10 or N, R 4 , R 5 are independently H, deuterium, and C 3-7 Cycloalkyl groups, C 2-4 Alkenyl group, C 2-4 Alkynyl group, F, Cl, amino group, -NH-C 1-2 Alkyl group, -N(C 1-2 Alkyl)2, C 1-2 alkyl group, and a 4- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; R 7 , R 8 are each independently H, deuterium, or R A2 , F, Cl, OH, CN, amino group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-4 Alkoxy group, haloC 1-4 Alkyl group, -NH-C 1-2 Alkyl group, -N(C 1-2alkyl)2, -S(O)R c , -S(O) 2 R c , -C(O)R c , -C(O)OR c , -C(O)N(R c )2, -OC(O)R c is selected from Or, as an option, R 7 and R 8 together with the atoms to which they are linked, form a 4- to 7-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, or an 8-membered carbocyclic ring, and the carbocyclic ring or heterocycloalkyl group may optionally be ═O, a halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; R 9 , R 10 are each independently H, deuterium, F, Cl, OH, CN, amino group, C 1-2 alkyl groups, R A2 is -(CH2) r -(4-6 membered monocyclic heterocycloalkyl containing 1-3 heteroatoms selected from N, O, and S), -(CH2) r -(7-10 membered spirocyclic heterocycloalkyl containing 1-3 heteroatoms selected from N, O, and S), -(CH2) r -(5-6 membered monocyclic heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -(CH2) r -(8-10 membered bicyclic heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -P(O)(R c )2, -Si(R c )3, -SF5, -S(O)(=NH)R cThe heterocycloalkyl group and the heterocyclic aryl group are optionally selected from halogen, D, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1 to 3 groups selected from an alkoxy group and NH; As a condition, the compound satisfies at least one of the following conditions: (1). R 1 , R 2 and R 3 At least one group of R A1 is selected from (2). R 4 and R 5 at least one group selected from the group consisting of C 3-7 Cycloalkyl groups, C 2-4 Alkenyl group, C 2-4 alkynyl groups, (3). R 7 , R 8 At least one group of R A2 is selected from (4). L2 is -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, -C(O)-, The definitions of other groups are consistent with any of the above technical proposals.

[0013] The fourth technical solution of the present invention relates to a compound of formula (I), (II), (Ib), its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or co-crystal, wherein R 2 , R 4 L1, together with the atom to which it is connected, forms a 6- to 7-membered cycloalkyl group, a phenyl group, and the cycloalkyl group optionally includes R A3 and R 1is not a heterocycloalkyl group, and the definition of other groups is consistent with any of the above technical proposals.

[0014] The fifth technical solution of the present invention relates to the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, wherein R 4 , R 5 together with the atom to which it is linked, form a phenyl group, a 5- to 6-membered cycloalkyl group, or a 5- to 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S, and the cycloalkyl group may optionally be R A3 and R 1 is R A1 or -O-HaloC 1-4 The definition of the other groups is consistent with any of the above technical proposals.

[0015] The sixth technical solution of the present invention relates to the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, wherein R L1 and R 9 together with the atoms to which it is attached form a 5- to 6-membered cycloalkyl group, said cycloalkyl group optionally being selected from R A3 and the definitions of the other groups are consistent with any of the above technical proposals.

[0016] The seventh technical solution of the present invention relates to the compound of the present invention, its stereoisomer, deuterated salt, solvate, or pharmaceutically acceptable salt or cocrystal, wherein each R A3 are each independently =O, halogen, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 The alkoxy group and the NH2 group substitution are selected, and the definitions of other groups are consistent with any of the above technical proposals.

[0017] The eighth technical solution of the present invention relates to the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, R 2 , R 4 L1 together with the atom to which it is linked forms a 6- to 7-membered cycloalkyl group, a phenyl group or a 5- to 7-membered cycloalkyl group, and the cycloalkyl group may optionally be R A3 and R 1 is not a heterocycloalkyl group, or R 4 , R 5 together with the atom to which it is linked, form a phenyl group, a 5- to 6-membered cycloalkyl group, or a 5- to 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S, and the cycloalkyl group may optionally be R A3 and R 1 is R A1 or -O-HaloC 1-4 alkyl groups, or R L1 and R 9 together with the atoms to which it is attached form a 5- to 6-membered cycloalkyl group, said cycloalkyl group optionally being selected from R A3 is further substituted with 1 to 3 groups selected from Each R A3 are each independently =O, halogen, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 selected from alkoxy and NH group substitutions; The definitions of other groups are consistent with any of the above technical proposals.

[0018] The ninth technical solution of the present invention relates to the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, R 1 is R A1, -O-HaloC 1-4 alkyl groups, wherein the alkyl groups are optionally selected from halogen, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; R 2 , R 3 are independently H, deuterium, and C 2-4 Alkenyl group, C 2-4 Alkynyl group, halogen, cyano group, nitro group, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 alkyl groups, R A1 is Haro C 2-4 Alkenyl group, C 2-4 Alkynyl group, -O-(CH2) r -R a , C 3-6 a monocyclic cycloalkyl group, a 5- to 6-membered monocyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; an 8- to 10-membered bicyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C 1-2 Alkyl-R a , -C 1-2 Alkyl-OR a , -C 1-2 Alkyl-NR b R a , -NR b -S(O)2-R a , -NR b -S(O)2-NR b R a , -O-NR b R a , -NH-OR b or -Se-(CH2) r -Ra, wherein the alkynyl, heteroaryl, and alkyl groups are optionally selected from halogen, deuterium, CN, OH, C 1-2Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1 to 3 groups selected from an alkoxy group and NH; r is selected from 0 or 1; Each R a CN, Halo C 1-4 Alkyl group, C 3-6 Monocyclic cycloalkyl groups, C 7-10 Spirocyclic cycloalkyl groups, C 4-8 Bridged Cycloalkyl Groups, C 4-9 Fused-ring cycloalkyl groups, 4- to 6-membered monocyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, 7- to 10-membered spirocyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, 4- to 8-membered bridged cyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, 4- to 6-membered fused-ring heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, phenyl groups, 8- to 10-membered aryl groups, 5- to 6-membered monocyclic heteroaryl groups containing 1 to 3 heteroatoms selected from N, O, and S, 8- to 10-membered bicyclic heteroaryl groups containing 1 to 3 heteroatoms selected from N, O, and S, -C(O)-R a1 wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally selected from halogen, ═O, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R b are H, deuterium, and C 1-2 Alkyl group, C 3-4 cycloalkyl groups, The definitions of other groups are consistent with any of the above technical proposals.

[0019] The tenth technical solution of the present invention relates to the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, R 1 is R A1 , -O-HaloC 1-4 alkyl groups, wherein the alkyl groups are optionally selected from halogen, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; R 2 , R 3 are independently H, deuterium, and C 2-4 Alkenyl group, C 2-4 Alkynyl group, halogen, cyano group, nitro group, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 alkyl groups, R A1 is Haro C 2-4 Alkenyl group, C 2-4 an alkynyl group, a 5- to 6-membered monocyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; an 8- to 10-membered bicyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C 1-2 Alkyl-R a , -C 1-2 Alkyl-OR a , -C 1-2 Alkyl-NR b R a , -NR b -S(O)2-R a , -NR b -S(O)2-NR b R a or -O-NR b R a , -NH-ORb or -Se-(CH2) r -Ra, wherein the alkynyl, heteroaryl, and alkyl groups are optionally selected from halogen, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R a CN, Halo C 1-4 Alkyl group, C 3-6 Monocyclic cycloalkyl groups, C 7-10 Spirocyclic cycloalkyl groups, C 4-8 Bridged Cycloalkyl Groups, C 4-9 Fused-ring cycloalkyl groups, 4- to 6-membered monocyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, 7- to 10-membered spirocyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, 4- to 8-membered bridged cyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, 4- to 6-membered fused-ring heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, phenyl groups, 8- to 10-membered aryl groups, 5- to 6-membered monocyclic heteroaryl groups containing 1 to 3 heteroatoms selected from N, O, and S, 8- to 10-membered bicyclic heteroaryl groups containing 1 to 3 heteroatoms selected from N, O, and S, -C(O)-R a1 wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally selected from halogen, ═O, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R bare H, deuterium, and C 1-2 Alkyl group, C 3-4 cycloalkyl groups, The definitions of other groups are consistent with any of the above technical proposals.

[0020] In the eleventh technical solution of the present invention, the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt has the structure of formula (III): [ka] X is CR 10 or N, R 9 , R 10 are each independently H, deuterium, F, Cl, OH, CN, amino group, C 1-2 alkyl groups, As a condition, the compound satisfies at least one of the following conditions: (1). R 1 , R 2 and R 3 At least one group of R A1 is selected from (2). R 7 , R 8 At least one group of R A2 is selected from (3). R 7 and R 8 , R 8 and R 9 A pair of these together with the atoms connected thereto form a 4- to 7-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, or an 8-membered carbocyclic ring or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the carbocyclic ring or heterocycloalkyl group may optionally be ═O, a halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4further substituted with 1 to 3 groups selected from an alkoxy group and NH; The definitions of other groups are consistent with any of the above technical proposals.

[0021] In the twelfth technical solution of the present invention, the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt has the structure of formula (III): [ka] X is CR 10 or N, R 9 , R 10 are each independently H, deuterium, F, Cl, OH, CN, amino group, C 1-2 alkyl groups, As a condition, the compound satisfies at least one of the following conditions: (1). R 1 , R 2 and R 3 At least one group of R A1 is selected from (2). R 7 , R 8 At least one group of R A2 is selected from The definitions of other groups are consistent with any of the above technical proposals.

[0022] In the thirteenth technical solution of the present invention, the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt has the structure of formula (IV) or (V): [ka] X is CR 10 or N, R 9 , R 10 are each independently H, deuterium, F, Cl, OH, CN, amino group, C 1-2 alkyl groups, L2 is -CH2-, -CD2-, -CHD-, -CR L1 RL2 -, -CHR L2 -,-CDR L2 -, C 2-4 alkyl group, -C(O)-, wherein the alkyl group is optionally selected from 1 to 3 R L1 is further substituted with As a condition, the compound satisfies at least one of the following conditions: (1). R 7 , R 8 At least one group of R A2 is selected from (2). R 4 and R 5 At least one group of 3-10 Cycloalkyl groups, C 2-6 Alkenyl group, C 2-6 alkynyl groups, (3). R 4 , R 5 together with the atom to which it is linked, form a 5- to 7-membered monocyclic carbocycle or a 5- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be A3 is further substituted with 1 to 3 groups selected from (4). R 2 , R 4 together with the atom to which it is linked, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be A3 is further substituted with 1 to 3 groups selected from (5). L2 is -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, -C(O)-, C 2-4 alkyl groups, wherein the alkyl groups are selected from 1 to 3 R L1 is replaced by (6). R 7 and R 8 , R 8 and R 9A pair of these together with the atoms connected thereto form a 4- to 7-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, or an 8-membered carbocyclic ring or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the carbocyclic ring or heterocycloalkyl group may optionally be ═O, a halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; The definitions of other groups are consistent with any of the above technical proposals.

[0023] In the fourteenth technical solution of the present invention, the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt has the structure of formula (IV) or (V): [ka] X is CR 10 or N, R 9 , R 10 are each independently H, deuterium, F, Cl, OH, CN, amino group, C 1-2 alkyl groups, L2 is -CH2-, -CD2-, -CHD-, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, C 2-4 alkyl group, -C(O)-, wherein the alkyl group is optionally selected from 1 to 3 R L1 is further substituted with As a condition, the compound satisfies at least one of the following conditions: (1). R 7 , R 8 At least one group of R A2 is selected from (2). R4 and R 5 At least one group of 3-10 Cycloalkyl groups, C 2-6 Alkenyl group, C 2-6 alkynyl groups, (3). R 4 , R 5 together with the atom to which it is linked, form a 5- to 7-membered monocyclic carbocycle or a 5- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be A3 is further substituted with 1 to 3 groups selected from (4). R 2 , R 4 together with the atom to which it is linked, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be A3 is further substituted with 1 to 3 groups selected from (5). L2 is -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, -C(O)-, C 2-4 alkyl groups, wherein the alkyl groups are selected from 1 to 3 R L1 is replaced by The definitions of other groups are consistent with any of the above technical proposals.

[0024] In the fifteenth technical solution of the present invention, the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt has the structure of formula (VI), (VII), (VIII), (IX): [ka] X is CR 10 or N, L2 is -CH2-, -CD2-, -CHD-, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, C 2-4alkyl group, -C(O)-, wherein the alkyl group is optionally selected from 1 to 3 R L1 is further substituted with R 9 , R 10 are each independently H, deuterium, OH, CN, amino group, C 1-4 Alkyl group, halo C 1-4 alkyl groups, R 1 is R A1 is selected from R 2 , R 3 are independently H, deuterium, and C 2-4 Alkenyl group, C 2-4 Alkynyl group, halogen, cyano group, nitro group, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 alkyl groups, The definitions of other groups are consistent with any of the above technical proposals.

[0025] The sixteenth technical solution of the present invention relates to the compound of formula (Ia) according to the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, R A4 is -CH2-CF=CR A4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , L3-R A4’ , -CH(C 1-2 Alkyl)-CR A4c =CR A4a R A4b , -C(C 1-2 Alkyl)2-CR A4c =CR A4a R A4b , -CH2-C(CN)=CR A4a R A4b or R A4 is -CH2-C(CH3)=CR A4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , L3-RA4’ , -CH(C 1-2 Alkyl)-CR A4c =CR A4a R A4b , -C(C 1-2 Alkyl)2-CR A4c =CR A4a R A4b , -CH2-C(CN)=CR A4a R A4b or R A4 is -CH2-CH=CR A4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , L3-R A4’ , -CH(C 1-2 Alkyl)-CR A4c =CR A4a R A4b , -C(C 1-2 Alkyl)2-CR A4c =CR A4a R A4b , -CH2-C(CN)=CR A4a R A4b is selected from R A4a , R A4b represents a 4-, 5-, or 6-membered monocyclic cycloalkyl group together with the carbon atom to which it is attached, C 7-10 Spirocyclic carbocycle, C 7-10 A fused carbocycle, a 5- or 6-membered heterocyclic cycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, or a 6-membered fused carbocycle, wherein the cycloalkyl group, the heterocycloalkyl group, optionally contains halogen, ═O, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, -COC 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 substituted with 1 to 3 groups selected from an alkoxy group and NH; L3 is C 3-6 Cycloalkyl groups, -CH(C 1-2 Alkyl)-C 1-2alkyl groups, R A4’ is C 3-6 A cycloalkyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S, and the cycloalkyl group, the heteroaryl group, optionally contains halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; The definitions of other groups are consistent with any one of the above technical solutions.

[0026] The seventeenth technical solution of the present invention relates to the compound of formula (Ia) according to the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, R A4 is -CH2-CF=CR A4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , L3-R A4’ or R A4 is -CH2-C(CH3)=CR A4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , L3-R A4’ or R A4 is -CH2-CH=CR A4a R A4b , -CH2-CH=CH-CH=CR A4a R A4b , L3-R A4’ is selected from R A4a , R A4b represents a 4-, 5-, or 6-membered monocyclic cycloalkyl group together with the carbon atom to which it is attached, C 7-10 Spirocyclic carbocycle, C 7-10A fused carbocycle, a 5- or 6-membered heterocyclic cycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, or a 6-membered fused carbocycle, wherein the cycloalkyl group, the heterocycloalkyl group, optionally contains halogen, ═O, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, -COC 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1 to 3 groups selected from an alkoxy group and NH; L3 is C 3-6 Cycloalkyl groups, -CH(C 1-2 Alkyl)-C 1-2 alkyl groups, R A4’ is C 3-6 A cycloalkyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S, and the cycloalkyl group, the heteroaryl group, optionally contains halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; The definitions of other groups are consistent with any one of the above technical solutions.

[0027] The eighteenth technical solution of the present invention relates to the compound of formula (Ia) according to the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, R A4 is -CH2-CH2-C 3-6 Cycloalkyl groups, -CH2-CF=CR A4a R A4b , L3-R A4’ , -CH(C 1-2 Alkyl)-CR A4c=CR A4a R A4b , -C(C 1-2 Alkyl)2-CR A4c =CR A4a R A4b , -CH2-C(CN)=CR A4a R A4b or R A4 is -CH2-CH2-C 3-6 Cycloalkyl groups, -CH2-C(CH3)=CR A4a R A4b , L3-R A4’ , -CH(C 1-2 Alkyl)-CR A4c =CR A4a R A4b , -C(C 1-2 Alkyl)2-CR A4c =CR A4a R A4b , -CH2-C(CN)=CR A4a R A4b or R A4 is -CH2-CH2-C 3-6 Cycloalkyl groups, -CH2-CH=CR A4a R A4b , L3-R A4 , -CH(C 1-2 Alkyl)-CR A4c =CR A4a R A4b , -C(C 1-2 Alkyl)2-CR A4c =CR A4a R A4b , -CH2-C(CN)=CR A4a R A4b is selected from R A4a , R A4b forms a 4-, 5-, or 6-membered cycloalkyl group together with the carbon atom to which it is attached, L3 is C 3-6 Cycloalkyl groups, -CH(C 1-2 Alkyl)-C 1-2 alkyl groups, R A4’ is C 3-6A cycloalkyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S, and the cycloalkyl group, the heteroaryl group, optionally contains halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; The condition is that the compound is R A4 -CH2-CF=CR A4a R A4b , L3-R A4’ or R A4 -CH2-C(CH3)=CR A4a R A4b , L3-R A4’ or R A4 -CH2-CH=CR A4a R A4b , L3-R A4’ To be selected from The definitions of other groups are consistent with any one of the above technical solutions.

[0028] The 19th technical solution of the present invention relates to the compound of formula (Ia) according to the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, R A4 is -CH2-CH2-C 3-6 Cycloalkyl groups, -CH2-CF=CR A4a R A4b , L3-R A4’ or R A4 is -CH2-CH2-C 3-6 Cycloalkyl groups, -CH2-C(CH3)=CR A4a R A4b , L3-R A4’ or R A4 is -CH2-CH2-C 3-6 Cycloalkyl groups, -CH2-CH=CRA4a R A4b , L3-R A4 is selected from R A4a , R A4b forms a 4-, 5-, or 6-membered cycloalkyl group together with the carbon atom to which it is attached, L3 is C 3-6 Cycloalkyl groups, -CH(C 1-2 Alkyl)-C 1-2 alkyl groups, R A4’ is C 3-6 A cycloalkyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S, and the cycloalkyl group, the heteroaryl group, optionally contains halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; The condition is that the compound is R A4 -CH2-CF=CR A4a R A4b , L3-R A4’ or R A4 -CH2-C(CH3)=CR A4a R A4b , L3-R A4’ or R A4 -CH2-CH=CR A4a R A4b , L3-R A4’ To be selected from The definitions of other groups are consistent with any one of the above technical solutions.

[0029] The twentieth technical solution of the present invention relates to the compound of formula (Ia) according to the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, R 1 is R A1, -O-HaloC 1-2 Alkyl group, -NH-haloC 1-2 Alkyl group, -OC 1-2 Alkyl group, C 1-2 Alkoxy group, halogen, cyano group, nitro group, OH, C 1-2 Alkyl group, C 2-4 Alkenyl group, -NH-C 1-2 Alkyl group, -N(C 1-2 alkyl)2, -NH-C 3-10 Cycloalkyl groups, -NHC(O)C 1-2 alkyl groups or 4-10 membered heterocycloalkyl groups containing 1-3 heteroatoms selected from N, O, and S, and the alkyl groups, alkoxy groups, cycloalkyl groups, and heterocycloalkyl groups are optionally selected from halogen, D, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 Alkoxy group, C 3-8 further substituted with 1 to 3 groups selected from a cycloalkyl group, a 4 to 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, a phenyl group, and NH; R 2 , R 3 are independently H, deuterium, and C 1-4 Alkoxy group, halogen, cyano group, nitro group, OH, C 1-2 Alkyl group, C 2-4 Alkenyl group, -NH-C 1-2 Alkyl group, -N(C 1-2 alkyl)2, wherein the alkyl and alkoxy groups are optionally selected from halogen, D, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1 to 3 groups selected from an alkoxy group and NH; X1 is selected from O and S; R 4 , R 5 are independently H, deuterium, and C 3-7 Cycloalkyl groups, C 2-4 Alkenyl group, C 2-4 Alkynyl group, F, Cl, amino group, -NH-C 1-2 Alkyl group, -N(C 1-2 Alkyl)2, C 1-2 alkyl group, and a 4- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; L1 is selected from a bond; The definitions of other groups are consistent with any of the above technical proposals.

[0030] The 21st technical solution of the present invention relates to the compound of formula (Ia) according to the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, R A4 teeth, [ka] or [ka] and further comprising R A4 teeth, [ka] or [ka] is selected from The definitions of other groups are consistent with any one of the above technical solutions.

[0031] The 22nd technical solution of the present invention relates to the compound of formula (Ia) according to the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, R A4 teeth, [ka] or [ka] and further comprising R A4 teeth, [ka] or [ka] is selected from The definitions of other groups are consistent with any one of the above technical solutions.

[0032] The 23rd technical solution of the present invention relates to the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, wherein: L1 is selected from a bond and O; L2 is selected from -CH2-, -C(O)-, -CHF-, -CF2-, and C(CH3)2-; R L1 , R L2 are each independently selected from H, deuterium, and F; R 6 , R 9 , R 10 are each independently selected from H, deuterium, F, Cl, OH, CN, and a methyl group; R 7 , R 8 are each independently H, deuterium, F, Cl, OH, CN, a methyl group, or R A2 is selected from R A2 teeth, [ka] is selected from R 2 , R 3 are each independently selected from H, deuterium, a vinyl group, and an ethynyl group; R 4 , R5 are each independently selected from H, deuterium, a cyclopropyl group, a vinyl group, and an ethynyl group; One option is R 4 , R 5 forms, together with the atom to which it is linked, a phenyl group, a cyclohexyl group, a cyclopentyl group, a thienyl group, a furyl group, a pyrrolyl group, a pyrazolyl group, or an isoxazolyl group; One option is R 2 , R 4 L1 together with the atom to which it is linked forms a cyclohexyl group or a phenyl group; One option is R L1 and R 9 forms a cyclopentyl group or a cyclohexyl group together with the atom to which it is linked, One option is R 7 and R 8 together with the atoms to which they are linked, form a 4- to 7-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, or an 8-membered carbocyclic ring, and the carbocyclic ring, heterocycloalkyl group, optionally, may be ═O, halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; R 1 teeth, [ka] -CH2CH3, -CH2CH2CH3, [ka] R A1 is selected from R A1 teeth, [ka] is selected from As a condition, the compound satisfies at least one of the following conditions: (1). R 1 is R A1 is selected from (2). R 4 and R 5 wherein at least one group is selected from a cyclopropyl group, a vinyl group, and an ethynyl group; (3). R 4 , R 5 forms, together with the atom to which it is linked, a phenyl group, a cyclohexyl group, a cyclopentyl group, a thienyl group, a furyl group, a pyrrolyl group, a pyrazolyl group, or an isoxazolyl group; (4). R 7 , R 8 At least one group of R A2 is selected from (5). R 2 , R 4 L1 together with the atom to which it is linked forms a cyclohexyl group or a phenyl group; (6). L1 is selected from O; (7) L2 is selected from -C(O)-, -CHF-, -CF2-, and -C(CH3)2-; (8). R 7 and R 8 , R 8 and R 9 A pair of these, together with the atoms connected thereto, forms a 4- to 7-membered carbocyclic ring or an 8-membered carbocyclic ring or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the carbocyclic ring, heterocycloalkyl group may optionally be substituted with ═O, F, Cl, deuterium, OH, C 1-2 Alkyl group, halo C 1-2 is further substituted with 1 to 3 groups selected from alkyl groups, The definitions of other groups are consistent with any one of the above technical solutions.

[0033] The 24th technical solution of the present invention relates to the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, wherein: L1 is selected from a bond and O; L2 is selected from -CH2-, -C(O)-, -CHF-, -CF2-, and C(CH3)2-; R L1 , R L2 are each independently selected from H, deuterium, and F; R 6 , R 9 , R 10 are each independently selected from H, deuterium, F, Cl, OH, CN, and a methyl group; R 7 , R 8 are each independently H, deuterium, F, Cl, OH, CN, a methyl group, or R A2 is selected from Or, as an option, R 7 and R 8 together with the atoms connected thereto, form a 4- to 7-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, or an 8-membered carbocyclic ring, or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the carbocyclic ring, the heterocycloalkyl group may optionally be ═O, a halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; R A2 teeth, [ka] is selected from R 2 , R 3 are each independently selected from H, deuterium, a vinyl group, and an ethynyl group; R 4 , R 5 are each independently selected from H, deuterium, a cyclopropyl group, a vinyl group, and an ethynyl group; One option is R 4 , R 5forms, together with the atom to which it is linked, a phenyl group, a cyclohexyl group, a cyclopentyl group, a thienyl group, a furyl group, a pyrrolyl group, a pyrazolyl group, or an isoxazolyl group; One option is R 2 , R 4 L1 together with the atom to which it is linked forms a cyclohexyl group or a phenyl group; One option is R L1 and R 9 forms a cyclopentyl group or a cyclohexyl group together with the atom to which it is linked, R 1 teeth, [ka] R A1 or R 1 teeth, [ka] is selected from R A1 teeth, [ka] or [ka] or [ka] is selected from As a condition, the compound satisfies at least one of the following conditions: (1). R 1 is R A1 is selected from (2). R 4 and R 5 wherein at least one group is selected from a cyclopropyl group, a vinyl group, and an ethynyl group; (3). R 4 , R 5forms, together with the atom to which it is linked, a phenyl group, a cyclohexyl group, a cyclopentyl group, a thienyl group, a furyl group, a pyrrolyl group, a pyrazolyl group, or an isoxazolyl group; (4). R 7 , R 8 At least one group of R A2 is selected from (5). R 2 , R 4 L1 together with the atom to which it is linked forms a cyclohexyl group or a phenyl group; (6). L1 is selected from O; (7) (7) L2 is selected from -C(O)-, -CHF-, -CF2-, and C(CH3)2-.

[0034] The 25th technical solution of the present invention is a compound of the present invention, its stereoisomer, deuterated product, solvate, or For pharmaceutically acceptable salts or co-crystals, wherein: L1 is selected from a bond and O; L2 is selected from -CH2-, -C(O)-, -CHF-, -CF2-, and C(CH3)2-; R L1 , R L2 are each independently selected from H, deuterium, and F; R 6 , R 9 , R 10 are each independently selected from H, deuterium, F, Cl, OH, CN, and a methyl group; R 7 , R 8 are each independently H, deuterium, F, Cl, OH, CN, a methyl group, or R A2 is selected from Or, as an option, R 7 and R 8 together with the atoms connected thereto, form a 4- to 7-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, or an 8-membered carbocyclic ring, or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the carbocyclic ring, the heterocycloalkyl group may optionally be ═O, a halogen, deuterium, CN, OH, C1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; R A2 teeth, [ka] is selected from R 2 , R 3 are each independently selected from H, deuterium, a vinyl group, and an ethynyl group; R 4 , R 5 are each independently selected from H, deuterium, a cyclopropyl group, a vinyl group, and an ethynyl group; One option is R 4 , R 5 forms, together with the atom to which it is linked, a phenyl group, a cyclohexyl group, a cyclopentyl group, a thienyl group, a furyl group, a pyrrolyl group, a pyrazolyl group, or an isoxazolyl group; One option is R 2 , R 4 L1 together with the atom to which it is linked forms a cyclohexyl group or a phenyl group; One option is R L1 and R 9 forms a cyclopentyl group or a cyclohexyl group together with the atom to which it is linked, R 1 teeth, [ka] R A1 or R 1 teeth, [ka] is selected from R A1 teeth, [ka] or [ka] or [ka] is selected from As a condition, the compound satisfies at least one of the following conditions: (1). R 1 is R A1 is selected from (2). R 4 and R 5 wherein at least one group is selected from a cyclopropyl group, a vinyl group, and an ethynyl group; (3). R 4 , R 5 forms, together with the atom to which it is linked, a phenyl group, a cyclohexyl group, a cyclopentyl group, a thienyl group, a furyl group, a pyrrolyl group, a pyrazolyl group, or an isoxazolyl group; (4). R 7 , R 8 At least one group of R A2 is selected from (5). R 2 , R 4 L1 together with the atom to which it is linked forms a cyclohexyl group or a phenyl group; (6). L1 is selected from O; (7) L2 is selected from -C(O)-, -CHF-, -CF2-, and C(CH3)2-.

[0035] The 26th technical solution of the present invention relates to the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, wherein: L1 is selected from a bond and O; L2 is selected from -CH2-, -C(O)-, -CHF-, -CF2-, and C(CH3)2-; R L1 , R L2are each independently selected from H, deuterium, and F; R 6 , R 9 , R 10 are each independently selected from H, deuterium, F, Cl, OH, CN, and a methyl group; R 7 , R 8 are each independently H, deuterium, F, Cl, OH, CN, a methyl group, or R A2 is selected from Or, as an option, R 7 and R 8 together with the atoms connected thereto, form a 4- to 7-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, or an 8-membered carbocyclic ring, or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the carbocyclic ring, the heterocycloalkyl group may optionally be ═O, a halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; R A2 teeth, [ka] is selected from R 2 , R 3 are each independently selected from H, deuterium, a vinyl group, and an ethynyl group; R 4 , R 5 are each independently selected from H, deuterium, a cyclopropyl group, a vinyl group, and an ethynyl group; One option is R 4 , R 5 forms, together with the atom to which it is linked, a phenyl group, a cyclohexyl group, a cyclopentyl group, a thienyl group, a furyl group, a pyrrolyl group, a pyrazolyl group, or an isoxazolyl group; One option is R 2 , R 4 L1 together with the atom to which it is linked forms a cyclohexyl group or a phenyl group; One option is R L1 and R 9 forms a cyclopentyl group or a cyclohexyl group together with the atom to which it is linked, R 1 teeth, [ka] R A1 or R 1 teeth, [ka] is selected from R A1 teeth, [ka] or [ka] or [ka] is selected from As a condition, the compound satisfies at least one of the following conditions: (1). R 1 is R A1 is selected from (2). R 4 and R 5 wherein at least one group is selected from a cyclopropyl group, a vinyl group, and an ethynyl group; (3). R 4 , R 5 forms, together with the atom to which it is linked, a phenyl group, a cyclohexyl group, a cyclopentyl group, a thienyl group, a furyl group, a pyrrolyl group, a pyrazolyl group, or an isoxazolyl group; (4). R 7 , R 8At least one group of R A2 is selected from (5). R 2 , R 4 L1 together with the atom to which it is linked forms a cyclohexyl group or a phenyl group; (6). L1 is selected from O; (7) (7) L2 is selected from -C(O)-, -CHF-, -CF2-, and C(CH3)2-.

[0036] The 27th technical solution of the present invention relates to the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, wherein: L1 is selected from a bond and O; L2 is selected from -CH2-, -C(O)-, -CHF-, -CF2-, and C(CH3)2-; R L1 , R L2 are each independently selected from H, deuterium, and F; R 6 , R 9 , R 10 are each independently selected from H, deuterium, F, Cl, OH, CN, and a methyl group; R 7 , R 8 are each independently H, deuterium, F, Cl, OH, CN, a methyl group, or R A2 is selected from Or, as an option, R 7 and R 8 together with the atoms connected thereto, form a 4- to 7-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, or an 8-membered carbocyclic ring, or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the carbocyclic ring, the heterocycloalkyl group may optionally be ═O, a halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4further substituted with 1 to 3 groups selected from an alkoxy group and NH; R A2 teeth, [ka] is selected from R 2 , R 3 are each independently selected from H, deuterium, a vinyl group, and an ethynyl group; R 4 , R 5 are each independently selected from H, deuterium, a cyclopropyl group, a vinyl group, and an ethynyl group; One option is R 4 , R 5 forms, together with the atom to which it is linked, a phenyl group, a cyclohexyl group, a cyclopentyl group, a thienyl group, a furyl group, a pyrrolyl group, a pyrazolyl group, or an isoxazolyl group; One option is R 2 , R 4 L1 together with the atom to which it is linked forms a cyclohexyl group or a phenyl group; One option is R L1 and R 9 forms a cyclopentyl group or a cyclohexyl group together with the atom to which it is linked, R 1 teeth, [ka] R A1 or R 1 teeth, [ka] is selected from R A1 teeth, [ka] or [ka] or [ka] is selected from As a condition, the compound satisfies at least one of the following conditions: (1). R 1 is R A1 is selected from (2). R 4 and R 5 wherein at least one group is selected from a cyclopropyl group, a vinyl group, and an ethynyl group; (3). R 4 , R 5 forms, together with the atom to which it is linked, a phenyl group, a cyclohexyl group, a cyclopentyl group, a thienyl group, a furyl group, a pyrrolyl group, a pyrazolyl group, or an isoxazolyl group; (4). R 7 , R 8 At least one group of R A2 is selected from (5). R 2 , R 4 L1 together with the atom to which it is linked forms a cyclohexyl group or a phenyl group; (6). L1 is selected from O; (7) L2 is selected from -C(O)-, -CHF-, -CF2-, and C(CH3)2-.

[0037] The 28th technical solution of the present invention relates to a compound of formula (Ia), its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or co-crystal, wherein: L1 is selected from a bond and O; R 2 , R 3 are each independently selected from H, deuterium, a vinyl group, and an ethynyl group; R 4 , R 5 are each independently selected from H, deuterium, a cyclopropyl group, a vinyl group, and an ethynyl group; One option is R 4 , R 5forms, together with the atom to which it is linked, a phenyl group, a cyclohexyl group, a cyclopentyl group, a thienyl group, a furyl group, a pyrrolyl group, a pyrazolyl group, or an isoxazolyl group; R 1 teeth, [ka] R A1 or R 1 teeth, [ka] is selected from R A1 teeth, [ka] is selected from X1 is selected from O and S; R A4 teeth, [ka] or [ka] is selected from.

[0038] As an alternative technical solution, a compound of formula (I) or (Ia), a stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt thereof, wherein R 1 -O-HaloC 1-4 is an alkyl group, and R 2 , R 3 is H and X1 is S, or R 6 , R 7 , R 8 , R 9 At least one of the A2 and R A2is -(4- to 10-membered heterocycloalkyl containing 1-3 heteroatoms selected from N, O, S, and Si), or -(5- to 10-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -P(O)(R c )2, -Si(R c )3, -SF5, B(OH)2, or -S(O)(=NH)R c The heterocycloalkyl and heteroaryl groups are optionally selected from halogen, ═O, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, C 3-6 Cycloalkyl groups, 4- to 7-membered heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; or R 1 is R A1 and R 2 , R 3 is H, X1 is O, and R A1 is C 2-6 Alkynyl group, -C 1-4 Alkyl-OR a , -NR b -S(O)2-R a and each R a is C 3-10 and a cycloalkyl group or a 4- to 10-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, wherein the cycloalkyl group and the heterocycloalkyl group are optionally selected from halogen, ═O, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 It is further substituted with 1 to 3 groups selected from an alkoxy group and NH2, and the other groups are as described in any of the above technical solutions.

[0039] The 29th technical solution of the present invention is a compound of formula (Ia), its stereoisomers, deuterated compounds, solvates, or a pharmaceutically acceptable salt or co-crystal, wherein: L1 is selected from a bond and O; R 2 , R 3 are each independently selected from H, deuterium, a vinyl group, and an ethynyl group; R 4 , R 5 are each independently selected from H, deuterium, a cyclopropyl group, a vinyl group, and an ethynyl group; One option is R 4 , R 5 forms, together with the atom to which it is linked, a phenyl group, a cyclohexyl group, a cyclopentyl group, a thienyl group, a furyl group, a pyrrolyl group, a pyrazolyl group, or an isoxazolyl group; R 1 teeth, [ka] R A1 or R 1 teeth, [ka] is selected from R A1 teeth, [ka] is selected from X1 is selected from O and S; R A4 teeth, [ka] or [ka] is selected from.

[0040] As an alternative technical solution, a compound of formula (I) or (Ia), a stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt thereof, wherein R 1 -O-HaloC 1-4 is an alkyl group, and R 2 , R 3 is H and X1 is S, or R 6 , R 7 , R 8 , R 9 At least one of the A2 and R A2 is -(4- to 10-membered heterocycloalkyl containing 1-3 heteroatoms selected from N, O, S, and Si), or -(5- to 10-membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -P(O)(R c )2, -Si(R c )3, -SF5, B(OH)2, or -S(O)(=NH)R c The heterocycloalkyl and heteroaryl groups are optionally selected from halogen, ═O, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, C 3-6 Cycloalkyl groups, 4- to 7-membered heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; or R 1 is R A1 and R 2 , R 3 is H, X1 is O, and R A1 is C 2-6 Alkynyl group, -C 1-4 Alkyl-OR a , -NR b -S(O)2-R a and each R a is C 3-10and a cycloalkyl group or a 4- to 10-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, wherein the cycloalkyl group and the heterocycloalkyl group are optionally selected from halogen, ═O, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 It is further substituted with 1 to 3 groups selected from an alkoxy group and NH2, and the other groups are as described in any of the above technical solutions.

[0041] In the 30th technical solution of the present invention, the compound of the present invention, its stereoisomer, deuterated product, solvate, or Pharmaceutically acceptable salts have the structure of formula (I): [ka] where: R 1 , R 2 , R 3 are each independently H, deuterium, or R A1 , -O-HaloC 1-4 Alkyl group, -NH-haloC 1-4 Alkyl group, -OC 1-4 Alkyl group, C 1-4 Alkoxy group, C 5-6 Alkoxy group, halogen, cyano group, nitro group, C 1-4 Alkyl group, C 2-6 Alkenyl group, -NH-C 1-4 Alkyl group, -N(C 1-4 alkyl)2, -NH-C 3-10 Cycloalkyl groups, -NHC(O)C 1-4 The alkyl group, alkoxy group, cycloalkyl group, and heterocycloalkyl group are optionally selected from alkyl groups and 4 to 10-membered heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, and the ... halogen atoms, D, CN, OH, C 1-4 Alkyl group, halo C 1-4Alkyl group, deuterium group C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterium group C 1-4 Alkoxy group, C 3-10 It is further substituted with a group selected from a cycloalkyl group, a 4- to 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, a phenyl group, and NH, with the proviso that R 1 , R 2 and R 3 are not simultaneously selected from H, R A1 is Haro C 2-6 Alkenyl group, C 2-6 Alkynyl group, -O-(CH2) r -R a , C 3-10 a cycloalkyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C 1-4 Alkyl-R a , -C 1-4 Alkyl-OR a , -C 1-4 Alkyl-NR b R a , -NR b -S(O)2-R a , -NR b -S(O)2-NR b R a , -O-NR b R a , -NH-OR b , -Se-(CH2) r -R a The alkynyl, heteroaryl, and alkyl groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R a CN, Halo C1-6 Alkyl group, C 3-10 a cycloalkyl group, a 4- to 10-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 6- to 10-membered aryl group; a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C(O)-R a1 wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally selected from halogen, ═O, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R b are H, deuterium, and C 1-4 Alkyl group, C 3-6 Cycloalkyl groups, haloC 1-4 Alkyl groups, deuterated C 1-4 alkyl groups, R a1 are OH, NH2, -NHC 1-4 Alkyl group, -N(C 1-4 alkyl)2, -NHC 3-10 Cycloalkyl groups, C 1-4 Alkoxy group, C 1-6 Alkyl group, C 3-10 selected from a cycloalkyl group, a 6- to 10-membered aryl group, and a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; X is CR 10 or N, X1 is selected from O and S; R 4 , R 5 are independently H, deuterium, and C 3-10 Cycloalkyl groups, C 2-6 Alkenyl group, C 2-6 Alkynyl group, halogen, amino group, -NH-C 1-4 Alkyl group, -N(C 1-4Alkyl)2, C 1-4 Alkyl group, halo C 1-4 an alkyl group, a 4- to 10-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; and a 6- to 10-membered aryl group; R 6 , R 7 , R 8 , R 9 , R 10 are each independently H, deuterium, or R A2 , halogen, OH, CN, amino group, C 1-4 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 1-4 Alkoxy group, haloC 1-4 Alkyl group, -NH-C 1-4 Alkyl group, -N(C 1-4 alkyl)2, -S(O)R c , -S(O) 2 R c , -C(O)R c , -C(O)OR c , -C(O)N(R c )2, -OC(O)R c The alkyl, alkenyl, alkynyl, and alkoxy groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 It is further substituted with 1 to 3 groups selected from an alkoxy group and NH2, with the proviso that R 7 and R 8 , R 8 and R 9 At least one pair of these, together with the atoms connected thereto, forms a 4- to 8-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and the carbocyclic ring and heterocycloalkyl group optionally contain ═O, halogen, deuterium, CN, OH, C1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; R A2 is -(CH2) r -(4- to 10-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from N, O, S, and Si), or -(CH) r -(5-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -P(O)(R c )2, -Si(R c )3, -SF5, N3, B(OH)2, or -S(O)(=NH)R c The heterocycloalkyl and heteroaryl groups are optionally selected from halogen, ═O, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, C 3-6 Cycloalkyl groups, 4- to 7-membered heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R c are independently H, OH, C 1-4 Alkyl group, C 3-7 Cycloalkyl groups, haloC 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 an alkoxy group, or NH2; each r is independently selected from 0, 1, 2, or 3; L1 is a bond, O, NH, S, -CD2-, -CHD-, -CR L1 RL2 -, C 1-4 alkyl group, —C(O)—, S(O), S(O)2, said alkyl group optionally being selected from R L1 is further substituted with L2 is O, NH, S, -CH2-, -CD2-, -CHD-, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, C 2-4 alkyl group, -C(O)-, S(O), S(O)2, said alkyl group optionally having 1 to 3 R L1 is further substituted with R L1 , R L2 are each independently a halogen, OH, CN, an amino group, or C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 a cycloalkyl group, a 4- to 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; One option is R 2 , R 4 L1, together with the atom to which it is linked, forms a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be selected from R A3 is further substituted with 1 to 3 groups selected from One option is R 4 , R 5 together with the atom to which it is linked, form a 5- to 7-membered monocyclic carbocycle or a 5- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be A3 and substituted with 1 to 3 groups selected from One option is R L2 and R 9 together with the atom to which it is linked, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be A3 further substituted with 1 to 3 groups selected from: One option is R 6 and R 10 together with the atoms connected thereto, form a 4- to 7-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, and B, an 8-membered carbocyclic ring, or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the carbocyclic ring, the heterocycloalkyl group, optionally may be ═O, a halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R A3 are each independently =O, halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 The group substitution is selected from alkoxy groups and NH2 groups.

[0042] In the 31st technical solution of the present invention, the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal has the structure of formula (I): [ka] During the ceremony, R 1 , R 2 , R 3 are each independently H, deuterium, or R A1 , -O-HaloC 1-4 Alkyl group, -NH-haloC 1-4 Alkyl group, -OC 1-4 Alkyl group, C 1-6 Alkoxy group, halogen, cyano group, nitro group, C 1-4 Alkyl group, -NH-C 1-4 Alkyl group, -N(C 1-4alkyl)2, -NH-C 3-10 Cycloalkyl groups, -NHC(O)C 1-4 alkyl groups or 4-10 membered heterocycloalkyl groups containing 1-3 heteroatoms selected from N, O, and S, and the alkyl groups, alkoxy groups, cycloalkyl groups, and heterocycloalkyl groups are optionally selected from halogen, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 Alkoxy group, C 3-10 It is further substituted with 1 to 3 groups selected from a cycloalkyl group, a 4 to 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, a phenyl group, and NH, with the proviso that R 1 , R 2 and R 3 are not simultaneously selected from H, R A1 is Haro C 2-6 Alkenyl group, C 2-6 Alkynyl group, -O-(CH2) r -R a , C 3-10 a cycloalkyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C 1-4 Alkyl-R a , -C 1-4 Alkyl-OR a , -C 1-4 Alkyl-NR b R a , -NR b -S(O)2-R a , -NR b -S(O)2-NR b R a , -O-NR b R a , -NH-OR b , -Se-(CH2) r -R aThe alkynyl, heteroaryl, alkyl, and cycloalkyl groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R a CN, Halo C 1-6 Alkyl group, C 3-10 a cycloalkyl group, a 4- to 10-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 6- to 10-membered aryl group; a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C(O)-R a1 wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally selected from halogen, ═O, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R b are H, deuterium, and C 1-4 Alkyl group, C 3-6 Cycloalkyl groups, haloC 1-4 Alkyl groups, deuterated C 1-4 alkyl groups, R a1 are OH, NH2, -NHC 1-4 Alkyl group, -N(C 1-4 alkyl)2, -NHC 3-10 Cycloalkyl groups, C 1-4 Alkoxy group, C 1-6 Alkyl group, C 3-10selected from a cycloalkyl group, a 6- to 10-membered aryl group, and a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; X is CR 10 or N, X1 is selected from O and S; R 4 , R 5 are independently H, deuterium, and C 3-10 Cycloalkyl groups, C 2-6 Alkenyl group, C 2-6 Alkynyl group, halogen, amino group, -NH-C 1-4 Alkyl group, -N(C 1-4 Alkyl)2, C 1-4 Alkyl group, halo C 1-4 an alkyl group, a 4- to 10-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; and a 6- to 10-membered aryl group; R 6 , R 7 , R 8 , R 9 , R 10 are each independently H, deuterium, or R A2 , halogen, OH, CN, amino group, C 1-4 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 1-4 Alkoxy group, haloC 1-4 Alkyl group, -NH-C 1-4 Alkyl group, -N(C 1-4 alkyl)2, -S(O)R c , -S(O) 2 R c , -C(O)R c , -C(O)OR c , -C(O)N(R c )2, -OC(O)R c The alkyl, alkenyl, alkynyl, and alkoxy groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; R A2 is -(CH2) r -(C 3-10 cycloalkyl), -(CH2) r -(4- to 10-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from N, O, S, and Si), or -(CH) r -(5-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -P(O)(R c )2, -Si(R c )3, -SF5, N3, B(OH)2, or -S(O)(=NH)R c wherein the cycloalkyl, heterocycloalkyl, and heteroaryl groups are optionally selected from halogen, ═O, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, C 3-6 Cycloalkyl groups, 4- to 7-membered heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R c are independently H, OH, C 1-4 Alkyl group, C 3-7 Cycloalkyl groups, haloC 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 an alkoxy group or NH2; each r is independently selected from 0, 1, 2, or 3; L1 is a bond, O, NH, S, -CD2-, -CHD-, -CR L1 RL2 -, C 1-4 alkyl group, —C(O)—, S(O), S(O)2, said alkyl group optionally being selected from R L1 is further substituted with L2 is a bond, O, NH, S, -CH2-, -CD2-, -CHD-, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, C 2-4 alkyl group, -C(O)-, S(O), S(O)2, said alkyl group optionally having 1 to 3 R L1 is further substituted with R L1 , R L2 are each independently a halogen, OH, CN, an amino group, or C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 a cycloalkyl group, a 4- to 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; One option is R 2 , R 4 L1, together with the atom to which it is linked, forms a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be selected from R A3 is further substituted with 1 to 3 groups selected from One option is R 4 , R 5 together with the atom to which it is linked, form a 5- to 7-membered monocyclic carbocycle or a 5- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be A3 and substituted with 1 to 3 groups selected from One option is R L2 and R 9 together with the atom to which it is linked, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be A3 further substituted with 1 to 3 groups selected from: Each R A3 are each independently =O, halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 selected from alkoxy and NH group substitutions; As a condition, R 6 and R 10 , R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these together with the atom connecting them forms a 4- to 8-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and the carbocyclic ring, the heterocycloalkyl group may optionally be ═O, [ka] Halogens, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 It is further substituted with 1 to 3 groups selected from an alkoxy group, a 5 to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, a 5 to 7-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and NH2.

[0043] As an alternative form of the 31st technical solution of the present invention, the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or co-crystal has the structure of formula (I): [ka] During the ceremony, R 1 , R2 , R 3 are each independently H, deuterium, or R A1 , -O-HaloC 1-4 Alkyl group, -NH-haloC 1-4 Alkyl group, -OC 1-4 Alkyl group, C 1-6 Alkoxy group, halogen, cyano group, nitro group, C 1-4 Alkyl group, -NH-C 1-4 Alkyl group, -N(C 1-4 alkyl)2, -NH-C 3-10 Cycloalkyl groups, -NHC(O)C 1-4 alkyl groups or 4-10 membered heterocycloalkyl groups containing 1-3 heteroatoms selected from N, O, and S, and the alkyl groups, alkoxy groups, cycloalkyl groups, and heterocycloalkyl groups are optionally selected from halogen, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 Alkoxy group, C 3-10 It is further substituted with 1 to 3 groups selected from a cycloalkyl group, a 4 to 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, a phenyl group, and NH, with the proviso that R 1 , R 2 and R 3 are not simultaneously selected from H, R A1 is Haro C 2-6 Alkenyl group, C 2-6 Alkynyl group, -O-(CH2) r -R a , C 3-10 a cycloalkyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C 1-4 Alkyl-R a , -C 1-4 Alkyl-OR a , -C 1-4 Alkyl-NR b R a, -NR b -S(O)2-R a , -NR b -S(O)2-NR b R a , -O-NR b R a , -NH-OR b , -Se-(CH2) r -R a The alkynyl, heteroaryl, alkyl, and cycloalkyl groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R a CN, Halo C 1-6 Alkyl group, C 3-10 a cycloalkyl group, a 4- to 10-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 6- to 10-membered aryl group; a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C(O)-R a1 wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally selected from halogen, ═O, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R b are H, deuterium, and C 1-4 Alkyl group, C 3-6 Cycloalkyl groups, haloC 1-4 Alkyl groups, deuterated C 1-4 alkyl groups, R a1are OH, NH2, -NHC 1-4 Alkyl group, -N(C 1-4 alkyl)2, -NHC 3-10 Cycloalkyl groups, C 1-4 Alkoxy group, C 1-6 Alkyl group, C 3-10 selected from a cycloalkyl group, a 6- to 10-membered aryl group, and a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; X is CR 10 or N, X1 is selected from O and S; R 4 , R 5 are independently H, deuterium, and C 3-10 Cycloalkyl groups, C 2-6 Alkenyl group, C 2-6 Alkynyl group, halogen, amino group, -NH-C 1-4 Alkyl group, -N(C 1-4 Alkyl)2, C 1-4 Alkyl group, halo C 1-4 an alkyl group, a 4- to 10-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; and a 6- to 10-membered aryl group; R 6 , R 7 , R 8 , R 9 , R 10 are each independently H, deuterium, or R A2 , halogen, OH, CN, amino group, C 1-4 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 1-4 Alkoxy group, haloC 1-4 Alkyl group, -NH-C 1-4 Alkyl group, -N(C 1-4 alkyl)2, -S(O)R c , -S(O) 2 R c , -C(O)R c , -C(O)OR c , -C(O)N(R c)2, -OC(O)R c The alkyl, alkenyl, alkynyl, and alkoxy groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; R A2 is -(CH2) r -(4- to 10-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from N, O, S, and Si), or -(CH) r -(5-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -P(O)(R c )2, -Si(R c )3, -SF5, N3, B(OH)2, or -S(O)(=NH)R c The heterocycloalkyl and heteroaryl groups are optionally selected from halogen, ═O, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, C 3-6 Cycloalkyl groups, 4- to 7-membered heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R c are independently H, OH, C 1-4 Alkyl group, C 3-7 Cycloalkyl groups, haloC 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 an alkoxy group or NH2; each r is independently selected from 0, 1, 2, or 3; L1 is a bond, O, NH, S, -CD2-, -CHD-, -CR L1 R L2 -, C 1-4 alkyl group, —C(O)—, S(O), S(O)2, said alkyl group optionally being selected from R L1 is further substituted with L2 is a bond, O, NH, S, -CH2-, -CD2-, -CHD-, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, C 2-4 alkyl group, -C(O)-, S(O), S(O)2, said alkyl group optionally having 1 to 3 R L1 is further substituted with R L1 , R L2 are each independently a halogen, OH, CN, an amino group, or C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 a cycloalkyl group, a 4- to 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; One option is R 2 , R 4 L1, together with the atom to which it is linked, forms a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be selected from R A3 is further substituted with 1 to 3 groups selected from One option is R 4 , R 5 together with the atom to which it is linked, form a 5- to 7-membered monocyclic carbocycle or a 5- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be A3 and substituted with 1 to 3 groups selected from One option is R L2 and R 9together with the atom to which it is linked, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be A3 further substituted with 1 to 3 groups selected from: Each R A3 are each independently =O, halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 selected from alkoxy and NH group substitutions; As a condition, R 6 and R 10 , R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these together with the atom connecting them forms a 4- to 8-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and the carbocyclic ring, the heterocycloalkyl group may optionally be ═O, [ka] Halogens, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 and 1 to 3 groups selected from an alkoxy group, a 5 to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, a 5 to 7-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and NH, with the proviso that in some embodiments, R 6 and R 10 , R 10 and R 7 , R7 and R 8 , R 8 and R 9 A pair of these, together with the atoms connected thereto, forms a 4- to 8-membered cycloalkyl group, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and the cycloalkyl group and heterocycloalkyl group optionally contain ═O, halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 It is further substituted with 1 to 3 groups selected from an alkoxy group, a 5 to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, a 5 to 7-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and NH2.

[0044] The 32nd technical solution of the present invention relates to the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, wherein: R 6 , R 7 , R 8 , R 9 , R 10 are each independently H, deuterium, -SF5, N3, halogen, OH, CN, amino group, C 1-2 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-2 Alkoxy group, haloC 1-2 Alkyl group, -NH-C 1-2 Alkyl group, -N(C 1-2 alkyl), wherein the alkyl, alkenyl, alkynyl, and alkoxy groups are optionally selected from halogen, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2Alkoxy group, deuterated C 1-2 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Other groups are as described in any of the above technical solutions.

[0045] In the 33rd technical solution of the present invention, the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal has the structure of formula (II), (II-a): [ka] L2 is a bond, -CH2-, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, -C(O)-, R L1 , R L2 are each independently a halogen, OH, CN, an amino group, or C 1-2 Alkyl group, C 1-2 Alkoxy group, C 3-4 a 4-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from cycloalkyl groups, N, O, and S; R 2 , R 3 are independently H, deuterium, and C 1-2 Alkoxy group, halogen, cyano group, nitro group, C 1-2 alkyl groups, alkoxy groups optionally further substituted with 1 to 3 groups selected from halogen, D, CN, OH and NH; R 1 is R A1 , -O-HaloC 1-4 Alkyl group, -NH-haloC 1-4 Alkyl group, C 1-4 Alkoxy group, halogen, cyano group, nitro group, C 1-4 Alkyl group, -NH-C 1-4 Alkyl group, -N(C 1-4 alkyl)2, -NH-C 3-10 Cycloalkyl groups, -NHC(O)C 1-4alkyl groups or 4-10 membered heterocycloalkyl groups containing 1-3 heteroatoms selected from N, O, and S, and the alkyl groups, alkoxy groups, cycloalkyl groups, and heterocycloalkyl groups are optionally selected from halogen, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 Alkoxy group, C 3-10 further substituted with 1 to 3 groups selected from a cycloalkyl group, a 4 to 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, a phenyl group, and NH; X is CR 10 or N, R 4 , R 5 are independently H, deuterium, and C 3-7 Cycloalkyl groups, C 2-4 Alkenyl group, C 2-4 Alkynyl group, F, Cl, amino group, -NH-C 1-2 Alkyl group, -N(C 1-2 Alkyl)2, C 1-2 alkyl group, and a 4- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; R 7 , R 8 are each independently H, deuterium, F, Cl, OH, CN, amino group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-4 Alkoxy group, haloC 1-4 Alkyl group, -NH-C 1-2 Alkyl group, -N(C 1-2 alkyl)2, -S(O)R c , -S(O) 2 R c , -C(O)R c , -C(O)OR c , -C(O)N(R c )2, -OC(O)Rc is selected from R 6 , R 9 , R 10 are each independently H, deuterium, F, Cl, OH, CN, amino group, C 1-2 alkyl groups, One option is R 2 , R 4 together with the atom to which it is linked, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be A3 is further substituted with 1 to 3 groups selected from Each R A3 are each independently =O, halogen, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 selected from alkoxy and NH group substitutions; As a condition, R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these, together with the atom connected thereto, forms a 4- to 8-membered cycloalkyl group, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and the cycloalkyl group, the heterocycloalkyl group, optionally, is ═O, [ka] Halogens, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4and 1 to 3 groups selected from an alkoxy group, a 5 to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, a 5 to 7-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and NH, with the proviso that in some embodiments, R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these, together with the atoms connected thereto, forms a 4- to 8-membered cycloalkyl group, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and the cycloalkyl group and heterocycloalkyl group optionally contain ═O, halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted by 1 to 3 groups selected from an alkoxy group, a 5 to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, a 5 to 7-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and NH; Other groups are as described in any of the above technical solutions.

[0046] In the 34th technical solution of the present invention, the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal has the structure of formula (III), (III-a): [ka] X is CR 10 or N, R 6 , R 7 , R 8 , R 9 , R 10are each independently H, deuterium, F, Cl, OH, CN, amino group, C 1-2 alkyl groups, One option is R 2 , R 4 together with the atom to which it is linked, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be A3 is further substituted with 1 to 3 groups selected from As a condition, R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these, together with the atom connected thereto, forms a 4- to 8-membered cycloalkyl group, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and the cycloalkyl group, the heterocycloalkyl group, optionally, is ═O, [ka] Halogens, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 It is further substituted with 1 to 3 groups selected from an alkoxy group, a 5 to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, a 5 to 7-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and NH2, and other groups are as described in any of the above technical solutions.

[0047] The 35th technical solution of the present invention relates to the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, wherein: R 1 is R A1 , -O-HaloC 1-4 Alkyl group, C1-4 alkyl groups, wherein the alkyl groups are optionally selected from halogen, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; R 2 , R 3 are independently H, deuterium, and C 2-4 Alkenyl group, C 2-4 Alkynyl group, halogen, cyano group, nitro group, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 alkyl groups, R A1 is Haro C 2-4 Alkenyl group, C 2-4 Alkynyl group, -O-(CH2) r -R a , C 3-6 Monocyclic cycloalkyl groups, C 5-8 Bicyclic Bridged Cycloalkyl Groups, C 6-10 Bicyclic spirocyclic cycloalkyl groups, 5-6 membered monocyclic heteroaryl groups containing 1-3 heteroatoms selected from N, O and S, 8-10 membered bicyclic heteroaryl groups containing 1-3 heteroatoms selected from N, O and S, -C 1-2 Alkyl-R a , -C 1-2 Alkyl-OR a , -C 1-2 Alkyl-NR b R a , -NR b -S(O)2-R a , -NR b -S(O)2-NR b R a , -O-NR b R a , -NH-OR b , -Se-(CH2) r -R aThe alkynyl, heteroaryl, alkyl, and cycloalkyl groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R a CN, Halo C 1-4 Alkyl group, C 3-6 Monocyclic cycloalkyl groups, C 7-10 Spirocyclic cycloalkyl groups, C 4-8 Bridged Cycloalkyl Groups, C 4-9 Fused-ring cycloalkyl groups, 4- to 6-membered monocyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, 7- to 10-membered spirocyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, 4- to 8-membered bridged cyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, 4- to 6-membered fused-ring heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, phenyl groups, 8- to 10-membered aryl groups, 5- to 6-membered monocyclic heteroaryl groups containing 1 to 3 heteroatoms selected from N, O, and S, 8- to 10-membered bicyclic heteroaryl groups containing 1 to 3 heteroatoms selected from N, O, and S, -C(O)-R a1 wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally selected from halogen, ═O, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R b are H, deuterium, and C 1-2 Alkyl group, C3-4 The cycloalkyl group is selected from the group consisting of cycloalkyl groups, and the other groups are as described in any of the above technical solutions.

[0048] The 36th technical solution of the present invention relates to the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, wherein: R 1 is R A1 , -O-HaloC 1-4 Alkyl group, C 1-4 alkyl groups, wherein the alkyl groups are optionally selected from halogen, D, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1 to 3 groups selected from an alkoxy group and NH; R 2 , R 3 are each independently H, deuterium, F, Cl, cyano group, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 alkyl groups, R A1 is -O-(CH2) r -R a , C 3-6 Monocyclic cycloalkyl groups, C 5-8 Bicyclic Bridged Cycloalkyl Groups, C 6-10 Bicyclic spirocyclic cycloalkyl groups, 5-6 membered monocyclic heteroaryl groups containing 1-3 heteroatoms selected from N, O and S, 8-10 membered bicyclic heteroaryl groups containing 1-3 heteroatoms selected from N, O and S, -C 1-2 Alkyl-R a , -C 1-2 Alkyl-OR a , -Se-(CH2) r -R a The heteroaryl, alkyl, and cycloalkyl groups are optionally selected from halogen, deuterium, CN, OH, C 1-2Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R a is Haro C 1-4 Alkyl group, C 3-6 Monocyclic cycloalkyl groups, C 7-10 Spirocyclic cycloalkyl groups, C 4-8 Bridged Cycloalkyl Groups, C 4-9 a fused-ring cycloalkyl group, a 4- to 6-membered monocyclic heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 7- to 10-membered spirocyclic heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 4- to 8-membered bridged cyclic heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 4- to 6-membered fused-ring heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a phenyl group; an 8- to 10-membered aryl group; a 5- to 6-membered monocyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; and an 8- to 10-membered bicyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S, wherein the alkyl group, cycloalkyl group, heterocycloalkyl group, aryl group, and heteroaryl group are optionally selected from halogen, ═O, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 It is further substituted with 1 to 3 groups selected from an alkoxy group and NH2, and the other groups are as described in any of the above technical solutions.

[0049] In the 37th technical solution of the present invention, the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal has the structure of formula (IV) or (V): [ka] X is CR 10 or N, R 9 , R 10 are each independently H, deuterium, F, Cl, OH, CN, amino group, C 1-2 alkyl groups, L2 is a bond, -CH2-, -CD2-, -CHD-, or -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, C 2-4 alkyl group, -C(O)-, wherein the alkyl group is optionally selected from 1 to 3 R L1 is further substituted with As a condition, R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these, together with the atom connected thereto, forms a 4- to 8-membered cycloalkyl group, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and the cycloalkyl group, the heterocycloalkyl group, optionally, is ═O, [ka] Halogens, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 It is further substituted with 1 to 3 groups selected from an alkoxy group and NH2, and the other groups are as described in any of the above technical solutions.

[0050] The 38th technical solution of the present invention relates to the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, wherein: R 6 and R 10, R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these together with the atoms to which they are connected form a 4-, 5-, 6-, 7-, or 8-membered carbocyclic ring, a 5-, 6-, or 7-membered heterocycloalkyl group containing 1, 2, or 3 heteroatoms selected from N, O, S, B, and Si, and the carbocyclic ring, heterocycloalkyl group may optionally be ═O, [ka] Halogens, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1, 2, or 3 groups selected from an alkoxy group, a 5-, 6-, or 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, or Si, a 5-, 6-, or 7-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, S, B, or Si, and NH; In some embodiments, R 6 and R 10 , R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these together with the atom to which they are connected form a 4-, 5-, 6-, 7-, or 8-membered cycloalkyl group, or a 5-, 6-, or 7-membered heterocycloalkyl group containing 1, 2, or 3 heteroatoms selected from N, O, S, B, and Si, and the cycloalkyl group, heterocycloalkyl group may optionally be ═O, [ka] Halogens, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1, 2, or 3 groups selected from an alkoxy group, a 5-, 6-, or 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, or Si, a 5-, 6-, or 7-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, S, B, or Si, and NH; In some embodiments, R 6 and R 10 , R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these together with the atoms connected thereto form a 4-, 5-, 6-, 7-, or 8-membered cycloalkyl group, or a 5-, 6-, or 7-membered heterocycloalkyl group containing 1, 2, or 3 heteroatoms selected from N, O, S, B, and Si, and the cycloalkyl group, heterocycloalkyl group, optionally, may be ═O, halogen, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1, 2, or 3 groups selected from an alkoxy group, a 5-, 6-, or 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, or Si, a 5-, 6-, or 7-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, S, B, or Si, and NH; In some embodiments, R 7 and R 8 , R 8 and R 9 A pair of these together with the atoms connected thereto form a 4-, 5-, 6-, 7-, or 8-membered cycloalkyl group, or a 5- or 6-membered heterocycloalkyl group containing 1, 2, or 3 heteroatoms selected from N, O, S, B, and Si, and the cycloalkyl group or heterocycloalkyl group optionally contains ═O, halogen, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1, 2, or 3 groups selected from alkoxy groups and NH; In some embodiments, R 7 and R 8 together with the atoms to which they are connected, form a 4-, 5-, 6-, 7-, or 8-membered cycloalkyl group, or a 5- or 6-membered heterocycloalkyl group containing 1, 2, or 3 heteroatoms selected from N, O, S, B, and Si, and the cycloalkyl group, heterocycloalkyl group, optionally, may be ═O, halogen, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1, 2, or 3 groups selected from alkoxy groups and NH; In some embodiments, R 7 and R 8 together with the atoms to which they are connected form a 4- or 5-membered cycloalkyl group, a 5-membered heterocycloalkyl group containing 1, 2 or 3 heteroatoms selected from N, O, S, B and Si, and the cycloalkyl group, heterocycloalkyl group optionally contains ═O, halogen, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1, 2, or 3 groups selected from alkoxy groups and NH; Other groups are as described in any of the above technical solutions.

[0051] The 39th technical solution of the present invention relates to the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, wherein: L1 is selected from a bond; L2 is selected from a bond, -CH2-, -CD2-, -CHD-, -C(O)-, -CHF-, -CDF-, -CF2-, CH(CH3)-, CD(CH3)-, C(CH3)2-; R 6 , R 9 , R 10 are each independently selected from H, deuterium, F, Cl, OH, CN, and a methyl group; R 7 , R 8 are each independently selected from H, deuterium, F, Cl, OH, CN, and a methyl group; R 2 , R 3 are each independently selected from H, deuterium, a vinyl group, and an ethynyl group; R 4 , R 5 are each independently selected from H, deuterium, a cyclopropyl group, a vinyl group, and an ethynyl group; One option is R 4 , R 5 forms, together with the atom to which it is linked, a phenyl group, a cyclohexyl group, a cyclopentyl group, a thienyl group, a furyl group, a pyrrolyl group, a pyrazolyl group, or an isoxazolyl group; One option is R 2 , R 4 L1 together with the atom to which it is linked forms a cyclohexyl group, a cycloheptyl group, a phenyl group, or a cyclopentyl group; One option is R L1 and R 9 forms a cyclopentyl group or a cyclohexyl group together with the atom to which it is linked, R 1 are -CF3, -CH2CH3, -CH2CH2CH3, [ka] is selected from In some embodiments, R 1 teeth, [ka] -CH2CH3, -CH2CH2CH3, [ka] is selected from As a condition, R 6 and R 10 , R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these, together with the atoms connected thereto, forms a 4- to 8-membered cycloalkyl group or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the cycloalkyl group, heterocycloalkyl group optionally contains ═O, F, Cl, deuterium, OH, C 1-2 Alkyl group, halo C 1-2 further substituted with 1 to 3 groups selected from an alkyl group and a 5- to 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si; In some embodiments, the proviso is that R 6 and R 10 , R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these, together with the atom connected thereto, forms a 4- to 8-membered cycloalkyl group or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the cycloalkyl group, heterocycloalkyl group optionally contains ═O, [ka] F, Cl, deuterium, OH, C 1-2 Alkyl group, halo C 1-2 further substituted with 1 to 3 groups selected from an alkyl group and a 5- to 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si; In some embodiments, the proviso is that R 6 and R 10 , R 10 and R7 , R 7 and R 8 , R 8 and R 9 A pair of these together with the atom connected thereto forms a 4-, 5-, or 6-membered cycloalkyl group or a 5- or 6-membered heterocycloalkyl group containing one Si atom, and the cycloalkyl group, heterocycloalkyl group optionally includes ═O, [ka] F, Cl, deuterium, OH, C 1-2 Alkyl group, halo C 1-2 further substituted with 1 to 3 groups selected from an alkyl group and a 5- to 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si; Other groups are as described in any of the above technical solutions.

[0052] Additionally, the compounds of the present invention, their stereoisomers, deuterated forms, solvates, or pharmaceutically acceptable salts or co-crystals have the structure of formula (VA): [ka] R 11a , R 11b , R 12a , R 12b are independently H, deuterium, OH, and C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 Alkoxy group, C 3-6 cycloalkyl groups, or R 11a , R 11b , R 12a , R 12b Any two of these, together with the atoms connecting them, are C 3-6 Forming a cycloalkyl group, optionally ═O, [ka] Halogens, deuterium, CN, OH, C 1-3 Alkyl group, halo C 1-3 Alkyl groups, deuterated C 1-3 Alkyl group, C 1-3 Alkoxy group, haloC 1-3 Alkoxy group, deuterated C 1-3 is further substituted with 1 to 3 groups selected from an alkoxy group; In some embodiments, R 11a , R 11b , R 12a , R 12b are independently H, deuterium, OH, and C 1-3 Alkyl group, halo C 1-3 alkyl group, or R 11a and R 11b , or R 12a and R 12b are C together with the atoms connected to them. 3-6 forming a cycloalkyl group, In some embodiments, R 11a , R 11b , R 12a , R 12b are independently H, deuterium, OH, and C 1-3 Alkyl group, halo C 1-3 alkyl group, or R 11a and R 11b , or R 12a and R 12b together with the atoms to which they are attached form a cyclopropyl group, Other groups are as described in any of the above technical solutions.

[0053] In the fortieth technical solution of the present invention, the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or co-crystal has the structure of formula (I): [ka] During the ceremony, R 1 , R 2 , R 3 are each independently H, deuterium, or R A1, -O-HaloC 1-4 Alkyl group, -NH-haloC 1-4 Alkyl group, -OC 1-4 Alkyl group, C 1-4 Alkoxy group, C 5-6 Alkoxy group, halogen, cyano group, nitro group, C 1-4 Alkyl group, C 2-6 Alkenyl group, -NH-C 1-4 Alkyl group, -N(C 1-4 alkyl)2, -NH-C 3-10 Cycloalkyl groups, -NHC(O)C 1-4 The alkyl group, alkoxy group, cycloalkyl group, and heterocycloalkyl group are optionally selected from alkyl groups and 4 to 10-membered heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, and the ... halogen atoms, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl group, deuterium group C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterium group C 1-4 Alkoxy group, C 3-10 It is further substituted with a group selected from a cycloalkyl group, a 4- to 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, a phenyl group, and NH, with the proviso that R 1 , R 2 and R 3 are not simultaneously selected from H, R A1 is Haro C 2-6 Alkenyl group, C 2-6 Alkynyl group, -O-(CH2) r -R a , C 3-10 a cycloalkyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C 1-4 Alkyl-R a , -C 1-4 Alkyl-OR a , -C 1-4 Alkyl-NR b R a , -NR b-S(O)2-R a , -NR b -S(O)2-NR b R a , -O-NR b R a , -NH-OR b , -Se-(CH2) r -R a The alkynyl, heteroaryl, alkyl, and cycloalkyl groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R a CN, Halo C 1-6 Alkyl group, C 3-10 a cycloalkyl group, a 4- to 10-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 6- to 10-membered aryl group; a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C(O)-R a1 wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally selected from halogen, ═O, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R b are H, deuterium, and C 1-4 Alkyl group, C 3-6 Cycloalkyl groups, haloC 1-4 Alkyl groups, deuterated C 1-4 alkyl groups, R a1 are OH, NH2, -NHC1-4 Alkyl group, -N(C 1-4 alkyl)2, -NHC 3-10 Cycloalkyl groups, C 1-4 Alkoxy group, C 1-6 Alkyl group, C 3-10 selected from a cycloalkyl group, a 6- to 10-membered aryl group, and a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; X is CR 10 or N, X1 is selected from O and S; R 4 , R 5 are independently H, deuterium, and C 3-10 Cycloalkyl groups, C 2-6 Alkenyl group, C 2-6 Alkynyl group, halogen, amino group, -NH-C 1-4 Alkyl group, -N(C 1-4 Alkyl)2, C 1-4 Alkyl group, halo C 1-4 an alkyl group, a 4- to 10-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; and a 6- to 10-membered aryl group; R 6 , R 7 , R 8 , R 9 , R 10 are each independently H, deuterium, or R A2 , halogen, OH, CN, amino group, C 1-4 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 1-4 Alkoxy group, haloC 1-4 Alkyl group, -NH-C 1-4 Alkyl group, -N(C 1-4 alkyl)2, -S(O)R c , -S(O) 2 R c , -C(O)R c , -C(O)OR c , -C(O)N(R c )2, -OC(O)Rc The alkyl, alkenyl, alkynyl, and alkoxy groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; R A2 is -(CH2) r -(4- to 10-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from N, O, S, and Si), or -(CH) r -(5-10 membered heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -P(O)(R c )2, -Si(R c )3, -SF5, N3, B(OH)2, or -S(O)(=NH)R c The heterocycloalkyl and heteroaryl groups are optionally selected from halogen, ═O, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, C 3-6 Cycloalkyl groups, 4- to 7-membered heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R c are independently H, OH, C 1-4 Alkyl group, C 3-7 Cycloalkyl groups, haloC 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 an alkoxy group, or NH2; each r is independently selected from 0, 1, 2, or 3; L1 is a bond, O, NH, S, -CD2-, -CHD-, -CR L1 R L2 -, C 1-4 alkyl group, —C(O)—, S(O), S(O)2, said alkyl group optionally being selected from R L1 is further substituted with L2 is O, NH, S, -CH2-, -CD2-, -CHD-, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, C 2-4 alkyl group, -C(O)-, S(O), S(O)2, said alkyl group optionally having 1 to 3 R L1 is further substituted with R L1 , R L2 are each independently a halogen, OH, CN, an amino group, or C 1-4 Alkyl group, C 1-4 Alkoxy group, C 3-6 a cycloalkyl group, a 4- to 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; One option is R 2 , R 4 L1, together with the atom to which it is linked, forms a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be selected from R A3 is further substituted with 1 to 3 groups selected from One option is R 4 , R 5 together with the atom to which it is linked, form a 5- to 7-membered monocyclic carbocycle or a 5- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be A3 and substituted with 1 to 3 groups selected from One option is R L2 and R 9together with the atom to which it is linked, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be A3 further substituted with 1 to 3 groups selected from: Each R A3 are each independently =O, halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 selected from alkoxy and NH group substitutions; As a condition, R 6 and R 10 , R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these together with the atoms connected thereto form a 4- to 8-membered carbocyclic ring or a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and the carbocyclic ring or heterocycloalkyl group may optionally be ═O, a halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 It is further substituted with 1 to 3 groups selected from an alkoxy group and NH2.

[0054] In the 41st technical solution of the present invention, the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal has the structure of formula (II): [ka] L2 is -CH2-, -CR L1 R L2 -, -CHR L2 -,-CDRL2 -, -C(O)-, X is CR 10 or N, R 4 , R 5 are independently H, deuterium, and C 3-7 Cycloalkyl groups, C 2-4 Alkenyl group, C 2-4 Alkynyl group, F, Cl, amino group, -NH-C 1-2 Alkyl group, -N(C 1-2 Alkyl)2, C 1-2 alkyl group, and a 4- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; R 7 , R 8 are each independently H, deuterium, or R A2 , F, Cl, OH, CN, amino group, C 1-4 Alkyl group, C 2-4 Alkenyl group, C 2-4 Alkynyl group, C 1-4 Alkoxy group, haloC 1-4 Alkyl group, -NH-C 1-2 Alkyl group, -N(C 1-2 alkyl)2, -S(O)R c , -S(O) 2 R c , -C(O)R c , -C(O)OR c , -C(O)N(R c )2, -OC(O)R c is selected from R 9 , R 10 are each independently H, deuterium, F, Cl, OH, CN, amino group, C 1-2 alkyl groups, R A2 is -(CH2) r -(4-6 membered monocyclic heterocycloalkyl containing 1-3 heteroatoms selected from N, O, and S), -(CH2) r -(7-10 membered spirocyclic heterocycloalkyl containing 1-3 heteroatoms selected from N, O, and S), -(CH2) r-(5-6 membered monocyclic heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -(CH2) r -(8-10 membered bicyclic heteroaryl containing 1-3 heteroatoms selected from N, O, and S), -P(O)(R c )2, -Si(R c )3, -SF5, -S(O)(=NH)R c The heterocycloalkyl and heteroaryl groups are optionally selected from halogen, D, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1 to 3 groups selected from an alkoxy group and NH; As a condition, R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these together with the atoms connected thereto form a 4- to 8-membered carbocyclic ring or a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and the carbocyclic ring or heterocycloalkyl group may optionally be ═O, a halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 It is further substituted with 1 to 3 groups selected from an alkoxy group and NH2, and the other groups are as described in any of the above technical solutions.

[0055] The 42nd technical solution of the present invention relates to the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, wherein: R 2 , R 4L1, together with the atom to which it is linked, forms a 5- to 7-membered cycloalkyl group, a phenyl group, and the cycloalkyl group optionally includes R A3 and R 1 is not a heterocycloalkyl group, or R 4 , R 5 together with the atom to which it is linked, form a phenyl group, a 5- to 6-membered cycloalkyl group, or a 5- to 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S, and the cycloalkyl group may optionally be R A3 and R 1 is R A1 or -O-HaloC 1-4 alkyl groups, or R L2 and R 9 together with the atoms to which it is attached form a 5- to 6-membered cycloalkyl group, said cycloalkyl group optionally being selected from R A3 is further substituted with 1 to 3 groups selected from Each R A3 are each independently =O, halogen, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 selected from alkoxy and NH group substitutions; Other groups are as described in any of the above technical solutions.

[0056] The 43rd technical solution of the present invention relates to the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt, wherein: R 1 is R A1 , -O-HaloC 1-4 alkyl groups, wherein the alkyl groups are optionally selected from halogen, D, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; R 2 , R 3 are independently H, deuterium, and C 2-4 Alkenyl group, C 2-4 Alkynyl group, halogen, cyano group, nitro group, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 alkyl groups, R A1 is Haro C 2-4 Alkenyl group, C 2-4 Alkynyl group, -O-(CH2) r -R a , C 3-6 a monocyclic cycloalkyl group, a 5- to 6-membered monocyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; an 8- to 10-membered bicyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C 1-2 Alkyl-R a , -C 1-2 Alkyl-OR a , -C 1-2 Alkyl-NR b R a , -NR b -S(O)2-R a , -NR b -S(O)2-NR b R a , -O-NR b R a , -NH-OR b , -Se-(CH2) r -R a The alkynyl, heteroaryl, alkyl, and cycloalkyl groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C1-2 further substituted with 1 to 3 groups selected from an alkoxy group and NH; r is selected from 0 or 1; Each R a CN, Halo C 1-4 Alkyl group, C 3-6 Monocyclic cycloalkyl groups, C 7-10 Spirocyclic cycloalkyl groups, C 4-8 Bridged Cycloalkyl Groups, C 4-9 Fused-ring cycloalkyl groups, 4- to 6-membered monocyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, 7- to 10-membered spirocyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, 4- to 8-membered bridged cyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, 4- to 6-membered fused-ring heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, phenyl groups, 8- to 10-membered aryl groups, 5- to 6-membered monocyclic heteroaryl groups containing 1 to 3 heteroatoms selected from N, O, and S, 8- to 10-membered bicyclic heteroaryl groups containing 1 to 3 heteroatoms selected from N, O, and S, -C(O)-R a1 wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally selected from halogen, ═O, deuterium, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C 1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Each R b are H, deuterium, and C 1-2 Alkyl group, C 3-4 cycloalkyl groups, Other groups are as described in any of the above technical solutions.

[0057] In the 44th technical solution of the present invention, the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or co-crystal has the structure of formula (III): [ka] X is CR 10 or N, R 9 , R 10 are each independently H, deuterium, F, Cl, OH, CN, amino group, C 1-2 alkyl groups, As a condition, R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these together with the atoms connected thereto form a 4- to 8-membered carbocyclic ring or a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and the carbocyclic ring or heterocycloalkyl group may optionally be ═O, a halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 further substituted with 1 to 3 groups selected from an alkoxy group and NH; Other groups are as described in any of the above technical solutions.

[0058] In the 45th technical solution of the present invention, the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal has the structure of formula (IV) or (V): [ka] X is CR 10 or N, R 9 , R 10 are each independently H, deuterium, F, Cl, OH, CN, amino group, C1-2 alkyl groups, L2 is -CH2-, -CD2-, -CHD-, -CR L1 R L2 -, -CHR L2 -,-CDR L2 -, C 2-4 alkyl group, -C(O)-, wherein the alkyl group is optionally selected from 1 to 3 R L1 is further substituted with As a condition, R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these together with the atoms connected thereto form a 4- to 8-membered carbocyclic ring or a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and the carbocyclic ring or heterocycloalkyl group may optionally be ═O, a halogen, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 It is further substituted with 1 to 3 groups selected from an alkoxy group and NH2, and the other groups are as described in any of the above technical solutions.

[0059] In the 46th technical solution of the present invention, the compound of the present invention, its stereoisomer, deuterated salt, solvate, or pharmaceutically acceptable salt or cocrystal thereof, wherein R A2 is -(CH2) r -(4-6 membered monocyclic heterocycloalkyl containing 1-3 heteroatoms selected from N, O, and S), -(CH2) r -(5-6 membered monocyclic heteroaryl containing 1-3 heteroatoms selected from N, O, S), wherein the heterocycloalkyl group, heteroaryl group is optionally selected from halogen, D, CN, OH, C 1-2 Alkyl group, halo C 1-2 Alkyl groups, deuterated C 1-2 Alkyl group, C1-2 Alkoxy group, haloC 1-2 Alkoxy group, deuterated C 1-2 further substituted with 1 to 3 groups selected from an alkoxy group and NH; r is selected from 0 and 1, Other groups are as described in any of the above technical solutions.

[0060] The 47th technical solution of the present invention relates to the compound of the present invention, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, wherein: L1 is selected from a bond and O; L2 is selected from -CH2-, -C(O)-, -CHF-, -CF2-, and C(CH3)2-; R L1 , R L2 are each independently selected from H, deuterium, and F; R 6 , R 9 , R 10 are each independently selected from H, deuterium, F, Cl, OH, CN, and a methyl group; R 7 , R 8 are each independently H, deuterium, F, Cl, OH, CN, a methyl group, or R A2 is selected from R A2 teeth, [ka] is selected from R 2 , R 3 are each independently selected from H, deuterium, a vinyl group, and an ethynyl group; R 4 , R 5 are each independently selected from H, deuterium, a cyclopropyl group, a vinyl group, and an ethynyl group; One option is R 4 , R 5 forms, together with the atom to which it is linked, a phenyl group, a cyclohexyl group, a cyclopentyl group, a thienyl group, a furyl group, a pyrrolyl group, a pyrazolyl group, or an isoxazolyl group; One option is R 2 , R 4 L1 together with the atom to which it is linked forms a cyclohexyl group, a phenyl group, or a cyclopentyl group; One option is R L1 and R 9 forms a cyclopentyl group or a cyclohexyl group together with the atom to which it is linked, R 1 teeth, [ka] -CH2CH3, -CH2CH2CH3, [ka] R A1 is selected from R A1 teeth, [ka] is selected from As a condition, R 6 and R 10 , R 10 and R 7 , R 7 and R 8 , R 8 and R 9 A pair of these together with the atoms connecting them forms a 4- to 8-membered carbocyclic ring or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the carbocyclic ring, heterocycloalkyl group may optionally be ═O, F, Cl, deuterium, OH, C 1-2 Alkyl group, halo C 1-2 It is further substituted with 1 to 3 groups selected from alkyl groups, and the other groups are as described in any of the above technical solutions.

[0061] Further, the present invention relates to a compound of formula (I), formula (Ia), formula (Ib), formula (II), formula (II-a), formula (III), formula (III-a), formula (IV), formula (V), formula (VA), a stereoisomer, a deuterated product, a solvate, or a pharmaceutically acceptable salt or co-crystal thereof, wherein R 7 and R8 are C together with the atoms connected to them. 4-8 forming a cycloalkyl group, said cycloalkyl group optionally being selected from the group consisting of ═O, [ka] Halogens, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 It is further substituted with 1 to 3 groups selected from an alkoxy group, a 5 to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, a 5 to 7-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and NH2.

[0062] Further, the present invention relates to a compound of formula (I), formula (Ia), formula (Ib), formula (II), formula (II-a), formula (III), formula (III-a), formula (IV), formula (V), formula (VA), a stereoisomer, a deuterated product, a solvate, or a pharmaceutically acceptable salt or co-crystal thereof, wherein R 7 and R 8 are C together with the atoms connected to them. 4-6 Monocyclic cycloalkyl groups, C 6-8 Bicyclic Bridged Cycloalkyl Groups, C 6-8 Bicyclic fused cycloalkyl groups, C 6-8 forming a bicyclic spirocycloalkyl group, said cycloalkyl group optionally being selected from the group consisting of: ═O, [ka] Halogens, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 It is further substituted with 1 to 3 groups selected from an alkoxy group and NH2.

[0063] Further, the present invention relates to a compound of formula (I), formula (Ia), formula (Ib), formula (II), formula (II-a), formula (III), formula (III-a), formula (IV), formula (V), formula (VA), a stereoisomer, a deuterated product, a solvate, or a pharmaceutically acceptable salt or co-crystal thereof, wherein R 7 and R 8 are C together with the atoms connected to them. 4-6 forming a monocyclic cycloalkyl group, said cycloalkyl group optionally being selected from the group consisting of ═O, [ka] Halogens, deuterium, CN, OH, C 1-4 Alkyl group, halo C 1-4 Alkyl groups, deuterated C 1-4 Alkyl group, C 1-4 Alkoxy group, haloC 1-4 Alkoxy group, deuterated C 1-4 It is further substituted with 1 to 3 groups selected from an alkoxy group and NH2.

[0064] Further, the present invention relates to a compound of formula (I), formula (Ia), formula (Ib), formula (II), formula (II-a), formula (III), formula (III-a), formula (IV), formula (V), formula (VA), a stereoisomer, a deuterated product, a solvate, or a pharmaceutically acceptable salt or co-crystal thereof, wherein R 7 and R 8 together with the atom connected thereto, represents a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cyclobutenyl group, a cyclopentenyl group, a cyclohexenyl group, [ka] and optionally halogen, deuterium, CN, OH, C 1-3 Alkyl group, halo C 1-3 Alkyl groups, deuterated C 1-3 Alkyl group, C 1-3 Alkoxy group, haloC 1-3 Alkoxy group, deuterated C 1-3It is further substituted with 1 to 3 groups selected from an alkoxy group and NH2. The present invention relates to a compound of formula (I), formula (Ia), formula (Ib), formula (II), formula (II-a), formula (III), formula (III-a), formula (IV), formula (V), formula (VA), formula (VI), formula (VII), formula (VIII), formula (IX), a stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or co-crystal thereof, and the compound is selected from the structures in Table 1 and Table 2 below, but is not limited thereto.

[0065] [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8]

[0066] [Table 2] Note: abs represents absolute configuration.

[0067] Next, the present invention further provides a pharmaceutical composition, which contains a compound according to any one of the above technical solutions, its stereoisomer, solvate, deuterated product, or pharmaceutically acceptable salt, and a pharmaceutically acceptable carrier and / or excipient.

[0068] Furthermore, the pharmaceutical composition or pharmaceutical formulation comprises 1 to 1500 mg of the compound according to any of the above technical aspects, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or co-crystal, and a pharmaceutically acceptable carrier and / or excipient.

[0069] Furthermore, the present invention further provides a use of the compound according to any one of the above embodiments, or a stereoisomer, solvate, deuterated product, or pharmaceutically acceptable salt or pharmaceutical composition thereof, in the manufacture of a medicament for treating / preventing a Myosin II-mediated disease, including, but not limited to, muscular dystrophy.

[0070] The present invention further provides a method for treating a disease in a mammal, the method comprising administering to a subject a therapeutically effective amount of a compound described in any one of the above technical solutions, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or cocrystal, and a pharmaceutically acceptable carrier and / or excipient, wherein the therapeutically effective amount is preferably 1-1500 mg, and the disease is preferably muscular dystrophy.

[0071] The present invention further provides a method for treating a disease in a mammal, comprising administering to said mammal a therapeutically effective amount of a compound according to the present invention, or a stereoisomer, deuterated form, solvate, pharmaceutically acceptable salt or co-crystal thereof, or a pharmaceutical composition thereof. In some embodiments, the mammal according to the present invention comprises a human.

[0072] As used herein, an "effective amount" or "therapeutically effective amount" includes administering a sufficient amount of a compound disclosed herein that relieves to some extent one or more symptoms of the disease or condition being treated. In some embodiments, the result is a reduction and / or alleviation of the signs, symptoms, or causes of a disease, or any other desired alteration of a biological system. For example, an "effective amount" for therapeutic use is that amount of a compound disclosed herein necessary to provide a clinically significant reduction in disease symptoms. Examples of therapeutically effective amounts include 1-1500 mg, 1-1400 mg, 1-1300 mg, 1-1200 mg, 1-1000 mg, 1-900 mg, 1-800 mg, 1-700 mg, 1-600 mg, 1-500 mg, 1-400 mg, 1-300 mg, 1-250 mg, 1-200 mg, 1-150 mg, 1-125 mg, 1-100 mg, 1-80 mg, 1-60 mg, 1-50 mg, 1-40 mg, 1-25 mg, 1-20 mg, 1-50 mg, 1-1 ... 500mg, 5~1000mg, 5~900mg, 5~800mg, 5~700mg, 5~600mg, 5~500mg, 5~400mg, 5~300mg, 5~250mg, 5~200mg, 5~150mg, 5~1 25mg, 5~100mg, 5~90mg, 5~70mg, 5~80mg, 5~60mg, 5~50mg, 5~40mg, 5~30mg, 5~25mg, 5~20mg, 10~1500mg, 10~1000mg, 10 ~900mg, 10~800mg, 10~700mg, 10~600mg, 10~500mg, 10~450mg, 10~400mg, 10~300mg, 10~250mg, 10~200mg, 10~150mg, 1 0~125mg, 10~100mg, 10~90mg, 10~80mg, 10~70mg, 10~60mg, 10~50mg, 10~40mg, 10~30mg, 10~20mg, 20~1500mg, 20~1000 mg, 20~900mg, 20~800mg, 20~700mg, 20~600mg, 20~500mg, 20~400mg, 20~350mg, 20~300mg, 20~250mg, 20~200mg, 20~15 0mg, 20~125mg, 20~100mg, 20~90mg, 20~80mg, 20~70mg, 20~60mg, 20~50mg, 20~40mg, 20~30mg, 50~1500mg, 50~1000mg,Examples of effective dosages include, but are not limited to, 50 to 900 mg, 50 to 800 mg, 50 to 700 mg, 50 to 600 mg, 50 to 500 mg, 50 to 400 mg, 50 to 300 mg, 50 to 250 mg, 50 to 200 mg, 50 to 150 mg, 50 to 125 mg, 50 to 100 mg, 100 to 1500 mg, 100 to 1000 mg, 100 to 900 mg, 100 to 800 mg, 100 to 700 mg, 100 to 600 mg, 100 to 500 mg, 100 to 400 mg, 100 to 300 mg, 100 to 250 mg, and 100 to 200 mg.

[0073] The present invention relates to a pharmaceutical composition or formulation comprising a therapeutically effective amount of a compound according to the present invention or a stereoisomer, deuterated form, solvate, pharmaceutically acceptable salt or co-crystal thereof, and a carrier and / or excipient. The pharmaceutical composition may be in the form of a unit dosage form (the amount of active ingredient in a unit dosage form is also referred to as the "formulation specification"). In some embodiments, the pharmaceutical composition contains 1-1500 mg, 5-1000 mg, 10-800 mg, 20-600 mg, 25-500 mg, 40-200 mg, 50-100 mg, 1 mg, 1.25 mg, 2.5 mg, 5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 110 mg, 120 mg, 125 mg, 130 mg, 140 mg, 150 mg, 160 mg, 170 mg, 180 mg, 190 mg, 200 mg, 21

[0033] The present invention relates to a compound of the present invention or a stereoisomer, deuterated form, solvate, pharmaceutically acceptable salt, or co-crystal thereof, including, but not limited to, 0 mg, 220 mg, 230 mg, 240 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 500 mg, 525 mg, 550 mg, 575 mg, 600 mg, 625 mg, 650 mg, 675 mg, 700 mg, 725 mg, 750 mg, 775 mg, 800 mg, 850 mg, 900 mg, 950 mg, 1000 mg, 1100 mg, 1200 mg, 1300 mg, 1400 mg, or 1500 mg of the compound of the present invention or a stereoisomer, deuterated form, solvate, pharmaceutically acceptable salt, or co-crystal thereof.

[0074] A method for treating a disease in a mammal, the method comprising administering to a subject a therapeutically effective amount of a compound of the present invention, its stereoisomer, deuterated form, solvate, or pharmaceutically acceptable salt or co-crystal, and a pharmaceutically acceptable carrier and / or excipient, wherein the therapeutically effective amount is preferably 1 to 1500 mg, and the disease is preferably muscular dystrophy.

[0075] A method for treating a disease in a mammal, the method comprising administering to a subject a pharmaceutical agent, a compound of the present invention, a stereoisomer, deuterated form, solvate, or pharmaceutically acceptable salt or co-crystal thereof, and a pharmaceutically acceptable carrier and / or excipient, in a daily amount of 1 to 1500 mg / day, which may be a single dose or divided doses, and in some embodiments, the daily amount is 10 to 1500 mg / day, 20 to 1500 mg / day, 25 to 1500 mg / day, 50 to 1500 mg / day, 75 to 1500 mg / day, 100 to 1500 mg / day, 200 to 1500 mg / day, 10 to 1000 mg / day, 20 to 1000 mg / day, 25 to 1000 mg / day, 50 to 10 ... In some embodiments, the doses include, but are not limited to, 5 to 1000 mg / day, 100 to 1000 mg / day, 200 to 1000 mg / day, 25 to 800 mg / day, 50 to 800 mg / day, 100 to 800 mg / day, 200 to 800 mg / day, 25 to 400 mg / day, 50 to 400 mg / day, 100 to 400 mg / day, and 200 to 400 mg / day. Daily doses include, but are not limited to, 1 mg / day, 5 mg / day, 10 mg / day, 20 mg / day, 25 mg / day, 50 mg / day, 75 mg / day, 100 mg / day, 125 mg / day, 150 mg / day, 200 mg / day, 400 mg / day, 600 mg / day, 800 mg / day, 1000 mg / day, 1200 mg / day, 1400 mg / day, and 1500 mg / day.

[0076] The present invention relates to a kit, which may comprise a composition in single-dose or multi-dose form, comprising a compound of the present invention or a stereoisomer, deuterated form, solvate, pharmaceutically acceptable salt or co-crystal thereof, wherein the amount of the compound of the present invention or a stereoisomer, deuterated form, solvate, pharmaceutically acceptable salt or co-crystal thereof is the same as the amount in the pharmaceutical composition.

[0077] In the present invention, the amounts of the compounds of the invention or their stereoisomers, deuterated forms, solvates, pharmaceutically acceptable salts or co-crystals are in each case calculated in terms of the form of the free base.

[0078] "Preparation specifications" refers to the weight of the active ingredient contained in one unit dosage form, one tablet, or each other unit dosage form.

[0079] Synthetic Route Those skilled in the art can combine known organic synthesis techniques to prepare the compounds of the present invention, and the starting materials are commercially available chemicals and / or compounds described in the chemical literature. "Commercially available chemicals" are those obtained from legitimate commercial sources, including companies such as Taitan Technology, Ananji Chemical, Shanghai Demo, Chengdu Kelong Chemical, Shaoyuan Chemical, Nanjing Yaoshi, Yaoming Kangde, and Bai Lingwei Technology.

[0080] Specific and similar reactants can be selectively identified through indexes of known chemicals produced by the American Chemical Society's Chemical Information Retrieval Service, which are available in many public and university libraries and online. Known chemicals not available in catalogs may optionally be produced by custom chemical synthesis businesses, many of which offer custom synthesis services (e.g., the companies listed above).

[0081] term Unless otherwise specified in the present invention, the terms used in the present invention have the following meanings.

[0082] Carbon, hydrogen, oxygen, sulfur, nitrogen or halogen in the groups and compounds described in the present invention include any of their isotopes, and carbon, hydrogen, oxygen, sulfur, nitrogen or halogen in the groups and compounds described in the present invention are optionally further substituted by one or more corresponding isotopes, where the carbon isotope is: 12 C and 13 C and 14 C, isotopes of hydrogen include protium (H), deuterium (D, also called heavy hydrogen), and tritium (T, also called tritium), and isotopes of oxygen include 16 O and 17 O and 18 Isotopes of sulfur include O and 32 S and 33 S and 34 S and 36 S and nitrogen isotopes include 14 N and 15 N and fluorine isotopes include 19 F, and the chlorine isotope is 35 Cl and 37 The isotopes of bromine include Cl and 79 Br and 81 Contains Br.

[0083] As used herein, "halogen" refers to F, Cl, Br, I, or an isotope thereof.

[0084] "Halogenated" or "halogen substituted" refers to substitution with one or more selected from F, Cl, Br, I, or isotopes thereof, and the upper limit of the number of halogen substituents is equal to the sum of the substitutable hydrogen atoms of the group to be substituted. Unless otherwise specified, the number of halogen substituents is any integer between 1 and the upper limit, and when the number of halogen substituents is greater than 1, they may be substituted with the same or different halogens. Usually, cases of 1 to 5 halogen substitutions, 1 to 3 halogen substitutions, 1 to 2 halogen substitutions, and 1 halogen substitution are included.

[0085] "Deuterium" refers to heavy hydrogen, an isotope of hydrogen (H), and has the same meaning as "D."

[0086] The term "deuterated" or "deuteride" refers to a group such as an alkyl group, a cycloalkyl group, an alkylene group, an aryl group, a heteroaryl group, a mercapto group, a heterocycloalkyl group, an alkenyl group, or an alkynyl group, in which a hydrogen atom is substituted with at least one deuterium atom, and the upper limit of the number of deuteration is equal to the sum of the numbers of hydrogen atoms that can be substituted in the substituted groups. Unless otherwise specified, the number of deuteration is any integer between 1 and the upper limit, such as 1 to 20 deuterium atom substitutions, 1 to 10 deuterium atom substitutions, 1 to 6 deuterium atom substitutions, 1 to 3 deuterium atom substitutions, 1 to 2 deuterium atom substitutions, or 1 deuterium atom substitution.

[0087] "C x-y " group refers to a group containing x to y carbon atoms, e.g., "C 1-6 "Alkyl group" refers to an alkyl group containing from 1 to 6 carbon atoms.

[0088] "Alkyl group" refers to a monovalent linear or branched saturated aliphatic hydrocarbon group. Typically, the alkyl group has 1 to 20 carbon atoms, or 1 to 8 carbon atoms, or 1 to 6 carbon atoms, or 1 to 4 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, neobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, and the like, and the alkyl group may be further substituted with a substituent.

[0089] "Alkylene group" refers to divalent straight and branched chain saturated alkyl groups. Examples of alkylene groups include, but are not limited to, methylene groups, ethylene groups, and the like.

[0090] A "halogenated alkyl group" refers to an alkyl group in which one or more hydrogen atoms are replaced with one or more halogen atoms (e.g., fluorine, chlorine, bromine, iodine, or isotopes thereof), and the upper limit of the number of halogen substituents is equal to the sum of the replaceable hydrogen atoms in the alkyl group. Unless otherwise specified, the number of halogen substituents is any integer between 1 and the upper limit. Typically, the alkyl group is substituted with 1 to 5 halogen atoms, or 1 to 3 halogen atoms, or 1 to 2 halogen atoms, or 1 halogen atom. When the number of halogen substituents is greater than 1, they may be substituted with the same or different halogen atoms. Specific examples include, but are not limited to, -CF3, -CH2Cl, -CH2CF3, -CCl2, CF3, etc.

[0091] An "alkoxy group" or "alkyloxy group" refers to an -O-alkyl group. For example, -OC 1-8 Alkyl group, -OC 1-6 Alkyl group, -OC 1-4 Alkyl group or -OC 1-2 Specific non-limiting examples include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentyloxy, n-hexyloxy, cyclopropoxy, and cyclobutoxy groups, and the alkoxy groups may be optionally substituted with a substituent.

[0092] A "halogenated alkoxy group" refers to an -O-halogenated alkyl group. For example, -O-haloC 1-8 Alkyl group, -O-haloC 1-6 Alkyl group, -O-haloC 1-4 Alkyl group or -O-haloC 1-2It is an alkyl group, and the upper limit of the number of halogen substituents is equal to the sum of the substitutable hydrogen atoms in the substituted group. Unless otherwise specified, the number of halogen substituents is any integer between 1 and the upper limit, and preferably 1 to 5 halogen substituents, 1 to 3 halogen substituents, 1 to 2 halogen substituents, or 1 halogen substituent. When the number of halogen substituents is more than 1, they may be substituted with the same or different halogens. Non-limiting examples include a monofluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, and a difluoroethyloxy group.

[0093] The term "alkenyl group" refers to a straight-chain or branched-chain hydrocarbon group containing at least one carbon-carbon double bond (C=C), and typically contains 2 to 18 carbon atoms, for example, 2 to 8 carbon atoms, further for example, 2 to 6 carbon atoms, further for example, 2 to 4 carbon atoms. Examples of alkenyl groups include vinyl, allyl, 1-propenyl, 2-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, and 2-methyl-3-butenyl. The alkenyl groups may optionally be further substituted with substituents, including, but not limited to, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 1-octenyl, 3-octenyl, 1-nonenyl, 3-nonenyl, 1-decenyl, 4-decenyl, 1,3-butadiene, 1,3-pentadiene, 1,4-pentadiene, and 1,4-hexadiene.

[0094] An "alkenylene group" refers to a straight-chain or branched-chain divalent unsaturated hydrocarbon group containing at least one carbon-carbon double bond (C=C), typically containing 2 to 18 carbon atoms, for example, 2 to 8 carbon atoms, further for example, 2 to 6 carbon atoms, and even further for example, 2 to 4 carbon atoms; a non-limiting embodiment includes an ethynylene group, which alkenylene group may be optionally substituted with a substituent.

[0095] The term "alkynyl group" refers to a straight-chain or branched-chain hydrocarbon group containing at least one carbon-carbon triple bond (C≡C), typically containing 2 to 18 carbon atoms, preferably 2 to 8 carbon atoms, more preferably 2 to 6 carbon atoms, and even more preferably 2 to 4 carbon atoms. Examples include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 4-pentyl, 3-pentyl, 1-methyl-2-butynyl, 2-hexynyl, 3-hexynyl, 2-heptynyl, 3-heptynyl, 4-heptynyl, 3-octynyl, 3-nonynyl, and 4-decynyl groups, and the alkynyl group may be optionally substituted.

[0096] "Alkynylene group" refers to a straight or branched chain divalent unsaturated hydrocarbon group containing a carbon-carbon triple bond (C≡C), typically containing 2 to 18 carbon atoms, preferably 2 to 8 carbon atoms, more preferably 2 to 6 carbon atoms, and even more preferably 2 to 4 carbon atoms; non-limiting examples include ethynylene, propynylene, and butynylene groups, which alkynylene groups may be optionally substituted.

[0097] "Cycloalkyl group" refers to a saturated or partially unsaturated non-aromatic carbocyclic hydrocarbon group that does not contain a cycloheteroatom. Cycloalkyl groups can be monocyclic, bicyclic, or polycyclic, and bicyclic or polycyclic groups can be parallel, spirocyclic, bridged, or combinations thereof. Bicyclic or polycyclic groups can contain one or more aromatic rings, but the ring system as a whole does not have aromatic character, and the linking point can be on an aromatic or non-aromatic ring. Typically, cycloalkyl groups contain 3 to 20 carbon atoms, preferably 3 to 8 carbon atoms, and more preferably 3 to 6 carbon atoms; if monocyclic, 3 to 15 carbon atoms, or 3 to 10 carbon atoms, or 3 to 8 carbon atoms, or 3 to 6 carbon atoms; if bicyclic or polycyclic, 5 to 12 carbon atoms, or 5 to 11 carbon atoms, or 6 to 10 carbon atoms; non-limiting examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, butenyl, cyclopentenyl, cyclohexenyl, [ka] and the like, and cycloalkyl groups may be optionally substituted with substituents.

[0098] A "cycloalkylene group" is a divalent group of a cycloalkyl group.

[0099] "Aryl group" refers to a carbocyclic ring having aromatic character and containing no heteroatoms, including monocyclic aryl groups, fused-ring aryl groups, and aryl-fused cycloalkyl groups, where the aryl group is the linking site when fused to a cycloalkyl group. Typically, they contain 6 to 14 carbon atoms, and even 6 to 10 carbon atoms. Non-limiting examples include phenyl, naphthyl, anthracenyl, phenanthrenyl, and the like. [ka] wherein the aryl group may be optionally substituted with a substituent.

[0100] "Carbocycle" or "carbocyclic group" refers to a saturated, partially unsaturated, or aromatic carbon ring, and includes aryl and cycloalkyl groups. Carbocycles can be monocyclic, bicyclic, or polycyclic, and bicyclic or polycyclic rings include bridged, parallel, and spiro rings, as well as combinations thereof. Carbocycles typically have 3 to 12 carbon atoms, or 3 to 10 carbon atoms, or 3 to 6 carbon atoms. In non-limiting examples, monocyclic carbocycles include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, or phenyl, and bicyclic bridged rings include [ka] and the like, and the bicyclic parallel ring is [ka] and the like, and the bicyclic spiro ring is [ka] etc., and carbocycles may be optionally substituted with substituents.

[0101] A "heterocycloalkyl group" refers to a saturated or partially unsaturated non-aromatic carbocyclic ring containing one, two, three, or four heteroatoms selected from N, S, and O. A heterocycloalkyl group may be monocyclic, bicyclic, or polycyclic, and the bicyclic or polycyclic ring may be bridged, parallel, spiro, or a combination thereof. A bicyclic or polycyclic ring may contain one or more aromatic or heteroaromatic rings, but the ring system as a whole does not possess aromaticity, and the linking site may be on an aromatic or non-aromatic ring. A heterocycloalkyl group typically has 3 to 20 ring members. A monocyclic heterocycloalkyl group typically has 3 to 15, 3 to 10, 3 to 8, or 3 to 6 ring members. A bicyclic or polycyclic heterocycloalkyl group typically has 5 to 12, 5 to 11, or 6 to 9 ring members. The heteroatoms N and S include their oxidation states. Non-limiting examples of heterocycloalkyl groups include azetidinyl, morpholinyl, piperazinyl, piperidinyl, tetrahydropyranyl, oxetanyl, pyranyl, azacyclopentenyl, azacyclohexenyl, oxolyl, oxynyl, and the like, and heterocycloalkyl groups may be optionally substituted.

[0102] "Heteroaromatic ring" or "heteroaryl group," unless otherwise specified, refers to a ring containing 1 to 4 heteroatoms selected from N, O, or S and their oxidation states, and having aromatic properties. The ring may be monocyclic, bicyclic, or polycyclic, and the bicyclic or polycyclic ring may be a bridged ring, a parallel ring, a spiro ring, or a combination thereof. If bicyclic or polycyclic, the heteroaryl group may be fused with an aryl group, or a heteroaryl group may be fused with a heteroaryl group, where both the heteroaryl group and the aryl group may be linking moieties. Non-limiting examples include furyl, thienyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, indolyl, purinyl, [ka] and the like, wherein said heteroaryl groups may be optionally substituted with substituents.

[0103] "Heterocyclo" or "heterocyclo group" refers to a saturated or unsaturated, aromatic or non-aromatic ring containing 1 to 4 heteroatoms selected from N, O, or S and their oxidation states, including heteroaryl and heterocycloalkyl groups. Heterocyclo includes monocyclic heterocyclos, bridged bicyclic heterocyclos, fused bicyclic heterocyclos, and spiro bicyclic heterocyclos, or combinations thereof. Typically, the heterocyclo is a 3- to 12-membered heterocyclo, a 5- to 12-membered heterocyclo, or a 5- to 7-membered heterocyclo. Heterocyclo groups may be attached at a heteroatom or a carbon atom, and non-limiting examples include oxiranyl, azacyclopropyl, oxetanyl, azetidinyl, 1,3-dioxolanyl, 1,4-dioxolanyl, 1,3-dioxanyl, piperazinyl, azacycloheptyl, pyridyl, furyl, thienyl, pyranyl, N-alkylpyrrolyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyridazinyl, imidazolyl, piperidinyl, piperidyl, morpholinyl, thiomorpholinyl, 1,3-dithianyl, dihybridyl, methyl ... a thiazolyl group, a benzopyridyl group, a dihydropyranyl group, a dithiolanyl group, a tetrahydrofuranyl group, a tetrahydropyrrolyl group, a tetrahydroimidazolyl group, an oxazolyl group, a dihydrooxazolyl group, a tetrahydrooxazolyl group, a tetrahydrothiazolyl group, a tetrahydropyranyl group, a benzimidazolyl group, a benzopyridyl group, a pyrrolopyridyl group, a benzodihydrofuryl group, an azabicyclo[3.2.1]octyl group, an azabicyclo[5.2.0]nonyl group, an oxatricyclo[5.3.1.1]dodecyl group, an azaadamantyl group, and an oxaspiro[3.3]heptyl group; [ka] and the like, wherein heterocyclos may be optionally substituted with substituents.

[0104] A "heterocyclylene group" refers to a substituted or unsubstituted, saturated or unsaturated, aromatic or non-aromatic divalent heterocyclo group. Non-limiting examples include: [ka] Includes:

[0105] "Spiro ring" refers to a polycyclic group in which the rings share one carbon atom (called a spiro atom), which may contain zero or more double or triple bonds and zero to five heteroatoms selected from N, O, S, P, Si, and their oxidation states. Typically, the spiro ring is a 6- to 14-membered ring, or a 6- to 12-membered ring, or a 6- to 10-membered ring. Typically, the spiro ring is a 3-spiro3 (representing a 3-membered spiro3 ring), a 3-spiro4, a 3-spiro5, a 3-spiro6, a 4-spiro4, a 4-spiro5, a 4-spiro6, a 5-spiro5, or a 5-spiro6. Non-limiting examples of spiro rings are: [ka] wherein the spiro ring may be optionally substituted with a substituent.

[0106] "Parallel ring" or "fused ring" refers to a polycyclic group in which rings share two adjacent ring atoms and one chemical bond, and may contain one or more double or triple bonds. The parallel rings may contain 0 to 5 heteroatoms selected from N, S, O, P, Si, and their oxidation states. Typically, the parallel rings are 5 to 20-membered, 5 to 14-membered, 5 to 12-membered, or 5 to 10-membered rings. Typically, the parallel rings are 3-parallel 4-rings (representing parallel rings formed by a 3-membered ring and a 4-membered ring; based on the IUPC nomenclature, parallel rings with a 3-membered ring as the base ring are possible, and parallel rings with a 4-membered ring as the base ring are also possible, and the same applies below), 3-parallel 5-rings, 3-parallel 6-rings, 4-parallel 4-rings, 4-parallel 5-rings, 4-parallel 6-rings, 5-parallel 5-rings, 5-parallel 6-rings, or 6-parallel 6-rings. Non-limiting examples of parallel rings include purine, quinoline, isoquinoline, benzopyran, benzofuran, benzothiophene, [ka] wherein the parallel rings may be aromatic or non-aromatic and are optionally substituted with substituents.

[0107] A "bridged ring" refers to two rings that share two non-adjacent ring atoms and may contain one or more double or triple bonds. The bridged ring may contain 0 to 5 heteroatoms selected from N, S, O, P, Si, and their oxidation states. Typically, the bridged ring has 5 to 20, or 5 to 14, or 5 to 12, or 5 to 10 ring atoms. Non-limiting examples of bridged rings include adamantane, [ka] Includes.

[0108] "Substituted" or "substituent" means, unless otherwise specified, that optional substitution occurs in chemically permissible positions and the number of substituents complies with the rules of chemical bonding. Exemplary substituents are C 1-6 Alkyl group, C 2-6 Alkenyl group, C 2-6 Alkynyl group, C 3-8 Heteroalkyl groups, C 5-12 Aryl group, 5- to 12-membered heteroaryl group, hydroxy group, C 1-6 Alkoxy group, C 5-12 Aryloxy group, thiol group, C 1-6 Alkylthio group, cyano group, halogen, C 1-6 Alkylthiocarbonyl group, C 1-6 Alkylcarbamoyl group, N-carbamoyl group, nitro group, silyl group, sulfinyl group, sulfonyl group, sulfoxide, haloC 1-6 Alkyl group, halo C 1-6 Alkoxy group, amino group, phosphonic acid, -CO2(C 1-6 alkyl), -OC(=O)(C 1-6 alkyl), -OCO2(C 1-6 alkyl), -C(=O)NH2, -C(=O)N(C 1-6 alkyl)2, -OC(=O)NH(C 1-6 alkyl), -NHC(=O)(C 1-6 alkyl), -N(C 1-6alkyl)C(=O)(C 1-6 alkyl), -NHCO2(C 1-6 alkyl), -NHC(=O)N(C 1-6 alkyl)2, -HC(=O)NH(C 1-6 alkyl), -NHC(=O)NH2, -NHSO2(C 1-6 alkyl), -SO2N(C 1-6 alkyl)2, -SO2NH(C 1-6 alkyl), -SO2NH2, -SO2C 1-6 Examples include, but are not limited to, alkyl groups and the like.

[0109] "Optionally" or "optionally" means that the subsequently described event or circumstance may, but does not necessarily, occur, and the description includes both cases where the event or circumstance occurs and cases where it does not occur. For example, "an alkyl group optionally substituted with F" means that the alkyl group may, but is not necessarily, substituted with F, and includes cases where the alkyl group is substituted with F and cases where the alkyl group is not substituted with F.

[0110] "Pharmaceutically acceptable salts" refers to salts in which the compounds of the present invention retain the biological effectiveness and properties of the free acids or free bases and which are obtained by reaction of said free acids with non-toxic inorganic or organic bases, or by reaction of said free bases with non-toxic inorganic or organic acids.

[0111] A "pharmaceutical composition" refers to one or more of the compounds herein or stereoisomers, deuterated forms, solvates, pharmaceutically acceptable salts, or co-crystals thereof, or a mixture thereof with other components, wherein the other components include physiologically / pharmaceutically acceptable carriers and / or excipients.

[0112] The term "carrier" refers to a system that does not significantly stimulate the living body, does not eliminate the biological activity and properties of a given compound, and can change the drug's administration form and distribution in the body, control the drug's release rate, and deliver the drug to the target organ; non-limiting examples include microcapsules and microspheres, nanoparticles, liposomes, etc.

[0113] "Excipient" refers to a substance that is not itself a therapeutic agent, but is added to a pharmaceutical composition as a diluent, excipient, adhesive, and / or vehicle to improve its processing or storage properties, or to allow or facilitate the compound or pharmaceutical composition to form a dosage form for administration. As known to those skilled in the art, excipients can serve a variety of functions and may be described as wetting agents, buffers, suspending aids, lubricants, emulsifiers, disintegrants, absorbents, preservatives, surfactants, colorants, flavoring agents, and sweeteners. Examples of excipients include, but are not limited to, the following: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethylcellulose, ethyl cellulose, cellulose acetate, hydroxypropyl methylcellulose, hydroxypropyl cellulose, microcrystalline cellulose, and cross-linked carboxymethylcellulose (e.g., cross-linked sodium carboxymethylcellulose); (4) tragacanth gum powder; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository wax; (9) oils, such as peanut oil, cottonseed oil, safflower oil, goa oil, olive oil, and the like. (10) glycols, such as propylene glycol; (11) polyols, such as glycerin, sorbitol, mannitol, and polyethylene glycol; (12) esters, such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers, such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) water for endotoxin testing; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) pH buffer solutions; (21) polyesters, polycarbonates, and / or polyanhydrides; and (22) other non-toxic, compatible substances used in pharmaceutical formulations.

[0114] The compounds of the present invention may have particular geometric or stereoisomeric forms. In the present invention, all such compounds include cis and trans isomers, (-)- and (+)-enantiomers, (R)- and (S)-enantiomers, diastereomers, (D)-isomers, (L)-isomers, and racemic and other mixtures thereof, such as enantiomerically or diastereomerically enriched mixtures, all of which are within the scope of the present invention. Substituents of the compounds of the present invention may have other asymmetric carbon atoms. All of these isomers and mixtures thereof are within the scope of the present invention. In some embodiments, preferred compounds are isomeric compounds that exhibit superior biological activity. Purified or partially purified isomers and stereoisomers, or racemic or diastereomeric mixtures, of the compounds of the present invention are also within the scope of the present invention. Purification and separation of such materials can be achieved by standard techniques known in the art.

[0115] The compounds of the present invention further include tautomers thereof, for example, when a left-hand compound in which the pyrimidine ring is substituted with OH is described in the present invention, the right-hand tautomeric compound is also included. [ka]

[0116] The term "solvate" refers to a substance formed by intermolecular non-covalent bonding of a compound of the present invention or a salt thereof with a stoichiometric or non-stoichiometric solvent. When the solvent is water, it becomes a hydrate.

[0117] A "cocrystal" refers to a crystalline body formed by the association of an active pharmaceutical ingredient (API) and a co-crystal former (CCF) through hydrogen bonding or other non-covalent bonds, where the API and CCF are both solids in their pure states at room temperature and there is a fixed stoichiometric ratio between the components. Cocrystals are multi-component crystalline bodies, and include not only binary cocrystals formed between two neutral solids, but also multi-component cocrystals formed between a neutral solid and a salt or solvate. DETAILED DESCRIPTION OF THE INVENTION

[0118] The present invention will be described in detail below with reference to examples. Unless specific conditions are specified in the examples, the experiments were carried out according to general conditions. The examples are provided to better explain the present invention, and it should be understood that the present invention is not limited to the examples provided. Any non-essential improvements and adjustments made by those skilled in the art to the embodiments based on the above invention still fall within the scope of protection of the present invention.

[0119] Test Method The structure of the compound is confirmed by nuclear magnetic resonance (NMR) and / or mass spectrometry (MS). The NMR displacements (δ) are 10 -6 The NMR data are given in ppm (ppm). NMR measurements were performed using Bruker Avance III 400 and Bruker Avance 300 nuclear magnetic resonance spectrometers, with deuterated dimethyl sulfoxide (DMSO-d), deuterated chloroform (CDCl), and deuterated methanol (CD3OD) as solvents, and tetramethylsilane (TMS) as the internal standard. MS measurements were performed using Agilent 6120B (ESI) and Agilent 6120B (APCI). HPLC measurements were performed using an Agilent 1260DAD high-pressure liquid chromatograph (Zorbax SB-C 18 100 × 4.6 mm, 3.5 μM) Thin layer chromatography silica gel plates are Yantai Yellow Sea HSGF254 or Qingdao GF254 silica gel plates. The silica gel plates used for thin layer chromatography (TLC) are 0.15mm to 0.20mm in diameter, and the separation and purification of products by thin layer chromatography are 0.4mm to 0.5mm in diameter. For column chromatography, Yantai Yellow Sea silica gel 200-300 mesh silica gel was generally used as the carrier. Preparation of Intermediate 1 [ka]

[0120] Step 1: 2,2-Difluoroethanol-1-ol (16.5 g, 201.2 mmol) was dissolved in tetrahydrofuran (50 mL) and sodium hydride (7.44 g, 310 mmol) was added portionwise at 0 °C. The mixture was allowed to warm to room temperature and stirred for 40 min. 5-Bromo-2-chloropyrimidine (compound 1a) (30 g, 155.1 mmol) was added to the solution in tetrahydrofuran (50 mL) and stirred for 3 min. The mixture was diluted with water and extracted three times with ethyl acetate. The organic phase was collected, dried, and concentrated to give compound 1b (36 g crude), which was used directly in the next step. LC-MS (ESI): m / z=239.1[M+H] + .

[0121] Step 2: Compound 1b (38 g, 158.98 mmol), potassium acetate (39.01 g, 397.45 mmol), bis(pinacolato)diboron (52.48 g, 206.67 mmol), and chloro(2-dicyclohexylphosphino-2',4',6'-triisoporphyrinyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (12.51 g, 15.90 mmol) were dissolved in 1,4-dioxane (500 mL), purged with nitrogen gas three times, heated to 100 °C under a nitrogen atmosphere, and stirred for 3 h. The mixture was filtered while hot, and the filter cake was rinsed four times with ethyl acetate and four times with dichloromethane. The filtrate was collected and concentrated to give compound 1c (32 g crude), which was used directly in the next step. LC-MS (ESI): m / z=205.2[M+H] + .

[0122] Step 3: Compound 1c (30 g, 147.10 mmol), 6-bromo-3-pyridazinone (30.71 g, 176.52 mmol), tripotassium phosphate (40.59 g, 191.23 mmol), and (1,3-bis(2,6-diisopropylphenyl)imidazolidene)(3-chloropyridyl)dichloropalladium(II) (10.02 g, 14.71 mmol) were dissolved in a mixture of 1,4-dioxane (360 mL) and water (120 mL), purged with nitrogen gas three times, heated to 90° C. under a nitrogen atmosphere, and stirred for 3 hours. After cooling, the mixture was filtered, and the filter cake was washed with water, ethyl acetate, and dichloromethane, respectively. The filter cake was collected and dried to obtain Intermediate 1 (27 g crude), which was used directly. LC-MS (ESI): m / z=255.1[M+H] + . Example 56 [ka]

[0123] Step 1: Compound 56A (0.7 g, 5.22 mmol) was dissolved in dichloromethane (12 mL), thionyl chloride (1.24 g, 10.44 mmol) was added, and the mixture was stirred at room temperature for 2 hours. Direct concentration under reduced pressure gave compound 56B (0.8 g crude, 100%), which was used directly in the next step.

[0124] 1 H NMR (400MHz,DMSO-d6) δ 7.24 (d,1H),7.15 (t,1H),7.07 (d,1H),4.72 (s,2H),3.12 (s,4H).

[0125] Step 2: Compound 1D (0.6 g, 2.20 mmol, see WO2020097258A1 for synthetic methods), compound 56B (0.34 g, 2.20 mmol), and cesium carbonate (2.15 g, 6.60 mmol) were dissolved in acetonitrile (20 mL) and stirred at 80 ° C for 2 hours. After cooling, the mixture was directly concentrated. Water (10 mL) was added to the residue, and the mixture was extracted three times with ethyl acetate (15 mL × 3). The organic phase was collected, dried, and concentrated. The resulting residue was purified by reverse-phase column chromatography (acetonitrile:water (v:v) = 45:55) to give compound 56 (0.6 g, 70.23%).

[0126] 1 H NMR (400MHz,DMSO-d6) δ 9.15 (s,2H),8.10 (d,1H),7.24 (s,1H),7.16 - 7.10 (m,2H),7.04 (d,1H),5.27 (s,2H),5.11 (d,2H),3.09 (s,4H); LC-MS (ESI): m / z=389.1[M+H] + . Example 57 [ka]

[0127] Step 1: (2,3-Dihydro-1H-inden-5-yl)methanol (compound 57A) (0.3 g, 2.04 mmol) was dissolved in dichloromethane (6 mL) and thionyl chloride (0.49 g, 4.12 mmol) was added dropwise slowly under ice-water bath. The mixture was then allowed to warm to room temperature and react for 2 hours. The reaction mixture was directly concentrated to give compound 57B (0.5 g crude), which was used directly in the next step.

[0128] 1 H NMR (400MHz,DMSO-d6) 7.19-7.11 (m,3H),4.60 (s,2H),2.85-2.77 (m,4H),2.04-1.88 (m,2H).

[0129] Step 2: Compound 1D (0.25 g, 0.92 mmol), compound 57B (0.23 g, 1.38 mmol), and potassium carbonate (0.32 g, 2.32 mmol) were dissolved in N,N-dimethylformamide (8 mL), heated to 70 °C, and stirred for 2 hours. The reaction mixture was diluted with water and extracted three times with ethyl acetate. The organic phases were combined and concentrated, and the resulting residue was purified by preparative HPLC. Method: 1. Equipment: Waters 2767 Preparative Liquid Chromatography Column: SunFire@ Prep C18 (19 mm x 250 mm). 2. The sample was filtered through a 0.45 μm filter to prepare the sample solution. 3. Preparative chromatography conditions: a. Composition of mobile phases A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.5% ammonium acetate); b. Gradient elution, mobile phase A content: 50% to 80%; c. Flow rate: 20 mL / min; d. Elution time: 18 min; Retention time: 17 min. Compound 57 (160 mg, 43%) was obtained.

[0130] 1 H NMR (400MHz,DMSO-d6) δ 9.15 (s,2H),8.11 (d,1H),7.25 (s,1H),7.19 - 7.11 (m,3H),5.27 (s,2H),5.16-5.06 (m,2H),2.85-2.77 (m,4H),2.04-1.88 (m,2H); LC-MS (ESI): m / z=403.2[M+H] + . Example 60 [ka]

[0131] Step 1: Intermediate 1 (0.25 g, 0.98 mmol), compound 56B (0.19 g, 1.24 mmol), and potassium carbonate (0.34 g, 2.46 mmol) were dissolved in N,N-dimethylformamide (8 mL), heated to 70°C, and stirred for 3 hours. The reaction mixture was diluted with water and extracted three times with ethyl acetate. The organic phases were combined and concentrated, and the residue was purified by preparative HPLC. Method: 1. Equipment: Waters 2767 Preparative Liquid Chromatography Column: SunFire@ Prep C18 (19 mm x 250 mm). 2. The sample was filtered through a 0.45 μm filter to prepare the sample solution. 3. Preparative chromatography conditions: a. Composition of mobile phases A and B: Mobile phase A: acetonitrile, Mobile phase B: water (containing 0.5% ammonium acetate); b. Gradient elution, mobile phase A content: 30% to 70%; c. Flow rate: 20 mL / min; d. Elution time: 20 min; Retention time: 18 min. Compound 60 (120 mg, 33%) was obtained.

[0132] 1 H NMR (400MHz,DMSO-d6) δ 9.11 (s,2H),8.08 (d,1H),7.25 (d,1H),7.15 - 7.10 (m,2H),7.04 (d,1H),6.63-6.26 (m,1H),5.27 (s,2H),4.78-4.62 (m,2H),3.08 (s,4H); LC-MS (ESI): m / z=371.1[M+H] + . Example 61 [ka]

[0133] Step 1: Compound 61A (2.0 g, 10.91 mmol) was dissolved in tetrahydrofuran (25 mL) and stirred under a nitrogen atmosphere. n-Butyllithium (8.7 mL, 13.09 mmol, 1.5 M n-hexane solution) was added dropwise at -78 ° C. After the addition was completed, the mixture was stirred at the same temperature for 0.5 hours. Finally, N,N-dimethylformamide (1.04 g, 14.18 mmol) was added dropwise and stirred for 1 hour. Water was slowly added dropwise to the mixture at -78 ° C. to quench the reaction, and the mixture was extracted with ethyl acetate (30 mL × 3). The organic phase was collected, dried, and concentrated to give compound 61B (1.40 g crude, 97.1%), which was used directly in the next step.

[0134] Step 2: Compound 61B (1.4 g, 10.59 mmol) was dissolved in tetrahydrofuran (25 mL), the mixture was stirred at 0 °C, and methylmagnesium bromide (10.6 mL, 21.2 mmol, 2 M ether solution) was added dropwise. After the addition was complete, the mixture was allowed to warm to room temperature and react for 2 h. The reaction was quenched by adding water in an ice bath, extracted with ethyl acetate (30 mL × 3), and the organic phase was collected, dried, and concentrated to give compound 61C (1.3 g, crude, 82.83%), which was used directly in the next step.

[0135] Step 3: Compound 61C (0.60 g, 4.05 mmol) was dissolved in tetrahydrofuran (20 mL), triphenylphosphine (1.59 g, 6.07 mmol), compound 1D (1.21 g, 4.46 mmol), and diisopropyl azodicarboxylate (1.23 g, 6.07 mmol) were added dropwise at 0 °C. The mixture was then allowed to warm to room temperature and react overnight. The reaction mixture was directly concentrated, and the resulting residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate (v:v) = 1:1) to give compound 61 (700 mg, 42.96%).

[0136] 1H NMR ((400MHz,CDCl3) δ 8.94 (s,2H),7.54 (d,1H),7.33 (d,1H),7.19 (s,1H),7.05-7.00 (m,2H),6.41-6.36 (m,1H),4.88 (q,2H),3.14 (s,4H),1.82 (d,3H); LC-MS (ESI): m / z=403.1[M+H] + . Example 62 [ka]

[0137] Step 1: Compound 62A (1.0 g, 5.46 mmol) and tetrahydrofuran (25 mL) were added to a three-neck flask and stirred at -78 °C under nitrogen gas protection. Then, n-butyllithium (2.6 mL, 6.5 mmol, 2.5 M n-hexane solution) was slowly added dropwise. After the addition was complete, the mixture was stirred at the same temperature for 0.5 h. Finally, N,N-dimethylformamide (0.52 g, 7.10 mmol) was slowly added dropwise and stirred for 1 h. The reaction was quenched by the slow addition of water, and the mixture was extracted with ethyl acetate (30 mL × 2). The organic phase was collected, dried, and concentrated to give compound 62B (0.50 g crude, 69.3%), which was used directly in the next step.

[0138] Step 2: Compound 62B (0.22 g, 1.66 mmol) was dissolved in tetrahydrofuran (15 mL) and stirred at 0 °C. Then, diisobutylaluminum hydride (2.5 mL, 2.5 mmol, 1 M n-hexane solution) was slowly added dropwise. After the addition was completed, the mixture was returned to room temperature and stirred for 2 h. The mixture was stirred in an ice bath, and water (0.2 mL), 15% aqueous sodium hydroxide solution (0.2 mL), and water (0.5 mL) were added sequentially. The mixture was stirred for 10 min. Finally, the mixture was dried over anhydrous sodium sulfate, filtered, and the filter cake was washed with ethyl acetate. The collected solution was concentrated to give compound 62C (0.18 g, 80.8%), which was used directly in the next step.

[0139] Step 3: Compound 62C (0.18 g, 1.34 mmol) was dissolved in tetrahydrofuran (20 mL), triphenylphosphine (0.53 g, 2.01 mmol) and compound 1D (0.40 g, 1.47 mmol) were added, and diisopropyl azodicarboxylate (0.41 g, 2.01 mmol) was slowly added dropwise at 0 °C. The mixture was then slowly warmed to room temperature and stirred overnight. The mixture was directly concentrated, and the resulting residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate (v:v) = 1:1) to give compound 62 (55 mg, 10.57%).

[0140] 1 H NMR ((400MHz,CDCl3) δ 8.94 (s,2H),7.59 (d,1H),7.24 (d,1H),7.18 (t,1H),7.07 (d,1H),6.98 (d,1H),5.36 (s,2H),4.87 (q,2H),3.14-3.10 (m,4H); LC-MS (ESI): m / z=389.1[M+H] + . Examples 63 and 64 [ka]

[0141] Compound 61 (700.0 mg) was chiral resolved to give P1 (retention time: 1.855 min, designated as compound 63). SFC analysis method: Instrument: SHIMADZU LC-30AD, Chromatography column: Chiralcel WHELK column, Mobile phase: A for CO2, B for 0.05% DEA in MeOH, Gradient: 5-40% B gradient elution, Flow rate: 3 mL / min, Column temperature: 35 °C, Column pressure: 100 bar, Wavelength: 220 nm) and P2 (retention time: 2.536 min, designated as compound 64). Preparative method: Instrument: Waters 150 Prep-SFCA; Chromatography column: Chiralcel WHELK column; Mobile phase: A for CO₂, B for 0.1% NH₃·H₂O in MeOH; Gradient: 45% B gradient elution; Flow rate: 100 mL / min; Column temperature: 25°C; Wavelength: 220 nm; Cycle time: 5.0 min; Sample preparation: Sample concentration 10 mg / mL, acetonitrile solution; Sample injection: 10 mL / time. After separation, the mixture was dried and concentrated using a rotary evaporator at a bath temperature of 35°C. The solvent was then dried using a freeze dryer at -80°C to give Compound 63 (260 mg, 37.1%) and Compound 64 (256 mg, 36.6%).

[0142] Compound 63: 1 H NMR ((400MHz,CDCl3) δ 8.94 (s,2H),7.54 (d,1H),7.32 (d,1H),7.19 (s,1H),7.04-7.00 (m,2H),6.41-6.36 (m,1H),4.88 (q,2H),3.14 (s,4H),1.82 (d,3H);LC-MS (ESI): m / z=403.1[M+H] + .

[0143] Compound 64: 1H NMR ((400MHz,CDCl3) δ 8.94 (s,2H),7.54 (d,1H),7.32 (d,1H),7.19 (s,1H),7.04-7.00 (m,2H),6.41-6.36 (m,1H),4.88 (q,2H),3.14 (s,4H),1.82 (d,3H);LC-MS (ESI): m / z=403.1[M+H] + . Example 65 [ka]

[0144] Step 1: Compound 56B (3.5 g, 20.00 mmol), 6-bromo-3-pyridazinol (3.94 g, 20.00 mmol), and cesium carbonate (19.55 g, 60.00 mmol) were dissolved in acetonitrile (100 mL), heated to 80 °C, and stirred for 2.5 h. After direct concentration, the resulting residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate (v:v) = 3:1) to give compound 65A (4 g, 68.70%). LC-MS (ESI): m / z=291.1[M+H] + .

[0145] Step 2: Compound 65A (4 g, 13.74 mmol), 2-chloropyrimidine-5-boronic acid (4.35 g, 27.48 mmol), potassium carbonate (5.70 g, 41.22 mmol), and 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene](3-chloropyridine)dichloropalladium (0.94 g, 1.37 mmol) were dissolved in 1,4-dioxane (50 mL) and water (10 mL). The mixture was heated to 90 °C under nitrogen gas protection and stirred for 2.5 h. The mixture was directly concentrated, and the resulting residue was purified by silica gel column chromatography (petroleum ether:ethyl acetate (v:v) = 1:1) to give compound 65B (3.5 g, 78.44%). LC-MS (ESI): m / z=325.5[M+H] + .

[0146] Step 3: Trifluoropropanol (0.28 g, 2.48 mmol) was dissolved in tetrahydrofuran (5 mL), followed by the addition of sodium metal (0.043 g, 1.86 mmol). After the sodium had disappeared, compound 65B (0.20 g, 0.62 mmol) was added and stirred at room temperature for 1 h. Extraction was performed with water and ethyl acetate. The organic phase was collected, dried, and concentrated. The resulting residue was purified by reverse-phase column chromatography (water:acetonitrile (v:v) = 40:60) to give compound 65 (0.1 g, 40.09%).

[0147] 1 H NMR (400MHz,DMSO-d6) δ 9.09 (s,2H),8.08 (d,1H),7.24 (d,1H),7.15 - 7.09 (m,2H),7.04 (d,1H),5.27 (s,2H),4.61-4.58(m,2H),3.09 (s,4H),2.94 - 2.79 (m,2H); LC-MS (ESI): m / z=403.4[M+H] + . Example 66 [ka]

[0148] Step 1: 2-Fluoroethanol (0.20 g, 3.1 mmol) was dissolved in tetrahydrofuran (5 mL), followed by the addition of sodium metal (0.057 g, 2.48 mmol). After the sodium had disappeared, compound 65B (0.20 g, 0.62 mmol) was added and stirred at room temperature for 1 h. Extraction was performed with water and ethyl acetate. The organic phase was collected, dried, and concentrated. The residue was purified by reverse-phase column chromatography (water:acetonitrile (v:v) = 40:60) to give compound 66 (0.1 g, 45.77%).

[0149] 1H NMR (400MHz,DMSO-d6) δ 9.08 (s,2H),8.08 (d,1H),7.24 (d,1H),7.16 - 7.08 (m,2H),7.04 (d,1H),5.27 (s,2H),4.92 - 4.51 (m,4H),3.09 (s,4H); LC-MS (ESI): m / z=353.4[M+H] + . Example 67 [ka]

[0150] Step 1: Intermediate 1 (0.50 g, 1.97 mmol), compound 67A (0.50 g, 2.36 mmol), and cesium carbonate (1.30 g, 4.00 mmol) were added sequentially to acetonitrile (20 mL), heated to 80 °C, and stirred for 2 h. After cooling, the mixture was diluted with water and extracted three times with ethyl acetate. The combined organic phases were dried over anhydrous sodium sulfate and concentrated. The resulting residue was purified by reverse-phase column chromatography (acetonitrile:water (v:v) = 10% to 80%) to give compound 67 (420 mg, 55%).

[0151] 1 H NMR (400MHz,CDCl3) δ 8.93 (s,2H),7.56 (d,1H),7.34 (s,1H),7.27-7.25 (m,1H),7.19-7.17 (m,1H),7.06 (d,1H),6.32-6.02(m,1H),5.36 (s,2H),4.69-4.61 (m,2H),2.90-2.85 (m,4H),2.90-2.00 (m,2H); LC-MS (ESI): m / z=385.1[M+H] + . Example 68 [ka]

[0152] 3,3-Difluoropropan-1-ol (0.24 g, 2.48 mmol) was dissolved in tetrahydrofuran (5 mL), followed by the addition of metallic sodium (0.043 g, 1.87 mmol). After the sodium had disappeared, compound 65B (0.20 g, 0.62 mmol) was added and the mixture was allowed to react at room temperature for 1 hour. The mixture was extracted with water and ethyl acetate, and the organic phase was collected and concentrated under reduced pressure. The residue was purified by reverse-phase column chromatography (acetonitrile:water (v:v) = 10% to 80%) to give compound 69 (0.1 g, 41.96%).

[0153] 1 H NMR (400MHz,DMSO-d6) δ 9.08 (s,2H),8.07 (d,1H),7.24 (d,1H),7.15 - 7.08 (m,2H),7.04 (d,1H),6.42-6.11 (m,1H),5.27 (s,2H),4.52 (t,2H),3.09 (s,4H),2.46 - 2.29 (m,2H); LC-MS (ESI): m / z=385.1[M+H] + . Example 69 [ka]

[0154] 3-Fluoropropan-1-ol (0.19 g, 2.48 mmol) was dissolved in tetrahydrofuran (5 mL), followed by the addition of metallic sodium (0.043 g, 1.87 mmol). After the sodium had disappeared, compound 65B (0.20 g, 0.62 mmol) was added and the mixture was allowed to react at room temperature for 1 hour. The mixture was extracted with water and ethyl acetate, and the organic phase was collected and concentrated under reduced pressure. The resulting residue was purified by reverse-phase column chromatography (acetonitrile:water (v:v) = 10% to 80%) to give compound 69 (0.08 g, 35.22%).

[0155] 1H NMR (400MHz,DMSO-d6) δ 9.07 (s,2H),8.07 (d,1H),7.24 (d,1H),7.14 - 7.07 (m,2H),7.04 (d,1H),5.27 (s,2H),4.67 (t,1H),4.55 (t,1H),4.47 (t,2H),3.09 (s,4H),2.23 - 2.06 (m,2H); LC-MS (ESI): m / z=367.2[M+H] + . Example 70 [ka]

[0156] 3-Chloropropan-1-ol (0.23 g, 2.48 mmol) was dissolved in tetrahydrofuran (5 mL), followed by the addition of metallic sodium (0.043 g, 1.87 mmol). After the sodium had disappeared, compound 65B (0.20 g, 0.62 mmol) was added and the mixture was allowed to react at room temperature for 1 hour. The mixture was extracted with water and ethyl acetate, and the organic phase was collected and concentrated under reduced pressure. The resulting residue was purified by reverse-phase column chromatography (acetonitrile:water (v:v) = 10% to 80%) to give compound 70 (0.09 g, 37.92%).

[0157] 1 H NMR (400MHz,DMSO-d6) δ 9.07 (s,2H),8.07 (d,1H),7.24 (d,1H),7.17 - 7.08 (m,2H),7.04 (d,1H),5.27 (s,2H),4.49 (t,2H),3.80 (t,2H),3.09 (s,4H),2.28 - 2.15 (m,2H); LC-MS (ESI): m / z=383.1[M+H] + . Example 71 [ka]

[0158] Step 1: Compound 67A (2 g, 9.47 mmol), 6-bromo-3-pyridazinol (1.82 g, 10.42 mmol), and potassium carbonate (3.27 g, 23.68 mmol) were dissolved in N,N-dimethylformamide (30 mL), heated to 70 °C, and stirred for 3 h. After cooling, the mixture was diluted with water and extracted three times with ethyl acetate. The combined organic phases were concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography (ethyl acetate:petroleum ether (v:v) = 15%) to give compound 71B (2.5 g, 86%). LC-MS (ESI): m / z=305.2[M+H] + .

[0159] Step 2: Compound 71B (2.5 g, 8.19 mmol), (2-chloropyrimidin-5-yl)boronic acid (1.95 g, 12.29 mmol), potassium phosphate (2.61 g, 12.29 mmol), and 1,3-bis(2,6-diisopropylphenyl)imidazol-2-ylidene](3-chloropyridyl)dichloropalladium(II) (0.56 g, 0.82 mmol) were dissolved in a mixture of 1,4-dioxane (30 mL) and water (10 mL). The mixture was stirred at 90 °C for 3 hours under nitrogen gas protection. After cooling, water was added directly to precipitate a solid, which was then filtered. The filter cake was washed three times with ethyl acetate and dried to give compound 71C (1.8 g, 65%). LC-MS (ESI): m / z=339.3[M+H] + .

[0160] Step 3: 3-Fluoropropanol (0.46 g, 5.90 mmol) was dissolved in tetrahydrofuran (10 mL), sodium metal (68 mg, 2.96 mmol) was added, and the mixture was stirred at room temperature until the sodium metal completely disappeared. Next, compound 71C (200 mg, 0.59 mmol) was added to the reaction mixture, and the mixture was stirred for 2 hours. The mixture was extracted with water and ethyl acetate, and the organic phase was washed with saturated brine. The organic phase was collected and concentrated under reduced pressure. The residue was purified by reverse-phase column chromatography (acetonitrile:water (v:v) = 10% to 80%) to give compound 71 (22 mg, 9.8%).

[0161] 1 H NMR (400MHz,CDCl3) δ 8.90 (s,2H),7.55 (d,1H),7.35 (s,1H),7.28-7.25 (m,1H),7.19-7.17 (m,1H),7.05 (d,1H),5.36 (s,2H),4.74-4.72 (m,1H),4.63-4.55 (m,3H),2.90-2.85 (m,4H),2.30-2.18 (m,2H),2.09-2.00 (m,2H); LC-MS (ESI): m / z=381.3[M+H] + . Example 72 [ka]

[0162] Step 1: Compound 72A (1.00 g, 5.08 mmol), (tributyltin)methanol (1.96 g, 6.10 mmol), and chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (0.40 g, 0.51 mmol) were added sequentially to 1,4-dioxane (30 mL), the mixture was purged with nitrogen gas three times, the temperature was raised to 110°C, and the reaction was stirred for 2 hours. After the reaction was completed, the mixture was cooled to room temperature, and ethyl acetate (100 mL) and saturated saline (100 mL) were added to separate the layers. The organic phase was collected and washed three times with saturated saline, then dried over anhydrous sodium sulfate. After filtration, the filtrate was concentrated under reduced pressure, and the resulting residue was purified by chromatography (ethyl acetate:petroleum ether (v:v) = 0 to 100%) to obtain compound 72B (0.24 g, yield: 31.89%). LC-MS (ESI): m / z=149.1[M+H] + .

[0163] Step 2: Compound 72B (0.24 g, 1.62 mmol) was added to dichloromethane (10 mL), triethylamine (0.16 g, 1.62 mmol), and methanesulfonyl chloride (0.19 g, 1.62 mmol) was added dropwise in an ice bath. After the addition was complete, the mixture was stirred for 30 minutes. After the reaction was complete, ethyl acetate (100 mL) and aqueous sodium bicarbonate (100 mL) were added and the mixture was separated. The organic phase was collected, washed three times with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (ethyl acetate:petroleum ether (v:v) = 0-50%) to give compound 72C (0.18 g, yield: 49.10%). LC-MS (ESI): m / z=227.20[M+H] + .

[0164] Step 3: Compound 1D (90 mg, 0.33 mmol), compound 72C (75 mg, 0.33 mmol), and potassium carbonate (46 mg, 0.33 mmol) were added sequentially to acetonitrile (10 mL), heated to 70 °C, and stirred for 2 hours. After cooling to room temperature, ethyl acetate and saturated brine were added and the mixture was separated. The organic phase was collected, washed three times with saturated brine, and concentrated under reduced pressure. The resulting residue was purified by reverse-phase column chromatography (acetonitrile:water (v:v) = 5% to 80%) to give compound 72 (51 mg, yield: 38.41%).

[0165] 1 H NMR (400MHz,CDCl3) δ 8.94 (s,2H),7.70 - 7.59 (m,2H),7.53 - 7.48 (m,1H),7.34-7.32 (m,1H),7.11 (d,1H),5.45 (s,2H),4.91-4.85 (m,2H),3.95 (s,2H); LC-MS (ESI): m / z=403.50[M+H] + . Example 73 [ka]

[0166] Step 1: Compound 74D (0.20 g, 1.20 mmol) and dichloromethane (15 mL) were added to a single-neck flask and stirred at 0 °C. Sulfinyl chloride (0.29 g, 2.40 mmol) was then slowly added dropwise. After the addition was complete, the mixture was stirred at room temperature for 2 hours. The mixture was directly concentrated to give compound 73A (0.22 g, 99.29%), which was used directly in the next step.

[0167] Step 2: Compound 73A (0.22 g, 1.19 mmol) was dissolved in acetonitrile (15 mL), followed b...

Claims

1. A compound of formula (I), a stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or co-crystal thereof, 【Chemistry 1】 During the ceremony, R １ , R ２ , R ３ are each independently H, deuterium, or R Ａ１ , —O-haloC １－４ Alkyl group, -NH-haloC １－４ Alkyl group, —OC １－４ Alkyl group, C １－６ Alkoxy group, halogen, cyano group, nitro group, C １－４ Alkyl group, —NH—C １－４ alkyl group, —N(C １－４ alkyl) ２ , —NH—C ３－１０ Cycloalkyl groups, —NHC(O)C １－４ alkyl groups or 4- to 10-membered heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, and the alkyl, alkoxy, cycloalkyl, and heterocycloalkyl groups are optionally selected from halogen, D, CN, OH, C １－４ Alkyl group, halo C １－４ Alkyl groups, deuterated C １－４ Alkyl group, C １－４ Alkoxy group, halo C １－４ Alkoxy group, deuterated C １－４ Alkoxy group, C ３－１０ a cycloalkyl group, a 4- to 6-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S, a phenyl group, and NH ２ and is further substituted with 1 to 3 groups selected from R １ , R ２ and R ３ are not simultaneously selected from H, R Ａ１ Halo C ２－６ Alkenyl group, C ２－６ Alkynyl group, —O—(CH ２ ) ｒ -R ａ , C ３－１０ a cycloalkyl group, a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; １－４ Alkyl-R ａ , -C １－４ Alkyl-OR ａ , -C １－４ Alkyl-NR ｂ R ａ , -NR ｂ -S(O) ２ -R ａ , -NR ｂ -S(O) ２ -NR ｂ R ａ , —O—NR ｂ R ａ , —NH—OR ｂ , -Se-(CH ２ ) ｒ -R ａ The alkynyl, heteroaryl, alkyl, and cycloalkyl groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C １－４ Alkyl group, halo C １－４ Alkyl groups, deuterated C １－４ Alkyl group, C １－４ Alkoxy group, halo C １－４ Alkoxy group, deuterated C １－４ Alkoxy groups and NH ２ is further substituted with 1 to 3 groups selected from Each R ａ CN, Halo C １－６ Alkyl group, C ３－１０ a cycloalkyl group, a 4- to 10-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 6- to 10-membered aryl group; a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; -C(O)-R ａ１ wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally selected from halogen, ═O, deuterium, CN, OH, C １－４ Alkyl group, halo C １－４ Alkyl groups, deuterated C １－４ Alkyl group, C １－４ Alkoxy group, halo C １－４ Alkoxy group, deuterated C １－４ Alkoxy groups and NH ２ is further substituted with 1 to 3 groups selected from Each R ｂ is H, deuterium, C １－４ Alkyl group, C ３－６ Cycloalkyl group, halo C １－４ Alkyl groups, deuterated C １－４ alkyl groups, R ａ１ OH, NH ２ , -NHC １－４ alkyl group, —N(C １－４ alkyl) ２ , -NHC ３－１０ Cycloalkyl group, C １－４ Alkoxy group, C １－６ Alkyl group, C ３－１０ selected from a cycloalkyl group, a 6- to 10-membered aryl group, and a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; X is CR １０ or N, X １ is selected from O, S, R ４ , R ５ are each independently H, deuterium, or C ３－１０ Cycloalkyl group, C ２－６ Alkenyl group, C ２－６ Alkynyl group, halogen, amino group, -NH-C １－４ alkyl group, —N(C １－４ alkyl) ２ , C １－４ Alkyl group, halo C １－４ an alkyl group, a 4- to 10-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 5- to 10-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; and a 6- to 10-membered aryl group; R ６ , R ７ , R ８ , R ９ , R １０ are each independently H, deuterium, or R Ａ２ , halogen, OH, CN, amino group, C １－４ Alkyl group, C ２－６ Alkenyl group, C ２－６ Alkynyl group, C １－４ Alkoxy group, halo C １－４ Alkyl group, —NH—C １－４ alkyl group, —N(C １－４ alkyl) ２ , -S(O)R ｃ , -S(O) ２ R ｃ , -C(O)R ｃ , -C(O)OR ｃ , -C(O)N(R ｃ ) ２ , -OC(O)R ｃ The alkyl, alkenyl, alkynyl, and alkoxy groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C １－４ Alkyl group, halo C １－４ Alkyl groups, deuterated C １－４ Alkyl group, C １－４ Alkoxy group, halo C １－４ Alkoxy group, deuterated C １－４ Alkoxy groups and NH ２ is further substituted with 1 to 3 groups selected from R Ａ２ is -(CH ２ ) ｒ -(C ３－１０ cycloalkyl), -(CH ２ ) ｒ -(4- to 10-membered heterocycloalkyl containing 1 to 3 heteroatoms selected from N, O, S, and Si), or -(CH ２ ) ｒ -(5- to 10-membered heteroaryl containing 1 to 3 heteroatoms selected from N, O, and S), -P(O)(R ｃ ) ２ , -Si(R ｃ ) ３ , -SF ５ , N ３ , B(OH) ２ or -S(O)(=NH)R ｃ wherein the cycloalkyl, heterocycloalkyl, and heteroaryl groups are optionally selected from halogen, ═O, D, CN, OH, C １－４ Alkyl group, halo C １－４ Alkyl groups, deuterated C １－４ Alkyl group, C １－４ Alkoxy group, halo C １－４ Alkoxy group, C ３－６ cycloalkyl groups, 4- to 7-membered heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, deuterated C １－４ Alkoxy groups and NH ２ is further substituted with 1 to 3 groups selected from Each R ｃ are each independently H, OH, or C １－４ Alkyl group, C ３－７ Cycloalkyl group, halo C １－４ Alkyl groups, deuterated C １－４ Alkyl group, C １－４ Alkoxy group, halo C １－４ Alkoxy group, deuterated C １－４ Alkoxy group or NH ２ is selected from each r is independently selected from 0, 1, 2, or 3; L １ is a bond, O, NH, S, -CD ２ -, -CHD-, -CR Ｌ１ R Ｌ２ -, C １－４ Alkyl group, —C(O)—, S(O), S(O) ２ wherein the alkyl group is optionally selected from R Ｌ１ is further substituted with L ２ is a bond, O, NH, S, -CH ２ -, -CD ２ -, -CHD-, -CR Ｌ１ R Ｌ２ --, --CHR Ｌ２ -, -CDR Ｌ２ -, C ２－４ Alkyl group, —C(O)—, S(O), S(O) ２ wherein the alkyl group is optionally selected from 1 to 3 R Ｌ１ is further substituted with R Ｌ１ , R Ｌ２ are each independently a halogen, OH, CN, an amino group, or C １－４ Alkyl group, C １－４ Alkoxy group, C ３－６ cycloalkyl groups, 4-6 membered heterocycloalkyl groups containing 1-3 heteroatoms selected from N, O, S; One option is R ２ , R ４ , L １ together with the atoms to which it is attached, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be Ａ３ is further substituted with 1 to 3 groups selected from One option is R ４ , R ５ together with the atoms to which it is attached, form a 5- to 7-membered monocyclic carbocycle or a 5- to 7-membered heterocycle containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocycle or heterocycle may optionally be Ａ３ is substituted with 1 to 3 groups selected from One option is R Ｌ２ and R ９ together with the atoms to which it is attached, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be Ａ３ is further substituted with 1 to 3 groups selected from Each R Ａ３ are each independently ═O, halogen, deuterium, CN, OH, C １－４ Alkyl group, halo C １－４ Alkyl groups, deuterated C １－４ Alkyl group, C １－４ Alkoxy group, halo C １－４ Alkoxy group, deuterated C １－４ Alkoxy groups and NH ２ is selected from the group substitutions As a condition, R ６ and R １０ , R １０ and R ７ , R ７ and R ８ , R ８ and R ９ A pair of these together with the atoms to which they are connected form a 4- to 8-membered carbocyclic ring, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and the carbocyclic ring, heterocycloalkyl group may optionally be selected from ═O, 【Chemistry 2】 Halogens, deuterium, CN, OH, C １－４ Alkyl group, halo C １－４ Alkyl groups, deuterated C １－４ Alkyl group, C １－４ Alkoxy group, halo C １－４ Alkoxy group, deuterated C １－４ an alkoxy group, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si; a 5- to 7-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si; and NH ２ The compound, stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or co-crystal thereof, further substituted with 1 to 3 groups selected from:

2. R ６ , R ７ , R ８ , R ９ , R １０ are each independently H, deuterium, or —SF ５ , N ３ , halogen, OH, CN, amino group, C １－２ Alkyl group, C ２－４ Alkenyl group, C ２－４ Alkynyl group, C １－２ Alkoxy group, halo C １－２ Alkyl group, —NH—C １－２ alkyl group, —N(C １－２ alkyl) ２ The alkyl, alkenyl, alkynyl, and alkoxy groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C １－２ Alkyl group, halo C １－２ Alkyl groups, deuterated C １－２ Alkyl group, C １－２ Alkoxy group, halo C １－２ Alkoxy group, deuterated C １－２ Alkoxy groups and NH ２ 10. The compound of claim 1, a stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or co-crystal thereof, further substituted with 1 to 3 groups selected from:

3. having the structure of formula (II) or (II-a), 【Transformation 3】 L ２ is a bond, -CH ２ -, -CR Ｌ１ R Ｌ２ --, --CHR Ｌ２ -, -CDR Ｌ２ -, -C(O)-, R Ｌ１ , R Ｌ２ are each independently a halogen, OH, CN, an amino group, or C １－２ Alkyl group, C １－２ Alkoxy group, C ３－４ a 4-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from cycloalkyl groups, N, O, and S; R ２ , R ３ are each independently H, deuterium, or C １－２ Alkoxy group, halogen, cyano group, nitro group, C １－２ alkyl groups, alkoxy groups, optionally selected from halogens, D, CN, OH and NH ２ is further substituted with 1 to 3 groups selected from R １ is R Ａ１ , —O-haloC １－４ Alkyl group, -NH-haloC １－４ Alkyl group, C １－４ Alkoxy group, halogen, cyano group, nitro group, C １－４ Alkyl group, —NH—C １－４ alkyl group, —N(C １－４ alkyl) ２ , —NH—C ３－１０ Cycloalkyl groups, —NHC(O)C １－４ alkyl groups or 4- to 10-membered heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, and the alkyl, alkoxy, cycloalkyl, and heterocycloalkyl groups are optionally selected from halogen, D, CN, OH, C １－４ Alkyl group, halo C １－４ Alkyl groups, deuterated C １－４ Alkyl group, C １－４ Alkoxy group, halo C １－４ Alkoxy group, deuterated C １－４ Alkoxy group, C ３－１０ Cycloalkyl groups, 4- to 6-membered heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, phenyl groups, and NH ２ is further substituted with 1 to 3 groups selected from X is CR １０ or N, R ４ , R ５ are each independently H, deuterium, or C ３－７ Cycloalkyl group, C ２－４ Alkenyl group, C ２－４ Alkynyl group, F, Cl, amino group, -NH-C １－２ alkyl group, —N(C １－２ alkyl) ２ , C １－２ alkyl groups, and 4-7 membered heterocycloalkyl groups containing 1-3 heteroatoms selected from N, O, and S; R ７ , R ８ are each independently H, deuterium, F, Cl, OH, CN, an amino group, or C １－４ Alkyl group, C ２－４ Alkenyl group, C ２－４ Alkynyl group, C １－４ Alkoxy group, halo C １－４ Alkyl group, —NH—C １－２ alkyl group, —N(C １－２ alkyl) ２ , -S(O)R ｃ , -S(O) ２ R ｃ , -C(O)R ｃ , -C(O)OR ｃ , -C(O)N(R ｃ ) ２ , -OC(O)R ｃ is selected from R ６ , R ９ , R １０ are each independently H, deuterium, F, Cl, OH, CN, an amino group, or C １－２ alkyl groups, One option is R ２ , R ４ together with the atoms to which it is attached, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be Ａ３ is further substituted with 1 to 3 groups selected from Each R Ａ３ are each independently ═O, halogen, deuterium, CN, OH, C １－２ Alkyl group, halo C １－２ Alkyl groups, deuterated C １－２ Alkyl group, C １－２ Alkoxy group, halo C １－２ Alkoxy group, deuterated C １－２ Alkoxy groups and NH ２ is selected from the group substitutions As a condition, R １０ and R ７ , R ７ and R ８ , R ８ and R ９ A pair of these together with the atom connected thereto forms a 4- to 8-membered cycloalkyl group, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and the cycloalkyl group, heterocycloalkyl group optionally includes ═O, 【Chemistry 4】 Halogens, deuterium, CN, OH, C １－４ Alkyl group, halo C １－４ Alkyl groups, deuterated C １－４ Alkyl group, C １－４ Alkoxy group, halo C １－４ Alkoxy group, deuterated C １－４ an alkoxy group, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si; a 5- to 7-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si; and NH ２ 10. The compound of claim 1, a stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or co-crystal thereof, further substituted with 1 to 3 groups selected from:

4. having the structure of formula (III) or (III-a), 【Transformation 5】 X is CR １０ or N, R ６ , R ７ , R ８ , R ９ , R １０ are each independently H, deuterium, F, Cl, OH, CN, an amino group, or C １－２ alkyl groups, One option is R ２ , R ４ together with the atoms to which it is attached, form a 5- to 7-membered carbocyclic ring or a 5- to 7-membered heterocyclic ring containing 1 to 3 heteroatoms selected from N, O, and S, and the carbocyclic ring or heterocyclic ring may optionally be Ａ３ is further substituted with 1 to 3 groups selected from As a condition, R １０ and R ７ , R ７ and R ８ , R ８ and R ９ A pair of these together with the atom connected thereto forms a 4- to 8-membered cycloalkyl group, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and the cycloalkyl group, heterocycloalkyl group optionally includes ═O, 【Transformation 6】 Halogens, deuterium, CN, OH, C １－４ Alkyl group, halo C １－４ Alkyl groups, deuterated C １－４ Alkyl group, C １－４ Alkoxy group, halo C １－４ Alkoxy group, deuterated C １－４ an alkoxy group, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si; a 5- to 7-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si; and NH ２ 10. The compound of claim 1, a stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or co-crystal thereof, further substituted with 1 to 3 groups selected from:

5. R １ is R Ａ１ , —O-haloC １－４ Alkyl group, C １－４ alkyl groups, wherein the alkyl groups are optionally selected from halogen, D, CN, OH, C １－４ Alkyl group, halo C １－４ Alkyl groups, deuterated C １－４ Alkyl group, C １－４ Alkoxy group, halo C １－４ Alkoxy group, deuterated C １－４ Alkoxy groups and NH ２ is further substituted with 1 to 3 groups selected from R ２ , R ３ are each independently H, deuterium, or C ２－４ Alkenyl group, C ２－４ Alkynyl group, halogen, cyano group, nitro group, OH, C １－４ Alkyl group, halo C １－４ Alkyl groups, deuterated C １－４ alkyl groups, R Ａ１ Halo C ２－４ Alkenyl group, C ２－４ Alkynyl group, —O—(CH ２ ) ｒ -R ａ , C ３－６ Monocyclic cycloalkyl groups, C ５－８ Bicyclic bridged ring cycloalkyl group, C ６－１０ a bicyclic spirocyclic cycloalkyl group, a 5- to 6-membered monocyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S, an 8- to 10-membered bicyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S, -C １－２ Alkyl-R ａ , -C １－２ Alkyl-OR ａ , -C １－２ Alkyl-NR ｂ R ａ , -NR ｂ -S(O) ２ -R ａ , -NR ｂ -S(O) ２ -NR ｂ R ａ , —O—NR ｂ R ａ , —NH—OR ｂ , -Se-(CH ２ ) ｒ -R ａ The alkynyl, heteroaryl, alkyl, and cycloalkyl groups are optionally selected from the group consisting of halogen, deuterium, CN, OH, C １－２ Alkyl group, halo C １－２ Alkyl groups, deuterated C １－２ Alkyl group, C １－２ Alkoxy group, halo C １－２ Alkoxy group, deuterated C １－２ Alkoxy groups and NH ２ is further substituted with 1 to 3 groups selected from Each R ａ CN, Halo C １－４ Alkyl group, C ３－６ Monocyclic cycloalkyl groups, C ７－１０ Spirocyclic cycloalkyl groups, C ４－８ Bridged Cycloalkyl Group, C ４－９ Fused-ring cycloalkyl groups, 4- to 6-membered monocyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, 7- to 10-membered spirocyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, 4- to 8-membered bridged cyclic heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, 4- to 6-membered fused-ring heterocycloalkyl groups containing 1 to 3 heteroatoms selected from N, O, and S, phenyl groups, 8- to 10-membered aryl groups, 5- to 6-membered monocyclic heteroaryl groups containing 1 to 3 heteroatoms selected from N, O, and S, 8- to 10-membered bicyclic heteroaryl groups containing 1 to 3 heteroatoms selected from N, O, and S, -C(O)-R ａ１ wherein the alkyl, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl groups are optionally selected from halogen, ═O, deuterium, CN, OH, C １－２ Alkyl group, halo C １－２ Alkyl groups, deuterated C １－２ Alkyl group, C １－２ Alkoxy group, halo C １－２ Alkoxy group, deuterated C １－２ Alkoxy groups and NH ２ is further substituted with 1 to 3 groups selected from Each R ｂ is H, deuterium, C １－２ Alkyl group, C ３－４ 5. The compound of any one of claims 1 to 4, a stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or co-crystal thereof, wherein the compound is selected from the group consisting of cycloalkyl groups.

6. R １ is R Ａ１ , —O-haloC １－４ Alkyl group, C １－４ alkyl groups, wherein the alkyl groups are optionally selected from halogen, D, CN, OH, C １－２ Alkyl group, halo C １－２ Alkyl groups, deuterated C １－２ Alkyl group, C １－２ Alkoxy group, halo C １－２ Alkoxy group, deuterated C １－２ Alkoxy groups and NH ２ is further substituted with 1 to 3 groups selected from R ２ , R ３ are each independently H, deuterium, F, Cl, a cyano group, OH, C １－２ Alkyl group, halo C １－２ Alkyl groups, deuterated C １－２ alkyl groups, R Ａ１ is -O-(CH ２ ) ｒ -R ａ , C ３－６ Monocyclic cycloalkyl groups, C ５－８ Bicyclic bridged ring cycloalkyl group, C ６－１０ a bicyclic spirocyclic cycloalkyl group, a 5- to 6-membered monocyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S, an 8- to 10-membered bicyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S, -C １－２ Alkyl-R ａ , -C １－２ Alkyl-OR ａ , -Se-(CH ２ ) ｒ -R ａ wherein the heteroaryl, alkyl, and cycloalkyl groups are optionally selected from halogen, deuterium, CN, OH, C １－２ Alkyl group, halo C １－２ Alkyl groups, deuterated C １－２ Alkyl group, C １－２ Alkoxy group, halo C １－２ Alkoxy group, deuterated C １－２ Alkoxy groups and NH ２ is further substituted with 1 to 3 groups selected from Each R ａ Halo C １－４ Alkyl group, C ３－６ Monocyclic cycloalkyl groups, C ７－１０ Spirocyclic cycloalkyl groups, C ４－８ Bridged Cycloalkyl Group, C ４－９ a fused-ring cycloalkyl group, a 4- to 6-membered monocyclic heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 7- to 10-membered spirocyclic heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 4- to 8-membered bridged ring heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a 4- to 6-membered fused-ring heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, and S; a phenyl group; an 8- to 10-membered aryl group; a 5- to 6-membered monocyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S; and an 8- to 10-membered bicyclic heteroaryl group containing 1 to 3 heteroatoms selected from N, O, and S, wherein said alkyl group, cycloalkyl group, heterocycloalkyl group, aryl group, and heteroaryl group are optionally selected from halogen, ═O, deuterium, CN, OH, C １－２ Alkyl group, halo C １－２ Alkyl groups, deuterated C １－２ Alkyl group, C １－２ Alkoxy group, halo C １－２ Alkoxy group, deuterated C １－２ Alkoxy groups and NH ２ 6. The compound of claim 5, or a stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or co-crystal thereof, further substituted with 1 to 3 groups selected from:

7. having the structure of formula (IV) or (V), 【Transformation 7】 X is CR １０ or N, R ９ , R １０ are each independently H, deuterium, F, Cl, OH, CN, an amino group, or C １－２ alkyl groups, L ２ is a bond, -CH ２ -, -CD ２ -, -CHD-, -CR Ｌ１ R Ｌ２ --, --CHR Ｌ２ -, -CDR Ｌ２ -, C ２－４ alkyl group, —C(O)—, said alkyl group optionally being selected from 1 to 3 R Ｌ１ is further substituted with As a condition, R １０ and R ７ , R ７ and R ８ , R ８ and R ９ A pair of these together with the atom connected thereto forms a 4- to 8-membered cycloalkyl group, a 5- to 7-membered heterocycloalkyl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si, and the cycloalkyl group, heterocycloalkyl group optionally includes ═O, 【Transformation 8】 Halogens, deuterium, CN, OH, C １－４ Alkyl group, halo C １－４ Alkyl groups, deuterated C １－４ Alkyl group, C １－４ Alkoxy group, halo C １－４ Alkoxy group, deuterated C １－４ Alkoxy groups and NH ２ 10. The compound of claim 1, a stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or co-crystal thereof, further substituted with 1 to 3 groups selected from:

8. L １ is selected from the join, L ２ is a bond, -CH ２ -, -CD ２ -, -CHD-, -C(O)-, -CHF-, -CDF-, -CF ２ -, CH(CH ３ )-, CD(CH ３ ) -, C(CH ３ ) ２ - is selected from, R ６ , R ９ , R １０ are each independently selected from H, deuterium, F, Cl, OH, CN, and a methyl group; R ７ , R ８ are each independently selected from H, deuterium, F, Cl, OH, CN, and a methyl group; R ２ , R ３ are each independently selected from H, deuterium, a vinyl group, and an ethynyl group; R ４ , R ５ are each independently selected from H, deuterium, a cyclopropyl group, a vinyl group, and an ethynyl group; One option is R ４ , R ５ forms, together with the atom to which it is linked, a phenyl group, a cyclohexyl group, a cyclopentyl group, a thienyl group, a furyl group, a pyrrolyl group, a pyrazolyl group, or an isoxazolyl group; One option is R ２ , R ４ , L １ together with the atom to which it is linked, form a cyclohexyl group, a cycloheptyl group, a phenyl group, or a cyclopentyl group, One option is R Ｌ１ and R ９ forms a cyclopentyl group or a cyclohexyl group together with the atom to which it is linked, R １ は、-CF ３ 、-CH ２ CH ３ 、-CH ２ CH ２ CH ３ 、 【Chemistry 9】 is selected from As a condition, R ６ and R １０ , R １０ and R ７ , R ７ and R ８ , R ８ and R ９ A pair of these together with the atom to which they are connected form a 4- to 8-membered cycloalkyl group or a 5- to 7-membered heterocycloalkyl group containing one Si atom, and the cycloalkyl group, heterocycloalkyl group optionally includes ═O, 【Chemistry 10】 F, Cl, deuterium, OH, C １－２ Alkyl group, halo C １－２ The compound of claim 1, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or co-crystal thereof, further substituted with 1 to 3 groups selected from an alkyl group, a 5- to 6-membered heteroaryl group containing 1 to 3 heteroatoms selected from N, O, S, B, and Si.

9. The compound of claim 1 , its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or co-crystal, wherein the compound is selected from one of the structures in Table 1 or Table 2.

10. A pharmaceutical composition or formulation comprising the compound according to any one of claims 1 to 9, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or co-crystal, and a pharmaceutically acceptable carrier and / or excipient.

11. 11. The pharmaceutical composition or formulation of claim 10, comprising 1 to 1500 mg of the compound of any one of claims 1 to 9, or a stereoisomer, deuterated form, solvate, or pharmaceutically acceptable salt or co-crystal thereof, and a pharmaceutically acceptable carrier and / or excipient.

12. Use of the compound according to any one of claims 1 to 9, its stereoisomer, deuterated product, solvate, or pharmaceutically acceptable salt or co-crystal, or the composition according to claims 10 to 11, in the manufacture of a medicament for treating / preventing a myosin II-mediated disease.

13. The use according to claim 12, wherein the Myosin II-mediated disease is selected from muscular dystrophy.

14. 10. A method for treating a disease in a mammal, said method comprising administering to a subject a therapeutically effective amount of a compound according to any one of claims 1 to 9, or a stereoisomer, deuterated form, solvate, pharmaceutically acceptable salt, or co-crystal thereof, wherein the therapeutically effective amount is preferably 1 to 1500 mg, and wherein the disease is preferably muscular dystrophy.

Images